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CHAPTER I:  INTRODUCTION 
OVERVIEW 
Atrial fibrillation (AF) is characterized by the uncoordinated beating of the atria 
of the heart in response to disorganized electrical activity.  AF leads to hemodynamic 
alterations that significantly impair cardiac output and are conducive to thrombus 
formation (1,2).  AF is of significant clinical importance not only because it is the most 
common chronic arrhythmia in patients over the age of 60, but also because of the 
associated morbidity and nearly two-fold increased risk of mortality.  Atrial fibrillation 
currently affects nearly 10% of the United States population over the age of 85, and it is 
forecasted to affect nearly 2% of the general population by 2050 (3,4).  Current strategies 
for treatment of atrial fibrillation focus on three major goals: 1) The acute reversion back 
to normal sinus rhythm using either synchronized electrical or pharmacological 
cardioversion, 2) Maintained prevention of systemic embolization using anticoagulation 
therapy with warfarin, and 3) Maintained ventricular rate control to avoid hemodynamic 
instability and tachycardia-induced cardiomyopathy (usually using agents to slow AV 
nodal conduction such as beta blockers or digoxin). 
Although acute cardioversion is generally effective, only 20-30% of cardioverted 
patients maintain normal sinus rhythm for more than one year.  Given that  patients with 
a prior AF episode are at significantly increased risk for recurrence of atrial fibrillation, 
there is strong rationale to suggest a fourth major goal of therapy, that is, to maintain 
prophylactic rhythm control (5-7).  Although effective for acute cardioversion, currently 
available Class I and III antiarrhythmics are not suitable for long-term use due to the high 
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rate of proarrhythmic ventricular side effects.  Since the risk of proarrhythmic, potentially 
lethal side-effects outweighs the benefit of maintained rhythm control in all but the most 
severe grades of AF (8,9), this has prompted a joint panel of the American Academy of 
Family Physicians (AAFP) and the American College of Physicians (ACP) to take the 
position that maintained antiarrhythmic therapy is generally not recommended in the 
treatment of atrial fibrillation.  There is thus a significant impetus for the development of 
new, longer-term antiarrhythmic therapies that can be used to successfully maintain 
normal sinus rhythm and prevent the recurrence of atrial fibrillation without risking the 
occurrence of potentially life-threatening, proarrhythmic ventricular side effects. 
Kv1.5 is a voltage-gated potassium channel that has emerged as an extremely 
promising target for such a ventricular-sparing antiarrhythmic therapy.  Kv1.5 mediates 
the ultrarapid delayed rectifier (Ikur) current in human atrial myocytes.  This current is a 
major contributor to atrial repolarization.  The absence of Ikur in ventricular myocytes 
(10) is consistent with the selective expression of Kv1.5 in the atria but not ventricular 
tissue (11,12).  This raises the intriguing possibility that inhibition of Kv1.5 function, and 
therefore repolarization, could serve to selectively lengthen the action potential duration 
in atrial myocytes.  The concomitant prolongation of atrial refractoriness would prevent 
the generation and propagation of extra or disorganized electrical activity in the atria 
while sparing ventricular function.  Very recent work has provided a handful of candidate 
drugs that are able to inhibit Kv1.5 activity with varying degrees of specificity (4,11,13-
16).  Although the exact mechanism of inhibition is largely unknown, these drugs do 
indeed serve to lengthen atrial action potentials and refractoriness without affecting 
ventricular refractoriness, ECG intervals, heart rate, or blood pressure (11,13,14).  While 
very promising, none of these drugs has progressed to clinical use, presumably due to 
unanticipated side effects related to their incomplete specificity for Kv1.5.  Based on 
these developments, it is clear that a better understanding of the basic mechanisms that 
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cells utilize to regulate the functional properties of Kv1.5 are likely to provide novel 
insights and therapeutic opportunities for the treatment of AF. 
At the outset, the overall goal of this dissertation was therefore to explore post-
translational mechanisms that can regulate the activity of Kv1.5.  As a result of these 
efforts, we have identified that Kv1.5 contains two putative target sequences for 
posttranslational modification by members of the Small Ubiquitin-like Modifier (SUMO) 
family of proteins.  I have found that these sequences are functional, and that Kv1.5 is 
reversibly modified by multiple members of the SUMO family.  Furthermore, loss of 
SUMOylation, either by disruption of the conjugation sites or expression of the SUMO-
deconjugating protease SENP2, leads to a selective hyperpolarizing shift in the voltage-
dependence of steady-state inactivation of the channel in a heterologous system without 
affecting other properties of the channel such as total current density or the voltage-
dependence of activation. 
Using whole-cell patch-clamp electrophysiological studies of acutely-dissociated 
murine and human cardiomyocytes, I find that it is possible to acutely modulate the 
voltage-dependence of steady-state inactivation of endogenous Ikur current by loading 
purified recombinant SUMO1 or SENP2 proteins into the pipette solution and allowing 
them to diffuse into the patched cardiomyocyte during the recordings.  Consistent with 
our studies in the heterologous system, diffusion of exogenous SENP2 into 
cardiomyocytes led to a depolarizing shift in the voltage-dependence of steady-state 
inactivation of endogenous Ikur current, while diffusion of exogenous SUMO1 led to a 
hyperpolarizing shift in the voltage-dependence of steady-state inactivation.  These 
effects of SUMO1 and SENP2 were specific, as the current densities of the major 
outward potassium currents Ito and Iss were unaffected by this treatment.  Furthermore, 
the ability of SENP2 to acutely modulate Kv1.5-mediated current was dependent on the 
presence of intact SUMOylation motifs on Kv1.5 as diffusion of SENP2 into patched 
HL-1 atrial myocytes transfected with wild-type Kv1.5 led to a similar hyperpolarizing 
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shift in the voltage-dependence of steady-state inactivation of the channel, but had no 
effect on a SUMOylation-motif-deficient mutant form of Kv1.5. 
In contrast to the studies in heterologous systems, analysis of the effects of 
alterations in SUMOylation in cardiomyocytes revealed that infusion of either SENP2 or 
a dominant-negative form of SUMO1 (SUMO1-∆GG) that cannot be covalently 
conjugated to target proteins led to a reduction in the total Ikur current density.  Since Ikur 
is the major potassium current responsible for regulating the duration of the plateau phase 
of the cardiac action potential (12), I also explored the effect of SUMOylation on the 
action potential duration (APD).  While diffusion of wild-type SUMO1 into acutely-
dissociated murine cardiomyocytes had no significant effect on the action potential 
duration, initial findings suggest that diffusion of SENP2 preparations into 
cardiomyocytes led to a specific prolongation of the plateau phase of the action potential 
and a significant increase in the APD.  Notably, a similar effect was observed for 
SUMO1-∆GG. 
Taken together, these data provide strong evidence that Kv1.5 is indeed post-
translationally modified by SUMO, and that this regulation has important functional 
consequences on both the magnitude and inactivation properties of the Ikur current, and by 
extension, on the duration of cardiomyocyte action potentials.  These findings are 
significant as they identify SUMO modification as a new point of regulation of Kv1.5 
function and thereby potentially add a level of specificity for the development of 
antiarrhythmic medications designed to modulate Ikur current.  The recent development of 
novel Kv1.5-targeted antiarrhythmic medications indicates that the strategy of selectively 
modulating Kv1.5 current is an effective method for achieving ventricular-sparing 
maintained rhythm control in patients with atrial fibrillation.  The discovery that Kv1.5 is 
a target of SUMOylation and that this modification has important and specific regulatory 
roles indicates that manipulation of this control mechanism may open novel opportunities 
for atrial-specific antiarrhythmic therapy. 
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The findings described in this thesis are also significant as they represent, to our 
knowledge, the first report of the SUMO modification of a voltage-gated ion channel and 
one of the first examples of how SUMO modification can regulate the function of a 
protein located on the plasma membrane.  As such, the findings expand the list of known 
functions of SUMOylation and reveal that, in addition to its more established roles in the 
regulation of nuclear proteins, this modification plays important roles at the plasma 
membrane  
In the following three sections of this chapter, I introduce the structure and 
function of Kv channels, describe our current understanding of the function and 
regulation of Kv1.5, and present an overview of the process of SUMOylation and its 
regulation. 
VOLTAGE-GATED POTASSIUM (KV) CHANNELS 
Introduction 
Voltage-gated potassium (Kv) channels form aqueous pores that mediate the 
highly selective and regulated passage of K+ ions across the hydrophobic core of the 
plasma membrane of electrically excitable cells.  The resting membrane potential of 
myocytes is approximately -70 mV, and under these conditions, it has been estimated that 
the probability of opening for a single Kv channel is less than 10-9 (17).  However, upon 
depolarization of the plasma membrane, Kv channels rapidly open to allow for the flow 
of approximately 106-108 ions/second for each channel with over a 100 times more 
selectivity for K+ over Na+ (18,19).  The regulation of this K+ conduction is critical for 
establishing the resting membrane potential and dictating the duration and frequency of 
action potentials in the heart and peripheral vascular beds and is thought to be a function 
of both the number of active channels expressed on a cell’s surface as well as the 
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properties of each channel’s activation and inactivation gates.  Defects that modulate the 
expression and/or gating properties of these important channels are thus linked to a wide 
range of cardiovascular diseases including long Q-T syndrome, chronic atrial fibrillation, 
chronic hypertension, and pulmonary arterial hypertension (20-24). 
Structure 
Kv channels are composed of four α-subunits, each of which contains 500-1000 
amino acids and six transmembrane domains (S1-S6) with both N- and C-terminal 
sequences residing in the cytoplasm (Figure I-1).  Kv channel α-subunits assemble into 
homotetramers in the endoplasmic reticulum through their membrane-spanning domains 
as well as via an N-terminal tetramerization (T1) domain (25). Heterotetrameric 
complexes composed of different α-subunits have unique properties and can be detected 
both in vitro and in vivo (26). Multiple Kv channel gene families (Kv1-Kv9) have been 
identified which encode more than 40 different mammalian α-subunit isoforms.  
Auxiliary cytosolic β-subunits can associate with Kv channel α-subunits and alter both 
membrane expression and channel properties.  Co-assembly between α- and β-subunits 
takes place in the endoplasmic reticulum as an early step in the biosynthetic pathway 
(27,28), and since only specific α /β subunit combinations are permissible, this interaction 
appears to be selective (29,30).  At least four Kv β-subunit gene families have been 
identified, with alternative mRNA splicing in the Kv1 and Kv2 β-families yielding 
additional diversity (31).  X-ray crystallographic data reveals that β-subunits tetramerize 
with four-fold symmetry similar to that of the α-subunits and interact directly with the 
similarly-organized T1 tetramerization domain of the α-subunits (32). 
Structure/function studies have characterized amino acids in Kv α-subunits involved in 
ion selectivity, activation and inactivation gating, and neurotoxin binding (33). The 
determination of the atomic structures of K+ channels from bacteria, as well as the recent 
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determination of the structure of rat Kv1.2 (34), support much of the structure/function 
data derived from multiple studies (35,36).  The S1-S6 segments of each α subunit 
arrange with four-fold symmetry around a central axis that forms the conducting pore of 
the channel (Figure I-1).  S5-S6 are in direct contact with this conducting pore and 
contain the activation and inactivation gates as well as the selectivity filter, while S1-S4 
are arranged around the perimeter of the channel and contain the voltage-sensor. 
Voltage-Dependence and Gating 
Based on the crystal structures of bacterial potassium channels trapped in the 
closed conformation (KcsA and KirBac1.1) and open conformation (MthK and KvAP), it 
has become apparent that the activation gate is contained on S6 (36-39).  In the closed 
conformation, the S6 segments from each α subunit form a bundle crossing at the plasma 
membrane/cytoplasm interface that occludes access of K+ (or quaternary ammonium ions 
such as the classic internal Kv channel blocker tetraethyl ammonium (TEA+)), to a large, 
almost 10Å-wide, aqueous inner cavity of the channel (18).  Upon activation, the S6 
helices bend at a well-conserved “PxP” motif (where P stands for proline and x any 
amino acid), and this inner cavity becomes accessible to the cytoplasm (40).  
“Deactivation,” which is distinct from “inactivation” (discussed below) is the re-closing 
of this activation gate. 
The selectivity filter of the channel is located along the extracellular third of the 
conduction pore and is composed of the so-called TXGYG “signature sequence” in the 
S5/S6 loop of Kv channels (41,42).  By lining the conduction pore with the backbone 
carbonyl oxygen atoms of the residues in this sequence spaced by the geometrical 
constraints of the glycine and threonine residues, the selectivity filter is able to provide 
four octahedral binding sites that are able to coordinate K+ ions with almost the exact 























Figure I-1. The Structure of Kv Channels 
(A) A schematic representation of a single Kv channel α subunit.  (B) Structural 
model of a Kv channel α subunit using the coordinates of Kv1.2 (34) color coded as in A. 
(C) Extracellular view of tetramerized channel color coded as in A. A potassium ion is 
shown in purple. (D) Side view of fully assemble channel as in C. Adapted from (19). 
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cavity of the channel (36,41).  Thus, the selectivity filter is able to effectively dehydrate 
K+ ions from the inner cavity and allow these ions to pass through the filter and on to the 
extracellular side of the channel where the K+ is again re-hydrated.  Due to the size 
constraints of the octahedral binding sites, however, the filter is unable to effectively 
dehydrate the smaller Na+ ions also present in the inner cavity. 
The ability of Kv channels to sense changes in transmembrane potential is thought 
to be primarily due to the location of four, key arginine residues located on the S4 
transmembrane helix (43).  The positively-charged guanidinium groups of these arginines 
provide a “gating charge” that, due to their location within the membrane, respond to 
changes in the local transmembrane electrical field and lead to the displacement of the S4 
helix (44).  The exact nature of the movement of the S4 helix upon this displacement is 
heavily debated with helix motion ranges between 2 and 20 Å.  Based on the crystal 
structure of Kv1.2 and scanning mutagenesis studies, there is general agreement, 
however, that this movement is transmitted to the S5/S6 pore-forming region of the 
neighboring α subunit via direct contact with the linker that connects the displaced S4 to 
S5 (19). 
As mentioned above, the current through Kv channels is regulated by the 
collective effects of two gates: the activation and inactivation gates.  Upon membrane 
depolarization, Kv channels rapidly transition from a closed, non-conducting 
conformation to an open conformation via a change in the S6 transmembrane segment as 
already described.  If the membrane is repolarized, conduction through the channel stops 
due to the re-closing of this gate through the process of “deactivation.”  However, for 
many Kv channels, if the membrane continues to be depolarized, channels enter a stable, 
non-conducting state in a process referred to as “inactivation.”  That is to say, upon 
sustained depolarization, channels activate to produce an outward potassium current.  
Over time, this current begins to decay due to the transition of channels from open to 
inactivated states.  The kinetics of this decay can vary widely between channels and can 
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be critical to the function of the channel.  For example, while both Kv1.5 and Kv4.2 
activate during the initial depolarization phase of the cardiac action potential, the very 
fast inactivation of Kv4.2 limits its effects to early (notch) repolarization, while the slow 
inactivation of Kv1.5 allows its effects to be distributed through the entire plateau phase 
of repolarization. 
Two major mechanisms of inactivation have been described in Kv channels.  The 
first, or “N-type inactivation,” has rapid kinetics (on the order of tens of milliseconds).  
This process is dependent on a region of the channel consisting of ~10 hydrophobic 
residues followed by a series of positively-charged amino acids.  This “inactivating 
peptide” is contributed by the extreme N-terminus of a subset of Kv channel α subunits or 
by specific accessory β subunits (45,46).  Upon activation of the channel, these residues 
enter the conducting pore leading to direct occlusion of the conduction path.  It is 
hypothesized that the hydrophobic residues directly interact with hydrophobic residues in 
the pore of the channel.  The positively-charged residues are thought to interact with 
acidic residues located on the S1/T1 linker and position the inactivating peptide in a 
location that facilitates its entry into the pore (47-49).  N-type inactivation is not directly 
voltage-sensitive, depending instead only on whether the channel is open or closed (50).  
This “ball and chain” model of inactivation was originally described for the squid axon 
sodium channel (51), but is present in Kv channels that contain such an N-terminal “ball” 
(Shaker, Kv1.4, Kv3.4, and Kv4 family members) and Kv channels that associate with 
cytoplasmic accessory subunits that contain a “ball” (Kvβ1.1 and Kvβ1.3)(45,46). 
Interestingly, N-type inactivation has been found to be highly regulated by certain 
forms of posttranslational modification.  Protein kinase C phosphorylation of the N-
terminus of Kv3.4 (52,53), protein kinase A phosphorylation of the N-terminus of 
Kvβ1.3 (54), and Src tyrosine kinase phosphorylation of the N-terminus of Shaker (55) 
have all been found to have inhibitory effects on N-type inactivation.  The current view is 
that the addition of negative charge to the “ball” interrupts the stabilizing interactions 
 10
with the acidic residues in the S1/T1 linker (45).  Consistent with this idea, PKA 
phosphorylation of the C-terminus of Shaker (which is located near the S1/T1 linker (see 
the crystal structure of Kv1.2 in Figure I-1)) and protonation of an N-terminal histidine in 
Kv1.4 both stimulate N-type inactivation (56,57).  Presumably, both of these 
modifications could serve to stabilize the interaction between the basic N-terminal “ball” 
and the acidic S1/T1 linker. 
The second major type of inactivation is called “C-type” inactivation and follows 
much slower kinetics than that of N-type with time constants in the range of 102-103 
milliseconds (45).  While C-type and N-type inactivation can exist simultaneously in 
some Kv channels, C-type inactivation persists after the deletion of the N-terminal “ball” 
in channels with N-type inactivation (58).  C-type inactivation is thought to be due to 
local conformational changes in the selectivity filter and outer pore of the channel.  
Studies based on the accessibility of engineered cysteine residues around the outer pore 
of the channel to thiol-reactive reagents (59) or on the fluorescence properties of 
cysteine-reactive dyes targeted to such cysteines (60-62), have demonstrated that upon 
sustained depolarization, the four α-subunits in this outer region undergo a localized 
conformational rearrangement that partially collapses the conducting pore across the 
selectivity filter.  The rearrangement of the selectivity filter during C-type inactivation is 
also manifested as a drop in the specificity of Kv channels for K+ over Na+ during C-type 
inactivation.  Thus, when K+ is replaced by Na+ in the recording solution, small Na+ 
currents can be detected in Kv channels that have undergone C-type inactivation (63).  
High extracellular K+ or TEA+ concentrations inhibit C-type inactivation by a so-called 
“foot in the door” mechanism.  These ions are able to bind the extracellular pore of the 
channel and prevent this conformational change (46). 
In contrast to studies of N-type inactivation, fewer studies describe modulation of 
C-type inactivation by forms of posttranslational modification.  One exception to this is 
the finding that the epidermal growth factor receptor (EGFr)-linked tyrosine kinase 
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phosphorylation of Kv1.3 significantly increases the rate of C-type inactivation (64).  
However, the mechanism by which this occurs is still poorly understood and may not be 
due to direct phosphorylation of Kv1.3, as mutation of tyrosine residues within consensus 
sequences for tyrosine kinases did not interrupt the effect of EGFr on Kv1.3 inactivation 
(45). 
In contrast to N-type inactivation, C-type inactivation is voltage-dependent.  
However, the mechanism of coupling to the S4 voltage sensor is not as well understood 
as in the case of activation.  The development and recovery from inactivation are 
sensitive to the transmembrane potential during times of sustained depolarization 
(58,65,66).  This voltage dependence, however, is limited to a narrow range of potentials 
(46).  For most Kv channels, the time constant of inactivation is sensitive to voltage only 
at potentials where the channel is partially activated (46).  This has led to the speculation 
that movement of the S4 activation sensor may be a required first step to drive the 
channel into a state where the conformational changes associated with C-type 
inactivation are then possible.  The conformational changes of C-type inactivation may 
not, by themselves, be intrinsically voltage-dependent, but may only be enabled after the 
voltage-dependent movement of the S4 sensor (46). 
In whole-cell patch-clamp studies, the steady-state voltage-dependence of 
inactivation can be measured by using a two-pulse protocol.  First, a prolonged 
depolarizing pulse is used to drive channels into a steady-state between the open and 
inactivated states.  This inactivating pulse is then immediately followed by a fast, 
strongly depolarizing “test pulse” to sample the number of channels that remain in the 
open, conducting conformation.  The relationship between the potential of the 
inactivating pulse and the number of channels that occupy the inactivated state at steady 
state represents the voltage-dependence of steady-state inactivation and can be described 
by the Boltzmann equation.  Importantly, mutations on the S4 of Kv1.4 that affect the 
gating charge of the voltage sensor have been found to shift the voltage-dependence of 
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steady-state inactivation, suggesting that the process is coupled to the movement of the 
S4 sensor, as well (65).  Despite the imprecise understanding of the atomic basis for the 
voltage-sensitivity of C-type inactivation, it is clear that this process is a major 
mechanism of regulation central to the physiological role of Kv channels. 
Surface expression, heterotetramerization, co-assembly with accessory subunits, 
posttranslational modifications, sensitivity to drugs, the kinetics of activation and 
inactivation, and the voltage-dependence of activation and inactivation are thus all critical 
parameters to defining a Kv channel, and differences in these parameters allow Kv 
channels to play important roles in a remarkably diverse array of physiological contexts.  
During my thesis, I have focused on the study of the effects of SUMOylation on the 
Shaker-family-related Kv channel Kv1.5 (Figure I-2).  In the following two sections, I 
cover the salient properties of Kv1.5 and subsequently describe the process of 
SUMOylation. 
KV1.5, A CARDIOVASCULAR POTASSIUM CHANNEL 
Cloning and Characterization 
Kv1.5 is an approximately 600 amino acid Kv channel α subunit that was 
simultaneously cloned by many laboratories using homology screening with Drosophila 
Shaker cDNA from rat heart (originally named “RK4”) (67), rat brain (“Kv1”) (68), a 
human ventricular library (“HK2”) (69), and a human insulinoma cell line (“hPCN1”) 
(70).  Northern blot analysis revealed that, in rat, Kv1.5 was expressed in the heart, aorta, 
and skeletal muscle, but was absent from the liver and only weakly expressed in the brain 
(67).  While mRNA expression in the ventricle and atrium was found to be comparable in 
the rat, Northern blot analysis of human tissue revealed that Kv1.5 mRNA was vastly 

























Figure I-2.  Phylogenetic Tree of Six Transmembrane Voltage K+ Channels 
Adapted from Coetzee et al. (1999) Ann NY Acad Sci 868, 233-85.  
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Cloned hPCN1 expressed in Xenopus laevis oocytes demonstrated that Kv1.5 
encoded a rapidly activating (time constant of activation was 8.33 milliseconds at 0 mV), 
slowly inactivating (time constant of inactivation was 1155 milliseconds at 30 mV), K+ 
selective, rectifying, outward current (70).  This current was found to be sensitive to 4-
AP in a use-dependent manner and insensitive to TEA+.  The threshold for activation was 
-25mV (with a V50 of activation of -6.0 mV), and the steady-state inactivation became 
apparent at voltages above -50mV (with a V50 of steady-state inactivation of -25 
mV)(70).  Similar properties were determined in Ltk- cells stably expressing HK2 (71) 
with the added findings that Kv1.5-mediated currents were sensitive to the antiarrhythmic 
quinidine in a state-dependent manner, as well as to the neurotoxin dendrotoxin.  As 
Kv1.5 lacks an N-type inactivation peptide sequence on its N-terminus, it does not 
display N-type rapid inactivation in either oocytes or Ltk- cells.  However, coexpression 
of Kv1.5 with Kv 1.1 or Kv 1.3, both of which contain N-type inactivation peptides, can 
confer N-type rapid inactivation to Kv1.5. 
Kv1.5 Mediates the Ikur Current in Cardiomyocytes 
Since Kv1.5 is abundantly expressed in the heart and is inhibited by the clinically-
prescribed antiarrhythmic quinidine, it was suggested that Kv1.5 may play a part in 
shaping the cardiac action potential.   To determine if a cloned channel mediates a 
specific current in a cardiac cell, it has been proposed that a certain set of criteria be met 
(72,73).  These criteria are as follows: 
 
1) The basic biophysical properties (kinetics and their voltage-dependence, 
conductance, rectification, ion selectivity) should be in reasonable 
agreement. 
2) The pharmacology of compounds known to interact directly with the 
channel pore should be similar. 
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3) Immunohistochemistry with isoforms-specific antibodies made against 
the cloned subunits should confirm that the channel protein is present in 
the cardiac myocytes. 
4) Affinity-purification from native tissue should confirm the protein 
composition of the native channel in terms of accessory subunits and 
heterotetramer formation. 
5) Deletion of the cloned channel using in vitro antisense approaches or in 
vivo suppression should further confirm the identity of the current that 
this gene supports. 
 
The cardiac action potential is mediated by the coordinated effects of Na+, K+, Cl-, 
and Ca2+ channels (Figure I-3).  Upon the initial Phase 0 depolarization mediated by 
rapid inward Na+ current, fast-activating Kv channels mediate an initial early 
repolarization (the Phase 1 “notch”).  The following plateau phase (Phase 2) is mediated 
by the balanced outward repolarizing currents of Kv channels and depolarizing, inward 
currents of Ca2+ and Na+.  The balance of these opposing currents, as well as the extent of 
the initial Phase 1 repolarization dictate the duration of the action potential and are thus 
critical to dictating the contraction properties of the cell as well as the frequency of the 
action potentials. 
Using different pulse protocols and pharmacological methods in whole-cell 
voltage-clamp studies of acutely dissociated myocytes from both mice (74) and humans 
(12), three distinct K+ currents have been identified and correlated to the cardiac action 
potential.  These are the Ito current, which is a rapidly-activating (<2 ms), fast inactivating 
(time constant of inactivation is 20-35 milliseconds at +30 mV), 4-AP insensitive current 
that mediates the initial Phase 1 early repolarization of action potential.  This current is 
thought to be mediated by Kv4 family members.  Ikur (or “Isus” as described by Wang, et 
al (12)) is a rapidly-activating, delayed rectifier, K+ current that is sensitive to 

























Figure I-3. The Underlying Na+, K+, Ca2+, and Cl- Currents of the Cardiac Action 
Potential 
Adapted from Snyders D. (1999) Cardiovasc Res. 42, 377-90. 
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mediated by Kv1.5.  Inhibition of this current by 4-AP causes a selective lengthening of 
the Phase 2 plateau of the cardiac action potential.  Finally, Iss is a 4-AP insensitive, slow 
activating, non-inactivating K+ current that is thought to be mediated by Kv2.1 and/or 
HERG (73).  These channels are important in Phase 3, late-stage repolarization. 
Careful characterization of the biophysical and pharmacological properties of Ikur 
seems to fulfill criteria 1 and 2 as listed above for assigning Kv1.5 to the Ikur current.  In 
human atrial myocytes (12), Ikur (or “Isus”) activates very rapidly (time constant of 
activation is 2.1 ms at +50 mV), has a threshold for activation near -30 mV, and has a 
steady-state half activation of -4.3 mV.  Ikur inactivates very slowly (the rate of 
inactivation was not reported) with a steady-state half inactivation of -48.3 mV in mouse 
myocytes (74).  Ikur was found to be highly sensitive to 4-AP (IC50 of 49 micromolar) and 
open-channel block by quinidine (IC50 of 6 micromolar), but insensitive to TEA+, Ba2+, 
and dendrotoxin.  These biophysical and pharmacological properties are very similar to 
those described for cloned Kv1.5 in oocytes and Ltk- cells, as described above. 
Toward filling criteria 3 listed above for assigning Kv1.5 as the molecular 
correlate to Ikur current, Mays et al. (75) successfully used two antibodies directed against 
the N-terminus and S1/S2 extracellular loop of Kv1.5 to determine that Kv1.5 protein is 
expressed in human atrial and ventricular myocytes.  Furthermore, using 
immunocytochemistry studies, they were able to localize Kv1.5 to the intercalated disks 
of these myocytes.  Interestingly, these immunofluorescent data are in contrast to 
northern blot data that suggest that Kv1.5 mRNA is preferentially expressed in atrial 
myocytes over ventricular myocytes in humans.  Mays et al. suggest that careful 
quantitation of expression levels by Western blotting might help to determine exactly 
what the difference of Kv1.5 protein expression might be between atrial and ventricular 
myocytes in humans, but report that they were unable to successfully conduct these 
studies.  At any rate, this finding that Kv1.5 protein is present in cardiomyocytes satisfies 
criteria 3 for assigning Kv1.5 to Ikur current. 
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Finally, studies in which cultured human atrial myocytes were incubated in 
medium containing antisense oligodeoxynucleotides directed against segments of the 
Kv1.5 mRNA coding sequence, determined Ikur current to be specifically and 
significantly reduced by approximately 50%, while Ito and Iss currents were left 
unaffected (76).  Furthermore, Ito and Iss were unaffected in ventricular myocytes that 
were exposed to similar Kv1.5 antisense oligodeoxynucleotides.  Similarly, studies that 
used gene targeting to replace Kv1.5 with 4-AP-insenstive Kv1.1 in transgenic mice, 
determined that the 4-AP sensitive component of ventricular myocyte outward potassium 
current was specifically dependent on Kv1.5 expression, and that Kv1.5 replacement had 
no effect on either the Ito or Iss currents (77).  Finally, electrophysiological studies of right 
atrial appendages taken during coronary artery bypass graft surgery from patients with 
chronic atrial fibrillation found a significant reduction in the magnitude of Ikur in these 
patients that was concomitant with a reduction in Kv1.5 protein expression (20).  This 
effect was specific, as protein levels of Kv2.1 were found to be unaffected.  These 
findings satisfy criteria 5 as listed above for assigning Kv1.5 to Ikur current. 
Taken together, the similarities in the biophysical and pharmacological properties 
of Kv1.5 and Ikur, the determination that Kv1.5 is expressed in human atrial myocytes, 
and the finding that the elimination of the Kv1.5 channel can knock down Ikur current in 
atrial myocytes, provide strong evidence that Kv1.5 mediates the Ikur repolarizing current 
critical to action potential phase 2 plateau repolarization in human atrial myocytes. 
Defects in Kv1.5 Are Associated with Cardiovascular Disease 
Due to its important role in action potential repolarization, it is not surprising that 
defects in Kv1.5 are associated with the life-threatening arrhythmia chronic atrial 
fibrillation (20).  Chronic atrial fibrillation is the most common chronic arrhythmia in 
patients over the age of 60 and is important clinically because of its associated morbidity 
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and increased risk of mortality (1.5-1.9-fold risk in the Framingham study) (1,2).  
Electrical remodeling in chronic and paroxysmal atrial fibrillation involves changes in 
Kv1.5 expression.  Study of right atrial appendages taken during coronary artery bypass 
surgery from patients suffering from persistent or paroxysmal atrial fibrillation 
determined that while the mRNA levels of Kv1.5 were unaffected compared to control 
groups, Kv1.5 protein expression was significantly decreased in these groups (78).  In a 
similar study (20), whole-cell patch clamp study of acutely dissociated atrial myocytes 
taken from the right atrial appendage of patients in chronic atrial fibrillation revealed that 
this observed reduction of Kv1.5 protein expression was paralleled by a dramatic 
decrease in Ikur current as compared to patients in sinus rhythm.  This effect was specific, 
as levels of Kv2.1 were unaffected between the two groups. 
Recently, genomic DNA screening of a patient diagnosed with lone atrial 
fibrillation refractory to treatment with flecainide (which is a class Ic antiarrhythmic that 
blocks both Na+ and K+ channels) and dofetilide (which is a new-generation class III 
antiarrhythmic that specifically blocks K+ channels with no associated Na+ channel 
blocking activity) revealed a heterozygous nonsense mutation in Kv1.5 (E375X) that 
resulted in a non-functional truncation mutant of the channel (79).  This mutation was 
also identified in the proband’s two siblings, both of whom suffered from either atrial 
fibrillation or paroxysmal atrial fibrillation, and was absent in the screening of 540 
unrelated, healthy controls.  The E375X mutation truncated Kv1.5 immediately after the 
S3 region of the channel, resulting in a non-conducting mutant that was still expressed 
and, presumably through successful tetramerization with WT channel mediated through 
its intact N-terminal TI tetramerization domain, exerted a dominant-negative effect on 
WT Kv1.5 current. 
Together, these findings establish a strong association between defects in Kv1.5 
function and atrial fibrillation.  In addition to its important role in cardiac myocytes, 
Kv1.5 also plays a central role in excitation-contraction coupling in the smooth muscle 
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cells of a wide number of vascular beds including the aorta, portal vein, cerebral arteries, 
mesenteric artery, and the coronary, renal, and pulmonary vasculature (80-87).  When Kv 
channels are activated in these cells, the concomitant increase in K+ efflux causes 
voltage-activated calcium channels to open, leading to a decrease in intracellular calcium 
and vasodilation.  By this mechanism, Kv1.5-mediated current is critical to regulating 
vascular tone and blood vessel diameter.  Furthermore, because of the high electrical 
input resistance of smooth muscle cells, the opening or closing of only a few Kv channels 
leads to large changes in the contractile state of the vessels (88).  Defects in Kv1.5 can 
lead to decreased Kv-mediated currents in pulmonary arterial smooth muscle cells and 
are associated with chronic hypoxic pulmonary arterial hypertension (PAH) (89), a 
clinically serious condition due to its increased risk for life threatening right ventricular 
failure.  Kv1.5 has been shown to participate in oxygen-sensitive channel complexes 
(86,87), and thus abnormalities in Kv1.5 and its associated role in excitation-contraction 
coupling in pulmonary arterial smooth muscle cells is thought to be an important 
predisposing factor that leads to PAH (90). 
Regulation of Kv1.5 
Because defects in Kv1.5 expression levels and function can have such significant 
physiological and pathophysiological consequences, there has been substantial interest in 
understanding the factors that regulate Kv1.5.  Recent studies have begun to identify 
regulatory mechanisms throughout the lifecycle of the channel—from its transcription, to 
its trafficking, to its insertion and removal from the plasma membrane.  I have outlined 
the major points of Kv1.5 regulation that have been identified below.  I will briefly 
describe these points and then focus on what is known about the posttranslational 
modification of Kv1.5, as this has been the focus of my work.   
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Regulation during development. 
Kv1.5 mRNA is first detected in rat ventricular myocytes at approximately 
postnatal day 15 (91).  This correlates with whole cell patch clamp studies that detected 
no Ikur current in developing mouse ventricular myocytes until about postnatal day 20, at 
which point there was approximately 10% of the Ikur current density present in adult 
ventricular myocytes (92).  Kv1.5 protein expression does not seem to follow this pattern, 
however.  In the same study that followed mRNA levels of Kv1.5, protein levels of 
Kv1.5 in rat ventricular myocytes were detected at postnatal day 5 and remained 
unchanged through adulthood.  The authors speculate that this may suggest a role for the 
post-transcriptional regulation of Kv1.5. 
Transcriptional control 
A number of studies have begun to identify roles for the glucocorticoid receptor 
(GR), thyroid hormone receptor (TR) , transcription factor Sp1, and CREB/ATF nuclear 
DNA-binding proteins CREB and CREM in regulating Kv1.5 expression on the 
transcriptional level.  Reduction of endogenous glucocorticoids in adrenalectomized rats 
resulted in a ~8-fold reduction in Kv1.5 mRNA and a ~6-fold reduction in Kv1.5 protein 
in ventricular myocytes compared to that of WT rats (93).  Furthermore, injection of 
dexamethasone (a glucocorticoid receptor agonist) rescued this loss, and in fact led a 
~50-fold increase in Kv1.5 mRNA levels and ~20-fold increase in Kv1.5 protein levels 
within one day of administration.  This regulation by dexamethasone was specific for 
Kv1.5, as mRNA and protein levels of Kv1.4 and Kv2.1 were unaffected by this 
treatment.  Interestingly, as well, this regulation by the GR appeared to be extremely 
tissue specific, as neither the adrenalectomy nor the administration of dexamethasone 
affected mRNA or protein levels of Kv1.5 in atrial myocytes.  Similarly, Kv1.5 mRNA 
levels were found to be modulated by TR as Kv1.5 mRNA levels were decreased in 
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hypothyroid rats, whereas Kv1.5 mRNA levels were greatly increased in hyperthyroid 
rats (94). 
Investigation of the 5’ flanking region of the Kv1.5 gene has revealed both a 
cAMP response element (CRE) consensus sequence and Sp1 transcription factor binding 
motif (95,96).  These binding motifs are functional as cAMP was found to induce a 6-
fold increase in Kv1.5 mRNA expression in primary neonatal rat atrial myocytes, and 
reporter constructs driven by the Kv1.5 5’ flanking regions were found to bind CRE-
binding protein (CREB) and CRE modulator protein (CREM)(96).  Furthermore, 
inhibition of Sp1 using a dominant-negative form of Sp1, decreased Kv1.5 promoter 
activity (as measured using a reporter construct under the control of the Kv1.5 5’ flanking 
region), while Sp1 over-expression increased promoter activity (95). 
Assembly and Trafficking 
As already mentioned, Kv1.5 is assembled into tetramers concurrent with 
synthesis in the endoplasmic reticulum and then trafficked to the Golgi via a “VXXSN” 
forward trafficking signal located on the C-terminus of the channel (97).  For many Kv 
channels, this ER-to-Golgi transport has been found to be dependent on interactions with 
accessory proteins such as the β-subunits, the K+ channel associated protein KChAP, and 
the K+ channel interacting protein KChIP (98).  Consistent with a chaperone-like role of 
KChAP for ER-to-Golgi trafficking of Kv1.5, KChAP has been shown to interact with 
the N-terminus of Kv1.5, but this interaction does not affect the properties of Kv1.5 
currents (99).  Importantly, these interactions with chaperone proteins are not necessary 
for Kv1.5 trafficking to the plasma membrane since the absence of either β-subunits or 
KChAP does not affect Kv1.5 current density.  As will be discussed later in this 
introduction, KChAP has also been identified as a member of the SUMO E3 ligase 
family (100).  This raises the interesting possibility these effects of KChAP on Kv 
channels could be, in part, due to modulation of the SUMO state of Kv channels.   
 23
Insertion into the Plasma Membrane 
The trafficking of Kv1.5 from the Golgi to the plasma membrane has recently 
been shown to provide another opportunity for regulation.  It has been shown that Kv1.5, 
but importantly not other closely-related Kv channel members such as Kv2.1, is targeted 
to specific plasma membrane microdomains such as caveolar-lipid rafts (101).  Depletion 
of cellular cholesterol and sphingolipids located in these lipid rafts leads to a 
hyperpolarizing shift in the voltage-dependence of activation and inactivation of Kv1.5, 
while not effecting non-raft-associated Kv channels such as Kv4.2, providing strong 
evidence that localization to these rafts has important consequences on the biophysical 
properties of the channel (101). 
Targeting of Kv1.5 to these lipid rafts is contingent on interactions with 
trafficking proteins such as caveolin (102).  In a caveolin-null cell line, Kv1.5 did not 
associate with membrane lipid rafts.  However, transfection of caveolin-1 back into these 
cells rescued the association of Kv1.5 with these rafts.  Similarly, expression of a 
caveolin-deletion mutant that has reduced ability to traffic to the plasma membrane led to 
the accumulation of intracellular Kv1.5 and a loss in plasma membrane expression.  
Consistent with the findings described above that disruption of lipid raft cholesterol and 
sphingolipids leads a hyperpolarizing shift in the voltage dependence of activation and 
inactivation of Kv1.5, expression of caveolin-1 led to a depolarization shift in the 
voltage-dependence of Kv1.5 activation and inactivation (102). 
Membrane-Associated Scaffolding Complexes 
The idea that Kv1.5 organizes into specific microdomains of the plasma 
membrane, allowing for local interactions to help regulate the activity of the channel, is 
supported by the finding that Kv1.5 interacts with the PDZ domain-containing proteins 
SAP97 and PSD95 (103).  SAP97 is a membrane-associated guanylate kinase (MAGUK) 
that is localized in lipid rafts and directly interacts with caveolin-3 .  Interestingly, SAP97 
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and caveolin-3 have both been shown to interact directly with the C- and N-termini of 
Kv1.5, respectively, and all three proteins have been shown to form a tripartite complex 
(103).  The fact that MAGUKs contain numerous protein interaction motifs (in addition 
to PDZ domains, they also contain the Src homology-3 (SH3) and guanylate kinase 
(GUK)-like domains) has prompted the speculation that the interaction between SAP97, 
caveolin-3, and Kv1.5 may serve as a nucleation site for the assembly of larger, 
macromolecular, regulatory complexes around the channel (103).  SAP97 and caveolin-3 
have both been shown to have important regulatory functions on the current density and 
voltage-dependence of activation of Kv1.5 in a heterologous system (103,104).  
Similarly, PSD95, which binds Kv1.5 via the T1 tetramerization domain of the channel, 
has been found to mediate the clustering of both the NMDA receptor and Kv1.4 to 
specific plasma membrane microdomains in neurons (104).  
Interactions with Other Signaling Pathways 
Activation of the receptors for platelet-derived growth factor (PDGF), fibroblast 
growth factor (FGF), human thrombin, or rat 5-HT1c (serotonin) leads to a reduction in 
Kv1.5 current density in Xenopus oocytes with a t1/2 of approximately 20 minutes (105).  
Because the downstream signaling pathways of each of these receptors involves the 
upregulation of phospholipase C (PLC) activity, it has been hypothesized that this effect 
on Kv1.5 current is mediated by PLC (105).  In support of this idea, a mutation that 
specifically prevents the FGF receptor from being able to activate PLC ablates this effect 
on Kv1.5, and simultaneous injection of IP3 and superfusion with a DAG analog (IP3 and 
DAG are the products of PLC hydrolysis of PIP2)  reproduces the effect.  Interestingly, in 
addition to the production of IP3 and DAG, depletion of PIP2 via PLC activity has been 
suggested to play a role in the regulation of other ion channels, including KCNQ 
channels. 
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The alpha and beta adrenergic G protein-coupled receptors have also been shown 
to modulate Ikur current in both human (106) and canine (107) atrial myocytes.  
Activation of beta-receptors (via isoproterenol) was found to increase Ikur current, while 
activation of alpha-receptors (via phenylephrine given in the presence of propralol to 
block beta-receptors) decreased Ikur current in human atrial myocytes.  These effects were 
inhibited by blocking the activities of protein kinase C (PKC) and protein kinase A 
(PKA), which are downstream effectors of the alpha- and beta-adrenergic receptors, 
respectively.  As Kv1.5 contains numerous consensus sites for phosphorylation by both 
PKA and PKC, it has been speculated that this adrenergic modulation may be mediated 
via posttranslational modification of the channel (106), although, as described below, this 
has not yet been directly demonstrated. 
Endocytosis and Recycling 
Work that I was involved with in the Martens laboratory (I helped generate an 
extracellular-tagged Kv1.5 that contains GFP inserted into first S1/S2 extracellular loop 
of the channel) has identified that endoyctosis also plays a critical regulatory role in 
Kv1.5 function (108).  Kv1.5 internalizes in a dynein-dependent manner to perinuclear 
endosomal compartments.  At 37 °C during basal conditions, this internalization occurs 
with a t1/2 of approximately 11 minutes and results in a reduction of surface-expressed 
channel.  Furthermore, a population of internalized Kv1.5 is recycled back to the plasma 
membrane in a Rab4- and Rab11-GTPase-dependent manner.  This defines an important 
role for internalization and recycling in the regulation of steady-state levels of surface-
expressed Kv1.5, and identifies trafficking proteins such as the Rab-GTPases as potential 
points of regulation of Kv1.5 current. 
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Posttranslational Regulation 
As previously mentioned, although the notion that posttranslational modification 
may play an important role in regulation of Kv1.5 function was noted when the channel 
was first cloned and sequence analysis revealed the presence of putative PKC and PKA 
phosphorylation sites, as well as a glycosylation site (70), sources of posttranslational 
modification of Kv1.5 are just beginning to emerge. 
Kv1.5 has not directly been demonstrated to be phosphorylated by PKA or PKC, 
however PKA and PKC-mediated phosphorylation of Kvβ accessory subunits has been 
shown to effect Kv1.5  / -subunit interactions and Kv -mediated inactivation properties 
(54,109).  Activation of PKA led to a reduction in Kvβ1.3-induced inactivation of Kv1.5 
that was dependent on a PKA phosphorylation site located on the N-terminus of Kvβ1.3.  
Similarly, inhibition of PKC prevented Kvβ1.2 or Kvβ1.3 from conferring N-type 
inactivation properties to Kv1.5, or from shifting the voltage-dependence of activation of 
Kv1.5 (54). 
Kv1.5 has been shown to be directly phosphorylated by Src tyrosine kinase, and 
this phosphorylation dramatically inhibited Kv1.5 current density (110).  Src tyrosine 
kinase was shown to bind to Kv1.5 via two, repeated Src homology 3 (SH3) domains on 
the N-terminus of Kv1.5, and this association resulted in the phosphorylation of the 
channel.  Furthermore, co-expression of Src tyrosine kinase almost completely inhibited 
total outward current of Kv1.5 in transfected HEK-293 cells. 
In addition to phosphorylation, Kv1.5 currents are posttranslationally modified by 
N-linked glycosylation (103) and S-acylation (111).  Mutation of serine 292 in human 
Kv1.5 results in a loss of channel glycosylation along with a depolarizing shift in the 
voltage-dependence of activation and reduction in current density of Kv1.5 (103).  These 
findings support the hypothesis that glycosylation in the Golgi regulates successful 
expression of Kv1.5 on the plasma membrane.  S-acylation involves the posttranslational, 
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reversible linkage of fatty acids to target proteins via a thioester bond.  Kv1.5 contains 
numerous intracellular cysteine residues and has been found to be S-acylated on both its 
N- and C-termini.  Pharmacological inhibition of this modification resulted in 
intracellular accumulation of Kv1.5 and targeting of the channel for proteasomal 
degradation, along with a dramatic reduction in total Kv1.5 current density.  From pulse-
chase experiments, this S-acylation was found to take place early in the biosynthetic 
pathway before the channel was glycosylated.  These findings present the possibility that 
S-acylation may play an important role in regulating the trafficking of only properly-
assembled Kv1.5 to the plasma membrane (111). 
Together, the above findings demonstrate that Kv1.5 current is carefully regulated 
throughout the lifecycle of the channel, and that modulation of these regulatory 
mechanisms can have important functional consequences on Kv1.5-mediated currents.  
Thus, these points of regulation offer potential targets for pharmacological control of 
Kv1.5.  As introduced above in the Overview and as detailed in Chapter II, we have 
identified that a number of Kv channels, including Kv1.5, contain evolutionarily 
conserved, canonical receptor sites for posttranslational modification by Small Ubiquitin-
like Modifier (SUMO) proteins.  Based on sequence analysis and reports that the Kv1.5-
interacting protein KChAP belongs to the PIAS family of SUMO E3 ligases (100), we 
suspected that these canonical motifs were functional, and that posttranslational 
modification by SUMO may offer a previously unrecognized source of Kv1.5 regulation.  
In the following section, I will thus introduce some fundamental aspects of post-





Small Ubiquitin-like Modifier (SUMO) proteins are approximately 11 kDa 
proteins that share a similar structural fold and enzymological pathway of conjugation to 
that of ubiquitin (112-115).  Although posttranslational modification of target proteins by 
SUMO was only recently discovered in 1996 (116,117), it has rapidly been found to be 
an essential process in S. cerevisiae (118), C. elegans (119), Arabidopsis thaliana (120), 
and mice (121) and has served as the founding class of a growing group of ubiquitin-like 
(Ubl) proteins including Nedd8, Apg12, Hub1, FAT10, and ISG15 (122).  The amino 
acid sequence, surface charge distribution, and functions of SUMO are distinct from 
those of ubiquitin and other Ubl proteins, however, and represent a unique and 
widespread form of posttranslational regulation. 
Four members of the SUMO family (SUMO-1-4) have been identified in humans.  
While SUMO-1-3 are ubiquitously expressed, SUMO-4 is limited mainly to the kidney, 
lymph nodes, and spleen (123).  All four SUMO members are initially expressed in an 
immature pro-form that cannot be conjugated to target proteins.  SUMO-specific 
proteases, which are discussed below, cleave a 2-11 amino acid sequence on the extreme 
C-terminus of this pro-form to expose a di-glycine motif that is necessary for 
conjugation.  Interestingly, it appears that SUMO-4 may be unable to be processed to its 
mature, conjugation-competent form, instead persisting in its pro-form (124).  The 
functional significance of SUMO-4 thus remains to be understood.   
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Conjugation Pathway 
Preparation of SUMO for modification of proteins involves two steps carried out 
by specific E1 activating (SAE1/SAE2) (125) and E2 transfer (UBC9) (126) enzymes.  
Although analogous to ubiquitin E1 and E2s, SAE1/SAE2 and UBC9 are SUMO-
specific, and there is no functional overlap with the ubiquitin conjugation pathway.  After 
processing, SAE1/SAE2 adenylates the C-terminal glycine of SUMO in an ATP-
dependent manner, which can then be linked to a catalytic cysteine residue on SAE2 via a 
high-energy thioester bond.  The SAE2-loaded SUMO is then transferred to the catalytic 
cysteine residue of UBC9 via the formation of a new thioester linkage.  UBC9 interacts 
directly with the core SUMOylation consensus sequence in the target protein to catalyze 
the formation of an isopeptide bond between the C-terminal SUMO glycine and the ε-
amino group of the target lysine (Figure I-4). 
Although SUMOylation can be achieved without E3 activity in vitro (unlike 
ubiquitination), proteins like RanBP2 (127,128), the polycomb family member Pc2 (129), 
and members of the PIAS family (PIAS-1, -2, -3, -x-α, -x-β, and –y) (127,130-134) have 
E3-like activity and enhance SUMO conjugation, potentially by stabilizing the tripartite 
interaction between Ubc9, activated SUMO, and the target protein.  Interestingly, and as 
mentioned above, the K+ channel associated protein KChaP, which interacts directly with 
the N-terminus of Kv1.5 and serves to modulate the current density of many Kv channels 
(99), has recently been identified as PIAS3β (100).  This clearly raises the intriguing 
possibility that PIAS3 may serve to regulate the SUMO modification of Kv1.5 described 
in this thesis. 
As with other ubiquitin-like proteins, SUMOylation is reversible, and specific 
cysteine proteases such as Ulp-1 and -2 in yeast, and SENP-1-3, and -5-8 in mammals 
release the SUMO moiety (135-137).  It appears that the subcellular localization of these 























Figure I-4. The SUMO Conjugation Pathway 
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SENP-1, for example, can traffic between the nucleus and cytoplasm (135,138); SENP-2 
is detected at nuclear pores, at nuclear bodies, or in the cytoplasm (136,139,140); SENP-
3 is nucleolar (141); and SENP-6 is both nuclear and cytoplasmic (137,142).  In addition 
to the isopeptidase activity of SUMO-specific proteases, SENPs also have C-terminal 
hydrolase activity necessary for the processing of immature pro-form SUMO to 
conjugation-competent SUMO (122).  While E1 and E2 conjugating enzymes are 
distributed in all tissues, differential expression of E3s and SENPs has been hypothesized 
to offer an additional layer of regulation of SUMO modification. 
The Consensus SUMOylation Motif 
Through the analysis of multiple SUMO modified proteins, a minimal consensus 
SUMOylation motif has been identified as ψ-K-X-E/D (where ψ is a large, hydrophobic 
residue and X is a non-conserved residue) (143).  Interestingly, a detailed description of 
these properties, including the additional feature that this core sequence is often flanked 
by proline or glycine residues, was already established in the definition of Synergy 
Control Motifs (SCMs).  These regulatory motifs, found in many transcription factors, 
were initially defined by our group (144) and soon afterwards shown to function as sites 
of SUMOylation (145,146).  Many groups, including ours, have shown that 
SUMOylation can be abolished by a lysine-to-arginine mutation and drastically reduced 
by mutations to the rest of this consensus sequence (134,146).  We have further 
determined in our analysis of transcription factor SUMOylation that substitution of the 
Pro/Gly residues flanking the core SUMOylation sites with amino acids other than 
glycine leads to a reduced interaction with Ubc9 and a concomitant reduction in 
SUMOylation (unpublished data).  Structural analysis indicates that these residues likely 
serve to facilitate exposure of the core SUMOylation site to the conjugation machinery.  
Interestingly, this idea that flanking residues to the core SUMOylation motif can play 
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important roles in facilitating Ubc9 binding appears to be a common theme.  Analysis of 
the transcription factors ELK1 (147), MEF2A (148), and GATA1 (148), has revealed that 
inclusion of a local negative charge just downstream of the core motif may serve to 
stabilize interactions with Ubc9, as well.  In the case of ELK1, this negative charge is 
produced by a cluster of glutamic acid and aspartic acid residues, whereas in the case of 
MEF2a and GATA1, this charge is provided by the phosphorylation of a serine residue 
just C-terminal to the core motif. 
The Function of SUMOylation 
As with other posttranslational modifications, the functional consequence of 
SUMOylation varies greatly depending on the specific target protein.  Since the 
discovery of SUMO just over ten years ago, well over 100 targets have now been 
identified, and this modification has been found to alter properties as diverse as the 
stability, subcellular localization, trafficking, and activity of its substrates.  Recently, it 
has begun to emerge that a common mechanism by which SUMOylation is able to 
regulate such a diverse array of effects may be by its ability to modulate inter- and 
intramolecular interactions (122).  In addition to the covalent interaction between its C-
terminal glycine and the target lysine of its substrate, structural and scanning mutagenesis 
analyses by our group and others have revealed that a well-conserved pocket contributed 
by residues emanating from the β2 strand and α1 helix of SUMO provides a surface for 
interactions with many other target proteins.  The structures of a PIASx peptide (149), 
thymine DNA glycosylase (150), and RanBP2 (151) in complex with SUMO via this 
surface have all recently been solved.  Furthermore, a comprehensive alanine-
replacement analysis of SUMO2 surface residues by our group (152) has revealed that 
disruption of four key basic residues (K33, K35, K42, and R50) that surround this pocket 
dramatically affects the ability of SUMO2 to inhibit transcription.  This is a key finding, 
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as it suggests that the functional consequence of SUMO on transcriptional inhibition is 
dependent not on the intrinsic properties of SUMO itself or on the SUMO-modified 
transcription factor, but instead on the successful recruitment of other regulatory 
complexes to the SUMO-modified factor. 
It should be mentioned that there are examples of SUMOylation inducing 
conformational changes in its covalently-bound target protein.  The most well-defined 
example of this is the SUMOylation of the DNA repair enzyme thymine DNA 
glycosylase (TDG).  Upon SUMO modification, TDG undergoes a conformational 
change that alters its affinity for DNA and thereby allows it to be released from its bound 
DNA.  This conformational change, however, is mediated by intra-molecular binding of a 
region of TDG to the β2-strand/α1-helix groove of the covalently-conjugated SUMO 
(150).  Thus, electrostatic interactions with this hydrophobic groove seem to be critical to 
SUMO function both in recruiting intra- and intermolecular binding partners. 
SUMO-interacting/binding motifs (SIM/SBMs) are just beginning to be 
recognized in proteins that are able to interact with this effector groove on SUMO.  
Analysis of p73α (153), PML (149,153,154), Daxx (155), SAE2 (149), PIAS E3 (149), 
RanBP2 (149,151), thymine DNA glycosylase (150), and RNF4 (156), among others, has 
revealed that one consensus SIM/SBM motif is the loosely-defined sequence V/I-X-V/I-
V/I (149).  In many proteins, this critical hydrophobic core is also surrounded by acidic 
residues.  Importantly, disruption of SIM/SBMs in these SUMO-interacting proteins has 
been found to interrupt function.  For example, disruption of the SIM/SBM in PML has 
been found to interrupt the formation of PML bodies (154).  Clearly, this short, 
degenerate sequence can be found in numerous proteins, so future work to determine 
added specificity of SIM/SBMs will be needed.  However, the idea that SUMO-
interacting candidate proteins might soon be able to be identified through a 
bioinformatics screen is exciting.  It has long been known that similar, non-covalent 
interactions are critical to the function of posttranslational modification by ubiquitin.  As 
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currently there are over 16 distinct ubiquitin-binding domain (UBDs), it is clearly very 
possible that many more SIM/SBMs will soon be determined (157,158). 
Extranuclear Targets of SUMOylation 
The overwhelming majority of targets of SUMOylation that have been described 
to date are located in, or near the nucleus.  These proteins regulate transcription, DNA 
repair, RNA processing, genome integrity, chromatin modification, and 
nucleocytoplasmic transport, among many other functions.  Recently, however, a role for 
SUMO modification outside of the nucleus has begun to emerge.  Numerous global 
proteomics analyses have repeatedly identified non-nuclear targets for SUMOylation.  
Furthermore, the SUMOylation conjugation machinery has long been known not to be 
limited to the nuclear compartment.  Recent reports have identified important roles for 
SUMOylation in the cytoplasm, mitochondria, endoplasmic reticulum, and plasma 
membrane (122,159).  Clearly, of particular interest to me during this thesis has been the 
idea that the SUMOylation machinery is functional and plays an important regulatory 
role for integral membrane proteins at the plasma membrane. 
The glucose transporters GLUT1 and GLUT4 were the first plasma membrane 
proteins shown to be SUMOylated (160).  Using a yeast-two-hybrid assay, it was initially 
found that Ubc9 interacts with the intracellular C-terminus of GLUT4.  This interaction 
was verified using an Ubc9 pulldown assay for both GLUT1 and GLUT4 transporters 
and localized to an 11-amino acid sequence on the C-termini of both transporters.  Both 
transporters were later found to be SUMO modified using Western Blotting techniques.  
Interestingly, stable overexpression of Ubc9 in skeletal muscle cells, resulted in a 65% 
reduction in the expression of GLUT1 and an almost 8-fold increase in the expression of 
GLUT4.  This led to the important functional consequence of decreased basal glucose 
transport, which is mediated by the GLUT1 transporter, and significantly increased 
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insulin-stimulated glucose transport mediated by the GLUT4 transporter.  Also 
interesting from this study was the finding that in 3T3-L1 adipocytes, L6 skeletal muscle 
myoblasts, and terminally differentiated myotubes, endogenous Ubc9 was present 
(although to differing extents) in subcellular fractions from the plasma membrane, high- 
and low-density microsomal membranes, nuclei/mitochondria, and (to a very low extent) 
the cytosol.  This report established that Ubc9 is present at the plasma membrane, and 
that SUMO modification can have important functional consequences for plasma 
membrane proteins. 
Following this initial discovery, multiple metabotropic glutamate receptor 
subunits and the ion channels K2P1, Kv1.5 (from the work in this thesis), GluR6, and 
GluR7a/b have been identified as targets for SUMO modification.  Metabotropic 
glutamate receptor (mGluR) subunits are a family of G-protein coupled receptors 
(GPCRs) that bind glutamate and modulate the activity of nearby ion channels to effect 
pre- or postsynaptic activity in neurons.  To date, mGluR2, 4, 7a, 7b, 8a, 8b (161,162), 
and the excitatory amino acid transporter 2 (EAAT2) (163) have all been shown to be 
SUMO modified.  The Group III presynaptic mGluR8a and b were the first of these 
receptor subunits found to be SUMOylated (162).  Using a yeast-two-hybrid assay of an 
adult rat brain cDNA library, it was identified that the cytoplasmic C-termini of mGluR8a 
and b interact with SUMO1, Ubc9, PIAS1, PIASγ, and PIASxβ.  While verification of 
these interactions using recombinant protein pull-down assays proved difficult, 
recombinant PIAS1 was found to bind mGluR8a and b robustly, and this interaction was 
mapped to a consensus SUMOylation motif on the C-termini of both receptor subunits.  
Interestingly, PIAS1 was also found to bind to all six members of the Group III glutamate 
receptor subunits (mGluR4, -6, -7a/b, and -8a/b).  Using Western Blot analysis, mGluR8a 
and b were found to be SUMO modified, and this modification could be disrupted by 
mutation of the target lysine in the identified consensus SUMOylation motifs.  Although 
not as extensively characterized, mGluR2, 4, 7a, and 7b have since been shown to serve 
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as substrates of SUMO modification using a bacterial SUMOylation assay.  The 
functional consequences of the SUMO modification these metabotropic glutamate 
receptor subunits is still unknown and awaits further study. 
Recently, a C-terminal fragment of the EAAT2 has been shown to be SUMO 
modified in a mouse model of amyotrophic lateral sclerosis (ALS) (163).  EAAT2 is a 
Na+-dependent glutamate transporter in glial cells that has been found to have decreased 
activity in patients with ALS or in a mutant superoxide dismutase 1 (SOD1) mouse 
model of ALS.  Interestingly, a source of this inhibition has been found to come from the 
caspase-3 cleavage of EAAT2 at a defined locus on the C-terminus of the transporter in 
response to mutant SOD1-induced oxidative stress.  Western Blot analysis of this C-
terminal fragment of EAAT2 (called the CTE) in spinal cord homogenates of mutant 
SOD1 mice revealed that the fragment migrated at a higher molecular weight than 
expected.  Based on the observation that the CTE contained a consensus SUMOylation 
motif and that this high migration seemed not to be due to oligomeric aggregation, the 
CTE was tested for SUMO modification.  The CTE could be immunoprecipitated from 
mutant SOD1 mouse spinal cord homogenates using a monoclonal anti-SUMO1 
antibody.  Additionally, the CTE was found to interact with Ubc9 and SUMO1 in a yeast-
two-hybrid assay, and to be SUMOylated in vitro.  Furthermore, SUMOylated CTE, but 
not unmodified CTE was targeted to promyelocytic leukemia (PML) nuclear bodies.  
Based on this observation and that PML bodies are known to regulate transcription, the 
authors propose the idea that EAAT2, through SUMO-mediated targeting of the CTE to 
PML bodies, may contribute to the pathology of ALS.  While this example of the SUMO 
modification of a glutamate transporter is unique, it is clear that SUMOylation of 
metabotropic glutamate receptors, in general, is emerging as a widespread and likely 
important regulatory mechanism in pathological and pathophysiological states. 
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SUMOylation of Ion Channels 
Four ion channels, including the K+ leak channel K2P1 (164), Kv1.5 as described 
in this thesis (165), the kainate receptor subunit GluR6 (166), and the ionotropic 
glutamate receptor subunits GluR7a/b (161) have been shown to be SUMO modified.  
While GluR7a/b has simply been shown to serve as a substrate for SUMO modification 
using a bacterial SUMOylation assay, SUMOylation of K2P1, Kv1.5, and GluR6 has 
been characterized to various extents and shown to have important regulatory 
consequences on the currents mediated by these channels. 
The potassium leak channel K2P1 was the first ion channel found to be SUMO 
modified (164).  K2P channels are a family of potassium-selective pores that influence 
the resting membrane potential and activity of excitable cells by remaining open across a 
physiological range of transmembrane potentials.  Over fifteen K2P channels have been 
identified and characterized since the original discovery of K2P0 in Drosophila 
melanogaster.  These channels have the common feature of being composed of four 
transmembrane segments with two pore-forming “P” loops.  While many members of the 
K2P family do not encode measurable currents in over-expressed systems, many others 
have been found to encode outward K+ currents dynamically regulated by a number of 
mechanisms including phosphorylation, pharmacological outer pore blockers, lipid 
interactions, G-protein interactions, and mechanical stretch.  A major unanswered 
question in the field involved the observation that while mRNA encoded by the founding 
mammalian member of these channels, K2P1, could be detected in the heart, brain, and 
kidney, currents from this channel could not be measured.  In 2005, Rajan et al. reported 
that while exogenous K2P1 was abundantly expressed on the plasma membrane of 
Xenopus oocytes and Cos7 cells, current through the channel could not be detected due to 
constitutive SUMOylation of lysine 274 on the C-terminus of the channel.  Upon 
disruption of this SUMOylation, either by mutation of the receptor lysine, or treatment 
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with SENP, a K+-selective, pH-sensitive, openly rectifying, macroscopic current could be 
detected.  
Confocal microscopy of oocytes overexpressing GFP-tagged Ubc9 revealed that 
GFP-Ubc9 displayed a uniform, non-polarized distribution on the plasma membrane of 
these cells. Interestingly, when co-expressed with K2P1, which was found to have 
expression polarized to the plasma membrane of the animal pole of oocytes, GFP-Ubc9 
expression reorganized and was restricted only to the animal pole, suggesting an 
interaction between the channel and Ubc9.  Endogenous Ubc9 was found to display a 
similar, uniform expression on the plasma membrane that could be polarized upon 
expression with K2P1.  Using a yeast-two-hybrid assay, Ubc9 was confirmed to interact 
with the C-terminus of K2P1.  These observations are striking because they clearly 
demonstrate that components of the SUMO conjugation machinery are present at the 
plasma membrane of oocytes, and suggest that targets of SUMO modification may be 
able to actively recruit this machinery while at the membrane. 
Co-expression of HA-tagged SUMO1 and K2P1 in oocytes revealed that K2P1 
appears to be a target for SUMO modification.  Immunoprecipitation of K2P1 and 
subsequent separation by SDS-PAGE and Western Blotting revealed the presence of ~45 
kDa protein species that was immunoreactive to antibodies directed against K2P1, HA-
SUMO1, and endogenous SUMO1.  Furthermore, disruption of K2P1 lysine 274 shifted 
the migration of this species to an apparent lower molecular weight and disrupted the 
immunoreactivity to either anti-HA or anti-SUMO1 antibodies.  This suggests that K2P1 
can be SUMO modified, and that this modification takes place at acceptor lysine 274.  
Similarly, treatment of immunoprecipitated K2P1 with wt SENP-1 caused the same shift 
in molecular weight, and the channel was no longer found to be immunoreactive to anti-
HA-SUMO1 antibodies.  This effect was shown to be dependent on the catalytic activity 
of SENP, as a C603S mutation that disrupts the activity of the protease, had no effect on 
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K2P1, but surprisingly, it was not investigated whether this effect of SENP was 
dependent on the presence of K2P1 lysine 274. 
Disruption of K2P1 SUMOylation, either by mutation of acceptor lysine 274 or 
co-expression of wt channel with SENP-1, was further found to unmask the silenced 
current of K2P1 and reveal a K+-selective, open rectifying, macroscopic current.  This 
was observed both in oocytes and Cos7 cells, and found to be dependent on the catalytic 
activity of SENP as C603S SENP-1 mutant had no effect on K2P1 current.  In a striking 
set of experiments, this effect of SUMOylation was shown to be acutely reversible.  
Single-channel currents could be recorded from patches of membrane from oocytes co-
expressing WT K2P1 and SENP-1.  When these patches were excised in inside-out mode 
and inserted into naïve oocytes expressing endogenous SUMOylation machinery, these 
single-channel currents were suppressed within 13 seconds, suggesting that acute 
exposure of the channel to SUMO could serve to block channel conductance.  When this 
same patch was withdrawn from the cell and re-inserted into an oocyte over-expressing 
SENP-1, single-channel current could be restored within 18 seconds, arguing that the 
effects of SUMOylation are also acutely reversible.  Furthermore, K274E K2P1 current 
was not inhibited by insertion into naïve cells, suggesting that the suppressive effect of 
these cells on K2P1 current was dependent on an intact SUMOylation motif.  Similarly, 
insertion of wt channel in oocytes expressing C603S SENP-1 did not induce current, 
suggesting that the activating effects of SENP were dependent on its catalytic activity.  
These sets of experiments were remarkable as they dramatically presented that 
SUMOylation could acutely control the function of ion channels expressed on the plasma 
membrane. 
It should be mentioned at this point, that many of the observations in this initial 
study have since been challenged and are highly intriguing.  Specifically, Feliciangeli et 
al (167), were unable to detect any SUMOylation of K2P1 using similar Western Blotting 
techniques, instead detecting only the lower migrating K2P1 species that Rajan et al. 
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identify as unmodified channel.  Additionally, while Feliciangeli et al. found that the 
K274E mutation increased K2P1 current as described, they found that the K274R 
mutation, which should also inhibit channel SUMOylation while preserving the basic 
charge of this residue, was unable to unmask K2P1 macroscopic currents.  These studies 
were undertaken with a slightly different construct of K2P1 that had a Heteractis crispa 
red (HcRed) fluorescent protein fused to the N-terminus of the channel.  However, the 
authors argue that there is no evidence that this should affect the results of the study or 
the ability of the channel to be SUMO modified.  In their original report, Rajan et al. 
described, but did not present, data in which they found that mutations of lysine 274 to 
arginine, glutamine, alanine, and cysteine all led to macroscopic current in oocytes.  They 
also presented data from Cos7 cells that demonstrate that the K274R mutation leads to 
the induction of K2P1 macroscopic current, although only to about one-fourth the extent 
of that induced by the K274E mutation.  This point is critical, as if the effects of the 
K274E mutation can be assigned to disruption of the SUMOylation of the channel, the 
K274R mutation must also be found to be able to recapitulate this effect.  However, if the 
effect of the K274E mutation on the channel is due instead to a charge effect by replacing 
the positively-charged lysine with a negatively-charged glutamic acid, the K274R 
mutation would be predicted to have a much less severe effect on K2P1 current density.  
Future experiments will clearly have to be conducted to resolve this issue. 
Several other aspects of the SUMOylation pattern of K2P1 are highly intriguing.  
The overwhelming majority of known SUMOylation targets are modified with very low 
stochiometries.  A common feature of SUMOylation appears to be that this modification 
can have significant functional effects on target proteins even though only 1-5% of the 
total cellular target protein normally appears to SUMO modified at any given time.  It has 
been speculated that SUMOylation of target proteins may be a very transient process, 
thus allowing for only a very small percentage of target protein to be captured in the 
modified state using biochemical techniques.  However, this phenomenon represents a 
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major, unanswered conundrum in the SUMOylation field.  The finding that K2P1 appears 
exclusively SUMOylated at any given time during basal conditions would thus be 
exceptional.  The observation that Ubc9, even when over-expressed, can be completely 
redistributed to membrane K2P1 would imply that the high rate of steady-state K2P1 
SUMOylation may be a result of an unequal balance between Ubc-9-mediated 
SUMOylation and low SENP-mediated deconjugation.  What is surprising about this, 
however, is that the same quantitative SUMOylation of K2P1 was observed in Cos7 cells, 
in which numerous targets of SUMOylation, including the plasma membrane-expressed 
Kv1.5 described in this thesis, are found to have low stochiometries of SUMOylation.  
This would imply that the complete SUMOylation of K2P1 is not merely caused by a 
lack of SUMO proteases either in the cell or at the plasma membrane, specifically.  As 
the conjugation of SUMO to target proteins is an ATP-dependent process, this finding 
that K2P1 is quantitatively SUMOylated, presumably due to a steady-state of active 
SUMOylation and deSUMOylation, raises the interesting point that this process would 
require a significant expenditure of energy on the part of the cell.  Feliciangeli et al. have 
noted this unusual finding and have reported that, in their hands, again using the slightly 
different HcRed-K2P1 fusion construct, they are unable to detect any SUMOylation of 
the channel, let alone stochiometric amounts of it. 
One last unique finding of K2P1 SUMOylation involves the identified 
SUMOylation motif.  The motif was identified as L-K-K-F, which does not conform to 
the canonical ψ-K-X-E/D description of SUMOylation motifs (where ψ is a hydrophobic 
residue, and x is any residue).  While there are numerous examples of proteins being 
targeted by SUMOylation at non-canonical SUMOylation motifs, this observation begs 
the question if there is any significance to the fact that this is an altered motif.  The 
properties of the sequence surrounding the acceptor lysine in SUMOylation motifs are 
thought to affect Ubc9 binding dynamics to the target protein. Is it thus possible that this 
non-canonical motif may increase the affinity of Ubc9 for K2P1 and provide a possible 
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mechanism for the observed quantitative SUMOylation of the channel?  The authors 
make the point that numerous proteins in the nucleus are SUMOylated at non-canonical 
motifs, thus suggesting that this is not a distinctive feature of extra-nuclear or plasma 
membrane-expressed target of SUMOylation.  However the significance of this newly-
identified motif remains to be more fully understood. 
While there are a number of distinct features of the reported K2P1 SUMOylation, 
and the SUMOylation patterns and role of the K274E mutation clearly remains 
controversial, this report was the first to identify a potential role for the SUMOylation of 
ion channels.  This report also laid the groundwork for further exploration of ion channel 
SUMOylation by confirming the presence of components of the SUMOylation machinery 
at the plasma membrane.  As an interesting note, this original report was published as we 
were actively investigating the role of SUMOylation in regulating the currents of Kv1.5.  
We reported our findings, which represented the first description of the SUMOylation of 
a voltage-gated ion channel, in 2006, and then, soon after, in 2007 the GluR6 kainate 
receptor was reported to be regulated by SUMO modification, as described below. 
The kainate receptor GluR6 subunit is widely expressed throughout the brain, 
being most enriched in the hippocampus.  By regulating neuronal excitability at both pre- 
and post-synaptic sites, GluR6 is thought to play important roles in synaptic plasticity, 
learning and memory, and epilepsy.  As is the case with other kainate receptor (KAR) 
subunits, GluR6 subunits are composed of an extracellular N-terminus, three 
transmembrane segments and a P loop, and an intracellular C-terminus.  These subunits 
can homo- or heterotetramerize to form a functional channel that is able to conduct Na+ 
or K+ ions in response to extracellular binding of the excitatory neurotransmitter 
glutamate. 
GluR6 was initially identified as a potential substrate of SUMOylation when it 
was found to interact with Ubc9 and PIAS3 in a yeast-two-hybrid screen (166). These 
interactions were verified using co-immunoprecipitation studies and mapped to a 13-
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amino acid sequence that contains a consensus SUMOylation motif on the C-terminus of 
the channel.  Interestingly, this consensus SUMOylation motif was fond to be absent in 
all other KARs subunits.  In rat brain extracts, a slow-migrating, GluR6-immunoreactive 
band was detected by Western Blot analysis and found to be sensitive to the SUMO 
protease inhibitor N-ethylmaleimide (NEM).  Furthermore, GluR6 was shown to co-
immunoprecipitate with SUMO1 in cultured hippocampal rat neurons, and WT, but not 
K886R GluR6 was able to serve as a substrate for SUMO modification in a bacterial 
SUMOylation assay. 
GluR6 is known to internalize from the cell surface in response to stimulation by 
kainate or N-methyl-D-aspartate (NMDA) (168).  This agonist-mediated endocytosis was 
found to be dependent on SUMO modification of the channel (166).  Application of 
kainate or glutamate led to the internalization of GluR6, as expected, but also led to a 
rapid increase in the amount of channel that could be recovered in the SUMOylated state.  
This agonist-induced stimulation of GluR6 SUMOylation occurred rapidly, as it could be 
detected in less than one minute and reached maximal conjugation (at three times basal 
levels) within ten minutes.  The effect was specific to GluR6 as kainate did not induce 
global increases in cellular SUMOylation.  Similarly, the effect was also agonist-specific 
as NMDA was able to induce strong GluR6 internalization, but was found to have no 
effect on channel SUMOylation. 
In immunocytochemical studies of cultured hippocampal neurons, co-localization 
of internalized GluR6 with SUMO-1 dramatically increased with time when treated with 
kainate, but showed no effect when treated with NMDA.  Moreover, transduction of these 
cells with SENP-1 dramatically inhibited this kainate-induced GluR6 internalization, but 
had no effect on NMDA-induced internalization.  Importantly, a catalytically-inactive 
mutant (C603S) of SENP-1 was found to have no effect on either kainate- or NMDA-
induced endocytosis.  Consistent with the idea that agonist-induced SUMOylation of 
GluR6 leads to the rapid internalization of the channel, SUMOylation of surface-
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expressed GluR6 could not be detected unless KAR endocytosis was inhibited by 
treatment with sucrose.  Furthermore, disruption of the consensus SUMOylation motif 
with the K886R mutation led to a dramatic loss of kainate-induced internalization in 
Cos7 cells. 
The SUMO modification of GluR6 subunits was found to have important 
functional consequences on the channel.  KAR-mediated excitatory postsynaptic currents 
(KAR-EPSCs) were recorded from CA3 neurons at the mossy fiber synapse in 
hippocampal slices.  When recombinant SUMO-1 was loaded in the recording pipette and 
allowed to diffuse into the patched neurons, the amplitude of KAR-EPSCs was found to 
decrease rapidly, reaching maximal inhibition within approximately five minutes of 
break-in.  Conversely, when SENP-1 was allowed to diffuse into these CA3 neurons, 
KAR-EPSC amplitude rapidly increased within a similar time period.  Importantly, no 
changes were detected in KAR-EPSC amplitudes when either C603S SENP-1 or 
conjugatable-deficient SUMO-1-∆GG was diffused into these cells, and AMPA receptor-
mediated EPSC amplitudes recorded from the same cells were found to be unaffected by 
SUMO-1 or SENP-1 treatment.  Taken together, these data provide strong evidence that 
upon kainate or glutamate-induced stimulation, GluR6 is SUMOylated and subsequently 
internalized.  This SUMO-mediated removal of channel from the plasma membrane 
surface has important functional consequences on the post-synaptic amplitude of KAR-
mediated EPSCs, and thus may have a potential role in the processes of learning and 
memory. 
There are some important observations that can be made from these first reports 
of SUMO modified ion channels.  The first observation involves the finding that the 
SUMO conjugation machinery appears accessible to integral membrane proteins on the 
plasma membrane.  As already mentioned, studies of GLUT1 and GLUT4 transporters, 
as well as of the K2P1 channel identified that Ubc9 is expressed at the plasma membrane.  
Additionally, immunocytochemical studies of cultured hippocampal neurons in the 
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GluR6 study, demonstrated that endogenous SUMO, Ubc9, and PIAS3 are all present not 
only in the nucleus, but also throughout dendrites and at PSD95-positive synapses.  
Future studies that characterize the subcellular localization of the E3 ligases and SENP 
proteases may offer insights into additional layers of regulation of SUMO modification at 
the membrane.  For example, SENP-1 has previously been found to be primarily 
expressed in the nucleus.  It will thus be interesting to determine if similar studies using 
other SENP isoforms that are known to be cytoplasmic might acutely modulate GluR6 
and K2P1 in different ways. 
The finding that both K2P1 and GluR6 can be acutely regulated by SUMO and 
SENP may also provide some information as to where in the cell ion channel 
SUMOylation occurs.  One could imagine that SUMOylation of K2P1 or GluR6 could 
take place at the plasma membrane or during the synthesis, trafficking, or recycling of the 
channel.  Transient SUMOylation of GluR6 during its synthesis, for example, could 
induce conformational changes or promote assembly with other binding partners that 
could persist throughout the lifecycle of the channel and affect its function at the plasma 
membrane.  This does not seem to be the case, however, since SUMO and SENP were 
found to be able to regulate both GluR6 and K2P1 channel activity within seconds to 
minutes of application.  According to this time frame, it seems more likely that 
SUMOylation affects channels in or near the plasma membrane where this modification 
can have immediate effects on function. 
It has been suggested that SUMOylation may serve to inhibit ion channel activity 
(122) since SUMOylation reduced current in both K2P1 and GluR6, while SENP served 
to increase these currents.  This generalization seems somewhat premature, however, 
since the mechanisms by which SUMO inhibits K2P1 and GluR6 are very different.  
Thus, while GluR6 current was inhibited by SUMOylation-promoted endocytosis, 
internalization does not appear to be involved in SUMOylation-induced inhibition of 
K2P1-mediated currents.  This suggests that SUMO may be acting by different 
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mechanisms in each channel.  Indeed, as described in this thesis, SUMO does not seem to 
inhibit the activity of Kv1.5 directly, but rather to protect the channel from inactivation.  
Thus, while further work may reveal a common mechanism for channel SUMOylation—
by promoting interactions with other binding partners, or inducing conformational 
changes, or modulating the local electrostatic environment, for example—the functional 
consequences of SUMOylation will most likely be dependent on the individual target 
channel. 
Finally, these studies provide some insight into the regulation of SUMO 
modification of ion channels.  GluR6 SUMOylation was clearly found to be induced by 
treatment with certain known agonists of the channel.  The mechanism by which agonist 
binding regulated SUMOylation of the channel is not clear, however.  It seems 
reasonable that conformational changes induced by ligand binding might serve to make 
the SUMOylation motif of the channel more accessible to SUMO conjugation machinery.  
Alternatively, such a conformational change could serve to stabilize transient 
SUMOylation of the channel by inhibiting access by SUMO proteases.  Interestingly, 
treatment of oocytes with a broad range of volatile anesthetics, long-chain free fatty 
acids, lysophospholipids, and classical regulators of kinases and phosphatases was shown 
to have no effect on the constitutive SUMOylation status of K2P1.  This suggests that 
regulation of channel SUMOylation is specific and potentially dependent on distinct 
conformational changes that modulate the accessibility of the SUMOylation motif by the 
SUMO machinery.  Clearly, further work is needed to fully understand this regulatory 
mechanism. 
In summary, although only recently appreciated, reversible control of ion 
channels through SUMOylation constitutes a unique and likely widespread mechanism 
for adaptive tuning of the electrical excitability of cells.  In the following chapters, I will 
describe our findings that Kv1.5 serves as a target for SUMOylation, and that this 
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modification can regulate the inactivation properties and amplitude of the channel in 
heterologous systems and isolated mouse and human primary cardiomyocytes.   
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CHAPTER II:  SUMO MODIFICATION REGULATES INACTIVATION OF 
THE VOLTAGE-GATED POTASSIUM CHANNEL Kv1.51 
INTRODUCTION 
The voltage-gated potassium (Kv) channel Kv1.5 mediates the IKur repolarizing 
current in human atrial myocytes (12) and regulates vascular tone in multiple peripheral 
vascular beds (80-87). Understanding the complex regulation of Kv1.5 function is of 
substantial interest since it represents a promising pharmacological target for the 
treatment of atrial fibrillation and hypoxic pulmonary hypertension.   
Using a bioinformatics approach, we identified that a number of Kv channels 
contain sequences that conform well to SUMOylation motifs.  Kv1.5 contains two 
consensus SUMOylation sequences that are highly conserved across species and that are 
located on cytoplasmic regions of the channel.  Concurrent with this observation, the Kv 
associated protein KChAP, which is known to modulate the surface expression and 
whole-cell current densities of several Kv channels, was identified as a member of the 
PIAS family of SUMO E3 ligases.  This raised the intriguing possibility that the 
consensus SUMOylation sites that we identified in Kv1.5 may be functional and 
contribute to a novel form of Kv channel regulation.   
Herein, we demonstrate that Kv1.5 interacts specifically with the SUMO 
conjugating enzyme Ubc9 and serves as a target for post-translational modification by 
SUMO1, 2, and 3 in Cos7 cells. In addition, purified recombinant Kv1.5 serves as a 
                                                 
1 With the exception of Figure II-5 and Figure II-6, the data in this chapter have been previously published 
as “Mark D. Benson, Quiju Li, Katherine Kiekhafer, David Dudek, Mathew Whorton, Roger K. Sunahara, 
Jorge A. Iñiguez-Lluhí and Jeffrey R. Martens (2007). SUMO Modification Regulates Inactivation of the 
Voltage-Gated Potassium Channel Kv1.5. Proc Natl Acad Sci USA. 104(6): 1805-10”  
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substrate in a minimal in vitro reconstituted SUMOylation reaction. The SUMO-specific 
proteases SENP2 and Ulp1 efficiently deconjugate SUMO from Kv1.5 in Cos7 cells and 
in vitro, and disruption of the two identified target motifs results in a loss of the major 
SUMO-conjugated forms of Kv1.5.  Selective analysis of surface-exposed proteins 
revealed that Kv1.5 is SUMO modified at the plasma membrane with a stochiometry 
comparable to that of the total cellular pool.  Moreover, exposure of Cos7 cells 
expressing SUMO3, Ubc9, and Kv1.5 to increasing concentrations of hydrogen peroxide 
demonstrates that oxidative stress may serve an important regulatory role in controlling 
Kv1.5 SUMOylation.  Functional analysis in whole-cell patch clamp electrophysiology 
revealed that loss of Kv1.5 SUMOylation, either by disruption of the conjugation sites or 
expression of the SUMO protease SENP2, leads to a selective ~15 mV hyperpolarizing 
shift in the voltage dependence of steady-state inactivation with no associated effects on 
the voltage-dependence of activation or total current density. 
Together, these data identify a novel role for reversible, post-translational 
modification by SUMO in the regulation of Kv1.5 inactivation and represent the first 
report of SUMOylation of a voltage-gated ion channel.  Given that a number of voltage-
gated ion channels contain well-conserved, consensus SUMOylation motifs, SUMO 
modification may constitute a unique and widespread mechanism for adaptive tuning of 
the electrical excitability of cells. 
EXPERIMENTAL PROCEDURES 
Expression plasmids, cell culture, and in vivo SUMOylation assays 
The expression vectors pCDNA3.1 hKv1.5 V5-His and pCDNA3.1 hKv1.5 N556 
V5-His consist of the full-length or the first 556 residues of human Kv1.5 inserted at the 
EcoRI and XhoI sites of pCDNA3.1 V5-HIS A (Invitrogen). Derivatives bearing K221R, 
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or K536R substitutions alone or in combination were generated by PCR. pCMV FLAG 
SENP2 (71-590) was a gift of Dr. Mary Dasso (NIH) and pEGFP-C1 was from Clontech. 
Other vectors are described in (134). COS-7 cells were maintained ad transfected as 
described (146).  For in vivo SUMOylation assays, 1.2 x 105 cells were seeded in 6-well 
plates and transfected with the indicated amounts of expression plasmids. The total 
amount of DNA per transfection was supplemented to 1.3 µg/well with pBSKS (-). For 
the data in Figure II-3A, 2 x 106 cells were seeded in 10 cm plates and the total amount of 
DNA was 12 µg/plate. In vivo SUMOylation assays were adapted from (134).  Cells were 
harvested 48 h after transfection and homogenized in 300 µl CHAPS lysis buffer (50 mM 
Na phosphate pH 8.0, 500 mM NaCl, 10 mM imidazole, 1% CHAPS, 20 mM NEM, 
supplemented with complete EDTA-free miniprotease inhibitor tablets (Roche), 1 
tablet/10 ml). After centrifugation (16,000 x g, 15 min), solublized proteins were 
incubated(1h, 25 °C) with 0.1 ml of Ni-NTA-agarose (Qiagen). The resin was 
sequentially washed (2 ml, thrice) with buffer 1 (50 mM Na phosphate pH 6.5, 400 mM 
NaCl, 10 mM imidazole, 0.1% CHAPS), buffer 2 (buffer 1 with 150 mM NaCl, no 
imidazole, and 8 M urea) and buffer 3 (50 mM Na phosphate pH 8.0, 50 mM NaCl, 0.1% 
CHAPS). Ulp1 treatment was carried out between washes 1 and 2 and consisted of 1h 
incubations at 30 °C with 242 pmol of purified GST or GST-Ulp1 after equilibration in 
buffer 2 without urea.  For the data in Figure II-3, the cells were lysed in 750 µl urea lysis 
buffer (CHAPS lysis buffer with 8 M urea instead of 1% CHAPS and no NEM) and 
washed in urea buffer 1 (wash buffer 1 with 8 M urea and 0.2% NP-40 instead of 0.1% 
CHAPS) and NP-40 buffer 2 (wash buffer 2 with no urea and 0.2% NP-40 instead of 
0.1% CHAPS). Proteins were eluted by incubating (55 °C, 20 min) in SDS Sample 
Buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 5% glycerol, 3.3 mM EDTA, 0.0075% 
bromphenol blue, 6.5 mM dithiothreitol), resolved by SDS PAGE (7.5%) and processed 
for immunoblotting using anti-V5 (Invitrogen), anti HA (HA-11, Covance), or anti-
FLAG (Sigma) mouse monoclonal antibodies.  For surface biotinylation studies, cells 
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transfected with HA-SUMO3, Ubc9, and Kv1.5-V5-His6 variants as described were 
washed with PBS at 4 °C (3 times) to remove amine-containing culture media and cells 
were treated with 2 mM Sulfo-NHS-biotin reagent (Pierce, Rockford, IL) for 1 hour at 
4°C with gentle rocking.  After the cells were washed thoroughly (3 times) with PBS + 
100 mM glycine (to quench and remove excess biotin reagent), cells were lysed in 
CHAPS lysis buffer and sonicated.  After centrifugation (16,000 x g, 15 min), soluble 
protein was loaded onto either streptavidin-agarose (Pierce) or Ni2+-agarose beads 
(Qiagen) and incubated at 4°C for 1 hr with rotation.  For sequential purifications, the 
streptavidin resin was washed three times with wash buffer 1 and then eluted with wash 
buffer 1 + 20 mM DTT for 30 minutes at 4°C.  Eluted samples were alkylated by addition 
of NEM, and loaded onto Ni2+-agarose beads and washed as described above.  For 
oxidative stress studies, 1.2 x 105 Cos7 cells were seeded in 6-well plates and transfected 
with 0.2 µg HA-SUMO3, 0.1 µg Ubc9, and 0.2 µgs WT or K221/536R Kv1.5 as 
indicated.  Forty-eight hours after transfection, cells were treated with 0, 0.1, or 1 mM 
H2O2 in phenol-red-free DMEM media as indicated for 2 hours at 37 °C (5% CO2).  
Cells were lysed in CHAPS lysis buffer and processed as above.  Detection was achieved 
with goat-anti-mouse IgG peroxidase conjugate (Bio-Rad) and Super Signal West Femto 
substrates (Pierce). All experiments were performed at least thrice with similar results. 
Purification of hKv1.5, protein-protein interaction and in vitro SUMO conjugation 
assays 
Purification of recombinant hKv1.5 was carried out as follows by David Dudek in 
the Martens laboratory.  A recombinant baculovirus for the expression of V5/His-hKv1.5 
was generated using the Bac-to-Bac expression System (Invitrogen). Sf9 cells were 
grown at 27 °C in SF-900 II media and harvested 60 hours after infection. After nitrogen 
cavitation lysis and clearing of cell debris by centrifugation (1780 x g, 10 min), a 
membrane fraction containing His-tagged hKv1.5 was isolated by ultracentrifugation at 
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100,000 x g for 35 min and extracted with 1% dodecyl maltoside (DDM). Solublized 
membrane proteins were recovered by ultracentrifugation (100,000 x g, 35 min.) and 
loaded onto a Ni2+-NTA sepharose column equilibrated with 50 mM Tris, pH 7.7, 50 mM 
NaCl, 0.1% DDM, and protease inhibitors. After washing with 20 column volumes of 20 
mM Hepes, pH 8.0, 300mM NaCl, 0.1% DDM, protease inhibitors, and increasing 
concentrations of imidazole (5, 10, 20, and 40mM), hKv1.5 was eluted with 20 mM 
Hepes, pH 8.0, 50mM NaCl, 150mM imidazole, 0.1% DDM and protease inhibitors. 
Fractions containing hKv1.5 were pooled, diluted into 20mM Hepes, pH 8.0 1mM 
EDTA, 0.1% DDM, and protease inhibitors (Buffer A), and applied to a source Q 
(HR5/5, Amersham) FPLC anion exchange column. hKv1.5 was eluted using a linear 
gradient of NaCl in buffer A, concentrated using a MiniCon (Millipore) concentrator and 
applied to a Superdex 200 HR 10/30 (Amersham) gel filtration column in 20mM Hepes, 
pH 8.0, 1mM EDTA, 50 mM NaCl, 0.1% DDM, and protease inhibitors. Peak protein 
fractions were pooled, and hKv1.5 was detected by immunoblot probing for the V5 
epitope. 
For protein-protein interaction assays, 2 x 106 cells were seeded in 10 cm plates 
and transfected with 5 µg of either pCDNA3.1 Kv1.5 V5-His or pCDNA3.1 Kv1.5 N556 
V5-His. Cells were harvested 48 h post-transfection in 750  l CHAPS lysis buffer 
sonicated, and centrifuged (16,000 x g, 15 min, 4 °C). 4.5  l of supernatant was 
processed as described (134) using buffers supplemented with 0.1% DDM. Samples were 
resolved by SDS-PAGE and processed for V5 epitope immunoblotting. In vitro 
SUMOylation assays were conducted as described (146) using purified hKv1.5 V5-His 
preparations as substrate. Reactions were carried out at 30 °C for 2h. Samples were 
resolved by SDS-PAGE, and processed for V5 epitope immunoblotting. 
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Electrophysiology 
For electrophysiological studies, 1 x 106 cells were seeded in 35 mm plates and 
co-transfected with 0.1 µg each of pEGFP-C1 and the indicated pCDNA3.1 hKv1.5 
plasmid. Electrophysiological recordings and analysis were conducted as previously 
described (86). The current-voltage (I-V) relationships and activation curves were 
measured using 250 ms voltage-clamp pulses applied in 10 mV steps between -80 mV 
and + 60 mV. Current was measured at the end of the 250 ms depolarization to obtain the 
steady-state I-V relationships. Tail current amplitude immediately following the 
capacitive transient was measured to obtain the voltage dependence of activation curves. 
Inactivation was measured using a 5s conditioning pulse applied in 10 mV steps from -60 
mV to +40 mV followed by a 500 ms test pulse at +30 mV. Current was measured at the 
end of the 500 ms test pulse. Normalized activation and inactivation curves were fitted to 
the Boltzmann equation and results are expressed as mean +/- standard error. Comparison 
of V50 values was carried out with an F test applied to global fits of pooled vs separate 
sets. 
RESULTS 
Kv1.5 harbors conserved SUMOylation motifs and interacts with Ubc9 
Scanning of the human Kv1.5 sequence using a search profile based on 
functionally characterized synergy control motifs in transcription factors identified two 
high-scoring sequences. The first, centered on Lys 221, lies between the T1 
tetramerization domain and the first transmembrane segment. The second, centered on 
Lys 536, is located in the C-terminal tail just beyond the sixth transmembrane segment 
(Figure II-1A). Structural modeling of Kv1.5 using the recent crystal structure of Kv1.2 




















Figure II-1. Kv1.5 contains two conserved consensus SUMOylation motifs and 
interacts with Ubc9. 
A) A schematic representation of Kv1.5. T1: tetramerization domain. S1-6: 
transmembrane domains. Aligned vertebrate Kv1.5 sequences centered on human K221 
(Motif 1) and human K536 (Motif 2) are on the left, whereas the corresponding regions in 
human Kv channels are at right. The core and flanking Gly/Pro residues of the motif are 
boxed. Asterisks indicate channels with predicted SUMOylation motifs. A SUMOylation 
consensus is shown above. B) Structural model of Kv1.5 using the coordinates of Kv1.2-
β2 (24). Modeled consensus SUMOylation motifs on each of the three depicted α-
subunits are highlighted in red. SUMO-2 is shown for comparison. C) In vitro interaction 
between Kv1.5 and Ubc9. Kv1.5 N556 corresponds to a C-terminal truncation lacking the 




to each other exposed to the side portals that provide cytoplasmic access to the pore of 
the channel. The model suggests that SUMO attachment to either K221 or K536 can be 
accommodated without undue alterations of the overall structure. The predicted 
SUMOylation sequences (Figure II-1A) conform to the canonical  -K-X-E/D pattern and 
the core sequence is flanked by nearby proline or glycine residues, a criterion included in 
our search model. Sequence comparison across vertebrate species revealed that they lie 
within regions of high local conservation since surrounding sequences, especially those 
C-terminal to the second motif, are far more divergent (not shown). Interestingly, 
whereas both sites are conserved in mammalian sequences, only one of the sites is 
present in avian, amphibian and fish species. Comparison to other human Kv family 
members reveals that the first motif is intact in Kv1.1 and Kv1.2.  
To determine if Kv1.5 can interact with the E2 SUMO-conjugating enzyme Ubc9, 
we subjected extracts from cells expressing V5/His epitope-tagged hKv1.5 to affinity 
chromatography using immobilized recombinant GST-Ubc9 or GST. Kv1.5 was retained 
efficiently on the GST-Ubc9 resin but failed to interact with GST alone (Figure II-1C). 
Titration of the GST-Ubc9 fusion indicates that the affinity of interaction is ~400 nM (not 
shown). Consistent with the location of the two predicted modification sites, a 57-amino 
acid C-terminal truncation of Kv1.5 (N556) which preserves both motifs also interacts 
efficiently (Figure II-1C right). The presence of putative modification sites and the 
interaction with Ubc9 makes Kv1.5 a likely target of SUMOylation. 
Kv1.5 is SUMO modified in vivo and in vitro 
To evaluate if Kv1.5 is SUMOylated in live cultured cells (in vivo), we isolated 
V5/His-tagged hKv1.5 from cells co-expressing HA-SUMO-3 and Ubc9 by Ni+-chelate 
chromatography under denaturing conditions. Western blot analysis of the preparations 
using anti-HA antibodies (Figure II-2A) indicates that two major HA-immunoreactive 
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bands (marked with arrows) are detected only in samples derived from cells co-
expressing SUMO and Kv1.5. These bands correspond to SUMO-modified Kv1.5 since 
they are also visible as minor V5-immunoreactive species (arrows on anti-V5 blot). As in 
the case of most SUMOylated proteins (112), the extent of Kv1.5 modification appears to 
be relatively low (~1%).  For the N556 C-terminal deletion mutant of Kv1.5, we detected 
a corresponding shift in the mobility of the HA- and V5-immunoreactive species 
confirming that the SUMO-conjugates do indeed derive from Kv1.5 and that the C-
terminal region is dispensable for SUMOylation. Omission of N-Ethylmaleimide (NEM), 
an inhibitor of SUMO-specific deconjugating enzymes, during sample preparation led to 
reduced recovery of both HA- and V5-immunoreactive SUMO-modified Kv1.5 species 
(Figure II-2B). Likewise, exposure of Kv1.5 to purified recombinant Ulp1, a yeast 
SUMO isopeptidase (169) during the Ni+-chelate chromatography released substantial 
amounts of the SUMO moiety from Kv1.5 (Figure II-2B). 
To examine whether Kv1.5 can serve as a substrate for SUMO modification in 
vitro, we obtained purified preparations of recombinant WT V5/His-tagged hKv1.5 after 
baculovirus expression in Sf9 cells. Incubation of this material in a reconstituted 
SUMOylation reaction containing homogenous, recombinant E1 activating (SAE1/SAE2) 
and E2 conjugating (Ubc9) enzymes along with purified SUMO-2 and an ATP 
regenerating system led to the appearance of slow-migrating, SUMO-2 conjugated forms 
of Kv1.5 (Figure II-2C, lane 1). The two lower bands (marked by arrows) correspond in 
size to the species seen in panels A and B. The additional higher MW species likely 
represent multiply SUMOylated forms due to the abundant SUMO chain formation that 
occurs under these in vitro conditions. Although not as extensive, a similar pattern of 
conjugation is observed with SUMO-1 (lane 6). Notably, when any one component is 
omitted from the reaction, no SUMO-modified species could be detected. These results 






















Figure II-2. Kv1.5 is SUMO modified in vivo and in vitro.  
A) Cos-7 cells were co-transfected as described in Experimental Procedures with 
200 ng pCDNA3 Ubc9 and as indicated, 200 ng pCDNA3 HA-SUMO3, 200 ng 
pCDNA3.1 hKv1.5 V5-His, 160 ng pCDNA3.1 hKv1.5 N556 V5-His or an equimolar 
amount of the corresponding empty vector. His-tagged proteins were purified and 
detected by immunoblotting with anti-HA (top panel) and anti-V5 (middle and bottom 
panels) antibodies. The middle panel is an over-exposed version of the lower panel. 
SUMO modified species of Kv1.5 are indicated with arrows and nonspecific bands with 
asterisks. B) Samples were transfected and processed as in A) except cells were harvested 
in the presence or absence of NEM as indicated, and samples were treated with GST or 
the SUMO-specific protease GST-Ulp1. Arrows indicate SUMO modified species of 
Kv1.5. C) Purified hKv1.5 was incubated with the indicated SUMO conjugation 
machinery components as described in Experimental Procedures. Arrows indicate 
SUMO-modified species of Kv1.5. 
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Modification of Kv1.5 by multiple SUMO isoforms requires intact SUMOylation 
motifs. 
In humans, three SUMO isoforms competent for conjugation have been identified. 
Whereas SUMO-2 and SUMO-3 are nearly identical, they share only 50% amino acid 
identity with SUMO-1 and there is mounting evidence for isoform-selective subcellular 
localization (112) and function (146). We find that each of these SUMO isoforms can be 
conjugated to Kv1.5 in vivo; however, they do so to different extents (Figure II-3A). In 
contrast to SUMO-3 modified forms, SUMO-2 and especially SUMO-1 conjugates are 
substantially less abundant and require longer exposures to be detected. Although this 
preference may be intrinsic to Kv1.5, it also reflects the relative levels of expression of 
the isoforms since free SUMO-3 accumulates to substantially higher levels than SUMO-2 
or SUMO-1. To determine if the two putative SUMOylation motifs that we identified 
serve as sites of conjugation, we replaced the predicted target lysines with non-
SUMOylatable arginine residues.  Mutation of the first (K221R) or second (K536R) 
motifs leads to a preferential loss of the higher and lower migrating SUMO conjugated 
species respectively (Figure II-3B, arrows). Although we have not assessed the 
stoichiometry or topology of the linkage within individual species, modification at 
different positions may lead to distinct migration patterns. The double mutant 
(K221/536R) however, leads to loss of the two major SUMO-modified Kv1.5 species. 
Consistent with the SUMOylation consensus, replacement of the conserved Glu 538 at 
the fourth position of the second motif by Arg (in the context of K221R) or mutation of 
the first hydrophobic position of both motifs to Asn (I220N/L535N) also severely 
compromised Kv1.5 SUMOylation (Figure II-8). In contrast, disruption of the motifs 
with the K221/536R mutations did not alter the recovery of ubiquitinated species in the 
presence of a proteasomal inhibitor (Figure II-4). These findings indicate that the 







Figure II-3. Modification of Kv1.5 by multiple SUMO isoforms requires intact 
SUMOylation motifs. 
A) Cos-7 cells were co-transfected with 3 µg each of pCDNA3 Ubc9, pCDNA3 
HA-SUMO1/2/or 3, and 1µg pCDNA3.1 hKv1.5 V5-His or an equimolar amount of the 
corresponding empty vector. Samples were analyzed as in Figure II-2A. Relative 
exposure times of the anti-HA immunoblots are indicated below each blot. Arrows 
indicate SUMO modified species of Kv1.5. B) Cos-7 cells were transfected with 
pCDNA3 based vectors for the indicated proteins. Transfection and sample analysis was 
as in Figure II-2A. SUMO-modified species are indicated with arrows, and non-specific 



































Figure II-4. Effect of Disruption of SUMOylation Motifs on Kv1.5 Ubiquitination. 
Cos-7 cells were co-transfected as described in Experimental Procedures with 
200 ng pCDNA3 HA-ubiquitin, 200 ng of the indicated pCDNA3.1 hKv1.5 V5-His 
plasmid, or an equimolar amount of the corresponding empty vector. Cells were treated 
with 10 µM lactacystin (Boston Biochem) for 1 hr at 37 °C.  Subsequent lysis in the 
presence of 20 mM NEM and protease inhibitors was as described in Figure II-2. His-
tagged proteins were purified and detected by immunoblotting with anti-HA (top panel) 
and anti-V5 (middle and bottom panels) antibodies as in Figure II-2. The middle panel is 
an over-exposed version of the lower panel. 
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Kv1.5 is SUMOylated at the plasma membrane. 
To probe if the stoichiometry of SUMOylation of Kv1.5 depends on the 
subcellular localization of the channel, we isolated channel expressed at the plasma 
membrane using a surface biotinylation approach and compared the SUMO modification 
of this pool of channels to that of total cellular Kv1.5.  As shown in Figure II-5A, 
treatment of Cos7 cells co-expressing HA-SUMO3, Ubc9, and either WT or 
SUMOylation-deficient K221/536R Kv1.5-V5-His6 with the cell-impermeant 
biotinylation reagent EZ-Link Sulfo-NHS-Biotin (Pierce, Rockford, IL) resulted in the 
selective retention of Kv1.5 on streptavidin-agarose resin (lanes 4-6).  Notably, the 
enrichment of the glycosylated species of Kv1.5 (marked with an asterisk) is detected in 
plasma membrane samples compared to those from the whole cell.  This is consistent 
with a preferential isolation of surface channel since membrane insertion occurs after the 
channel has traversed the ER and Golgi compartments where glycosylation takes place.  
The slower migrating species corresponds to glycosylated Kv1.5 since this form is 
sensitive to glycanase treatment (Figure II-5B).  A similar collapse to a single form is 
also observed for the total cellular Kv1.5.  To examine the SUMOylation state of the cell-
surface pool of Kv1.5, cells co-expressing HA SUMO3 and either WT or the 
SUMOylation deficient K221/536R mutant were surface biotinylated and the 
complement of modified plasma membrane proteins was purified by streptavidin-affinity 
chromatography.  Kv1.5 was isolated from this pool via a second, Ni2+-chelate 
chromatography under denaturing conditions.  As seen in Figure II-5C, we detect two 
HA-immunoreactive species (lane 5) with similar gel migration pattern and molecular 
weights to those derived from SUMO-modified Kv1.5 in total cellular samples (first two 
lanes).  These species are not detected in preparations derived from cells expressing the 
SUMOylation-deficient K221/536R Kv1.5, further indicating that they represent SUMO-






Figure II-5. Kv1.5 is SUMOylated at the Plasma Membrane. 
(A) Forty-eight hours after transfection with HA-SUMO3, Ubc9, and Kv1.5-V5-
His6 variants, Cos7 cells were surface biotinylated using a cell-impermeant, amine-
reactive ester biotinylation reagent and lysed in the presence of 1% CHAPS.  Whole cell 
lysates were centrifuged at 16,000 x g for 15 min, and soluble protein was loaded onto 
either a Ni2+-agarose or streptavidin-agarose resin and visualized by Western blotting.  
Kv1.5-V5-His6 was only retained by streptavidin-agarose resin after surface 
biotinylation.  The asterisk indicates glycosylated Kv1.5; the arrowheads indicate 
unmodified Kv1.5.  B)  Lysates prepared as in A were loaded onto either a Ni2+ resin or 
streptavidin-agarose resin and visualized by Western Blotting.  The higher-migrating 
species of V5-immunoreactive Kv1.5 (marked with an asterisk) was sensitive to 
treatment with glycanase (incubated for 30 minutes at 37 deg C with the agarose resin 
immediately before elution).  Arrowheads indicate unmodified Kv1.5.  C) Lysate 
prepared as in A was subjected to sequential purification by streptavidin-affinity 
chromatography followed by Ni2+-chelate chromatography as described in Experimental 
Procedures in the absence of glycanase.  Arrowheads indicate SUMO modified species 
of Kv1.5; the asterisk indicates glycosylated Kv1.5. 
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cellular Kv1.5, the extent of SUMO modification of surface-expressed Kv1.5 appears to 
be relatively low (~ 1%).  Notably, even after loading the equivalent of ~ 40 times more 
starting material, we recover only a very small fraction of total cellular Kv1.5 on the 
plasma membrane (visible on the anti-V5 blot in Figure II-5C).  In future studies, 
increasing the ratio between surface-expressed and total cellular channel may enable us to 
better visualize the SUMO-modified species of Kv1.5 derived from the plasma 
membrane.  These findings indicate that Kv1.5 is SUMO modified at the plasma 
membrane with approximately the same stochiometry as that for total cellular channel. 
Treatment of Cos7 cells with hydrogen peroxide regulates the SUMO modification 
of Kv1.5 
Oxidative stress is a widespread regulator of protein SUMOylation.  Moreover, 
recent data indicate that hydrogen peroxide can have direct effects on the biophysical 
properties of Kv1.5 (170).  To determine the effect of oxidative stress on the 
SUMOylation status of Kv1.5, we exposed Cos7 cells expressing HA-SUMO3, Ubc9, 
and either WT or SUMOylation-deficient K221/536R Kv1.5-V5-His6 to increasing 
concentrations of hydrogen peroxide.  As can be seen in Figure II-6, exposure of cells for 
120 minutes, led to a shift of the Kv1.5 SUMOylated species that we normally detect 
(marked with arrowheads) to higher molecular mass SUMO conjugates (indicated by a 
bracket).  Such higher-order species may represent SUMO chain formation on Kv1.5.  
This increase in overall modification and in high-molecular weight conjugates is dose-
dependent and absent in the SUMOylation-deficient K221/536R Kv1.5 mutant (last lane).  
These data provide preliminary evidence that oxidative stress may serve an important 





















Figure II-6. Effect of Oxidative Stress on Kv1.5 SUMOylation. 
Cos7 cells expressing Kv1.5-V5-His6, HA-SUMO3, and Ubc9 were treated with 
0, 0.1, 0r 1 mM H2O2 in phenol red free DMEM media as indicated for 2 hours at 37 °C.  
Lysates were enriched for Kv1.5 by Ni2+-chelate chromatography and probed with HA 
(top) and V5 (bottom) antibodies.  Arrowheads indicate SUMOylated Kv1.5 species.  
Bracket indicates higher-order SUMOylated Kv1.5. 
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Disruption of SUMOylation motifs alters Kv1.5 function 
To probe the functional role of the SUMOylation motifs in Kv1.5, we 
characterized the voltage-dependent potassium currents elicited by expression of Kv1.5 
forms harboring intact or disrupted SUMOylation motifs. Analysis of whole-cell patch-
clamp recordings indicated that the K221/536R substitutions had no effect on the total 
current density (Figure II-7A), nor on the voltage-dependence of channel activation 
(Figure II-7B). In contrast, the substitutions led to a specific ~15 mV hyperpolarizing 
shift in the half-maximal voltage of inactivation (V50) from the WT value of 0.33 +/- 1.2 
to -14.8 +/- 1.4 mV (p<0.0001). This shift occurs without appreciable alterations in the 
extent of inactivation (53.8 and 50.9% for WT and K221/536R respectively). Notably, 
reintroduction of the WT sequence at either position returned the V50 value to nearly WT 
levels (Figure II-7C). This indicates that the motifs are functionally equivalent and that 
the presence of a single intact motif is sufficient to exert a nearly complete effect.  
Moreover, mutation of other residues within the motifs also had a functional effect. In the 
context of the K221R mutant, addition of the E538R substitution in the second motif led 
to a significant shift in V50 from -4.0 +/- 0.9 to -8.8 +/- 1.2 mV (p<0.0005). Likewise, 
mutation of the first position in both motifs to Asn (I220N/L535N) led to a shift 
indistinguishable from that of the K221/536R mutant (-17.44 +/- 1.6 vs -14.8 +/- 1.4 mV 
p = 0.32) (Figure II-8B). Taken together, these data suggest that although not essential for 
assembly of functional Kv1.5 channels, the motifs selectively regulate their biophysical 
properties. 
SUMOylation regulates Kv1.5 inactivation 
The concurrent loss of SUMO modification and shift in the voltage dependence of 
inactivation in multiple SUMOylation motif mutants argues strongly in favor of 























Figure II-7. Disruption of SUMOylation motifs alters Kv1.5 inactivation. 
Cos-7 cells were co-transfected with 0.1 µg each of pEGFP-C1 (to identify 
transfected cells) and a pCDNA3 based vector for the expression of the indicated Kv1.5 
variant. Recordings were obtained as described in Experimental Procedures. A) I/V 
curves. Data represent average +/- SEM of 11 WT and 11 K221/536R cells. B) Voltage-
dependence of steady-state activation. (n= 11 and 10 for WT and K221/536R). C) 
Voltage-dependence of steady-state inactivation (n= 7-10 for each construct). The inset 








Figure II-8. Lysine-Sparing Disruptions of SUMOylation Motifs Alter Kv1.5 
Inactivation.  
A) Cos-7 cells were co-transfected and processed as in Figure II-2A.  Arrows 
indicate SUMO modified species of Kv1.5 in the anti-HA and anti-V5 immunoblots. B) 
Cos-7 cells were co-transfected with 0.1 µg of the indicated Kv1.5 plasmid and 0.1 µg 
pEGFP-C1 as in Figure II-7. Voltage dependence of steady-state inactivation was 
obtained as in Figure II-7C (n= 6 and 5 for K221R/E538R and I220N/L535N, 
respectively; data from WT, K221R, and KRKR are from Figure II-7).  The inset shows a 
schematic of each SUMOylation motif variant and the corresponding inactivation V50 
values. 
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for the functional effects exerted by the motifs. If this is indeed the case, reducing the 
levels of SUMOylation from WT Kv1.5 should lead to a similar alteration in the voltage 
dependence of inactivation. To test this hypothesis, we took advantage of a variant of the 
SUMO protease SENP2 lacking the first 70 N-terminal residues (FLAG-SENP2 71-590). 
This form displays enhanced activity against multiple SUMOylated substrates (136) and 
localizes to the cytoplasm (140). Co-expression of this SUMO protease led to the 
complete loss of Kv1.5 SUMO conjugates (Figure II-9A). In parallel, co-expression of 
SENP2 with WT Kv1.5 produced a ~14 mV hyperpolarizing shift in the voltage 
dependence of steady-state inactivation, altering the V50 from 0.33 +/- 1.2 mV in its 
absence to -13.5 +/- 0.9 mV in its presence (p<0.0001) (Figure II-9B). This effect is 
indistinguishable from that of the K221/536R mutant (V50 = -14.8 +/- 1.4 mV, p>0.4). 
Importantly, the effects of SENP2 require the integrity of the SUMOylation motifs in 
Kv1.5 since co-expression of SENP2 did not alter the V50 of the SUMOylation deficient 
K221/536R mutant (V50 = -12.3 +/- 0.9 mV, p>0.16). Taken together, these findings 
demonstrate that loss of SUMO modification of Kv1.5, either by point mutations at the 
SUMOylation motifs or co-expression with the SUMO-specific protease SENP2, leads to 
a significant hyperpolarizing shift in the voltage-dependence of inactivation without 
altering either the total current density or voltage-dependence of activation of the 
channel. 
DISCUSSION 
The present study identifies SUMOylation as a novel form of posttranslational 
modification of Kv1.5 and establishes that it exerts a selective regulatory function. While 
this is the first member of the voltage-gated ion family found to serve as a target for 
SUMO modification, multiple Kv channel α subunits, including Kv1.1 and Kv1.2, 
contain similarly located consensus SUMOylation motifs. SUMOylation may thus be a 























Figure II-9. SENP2-mediated loss of Kv1.5 SUMOylation alters inactivation. 
A) Cos-7 cells were co-transfected as in Figure II-2A with an additional 200 ng of 
pCMV or pCMV FLAG SENP2 (71-590). Samples were analyzed as in Figure II-2A. 
Whole-cell lysates were resolved by SDS-PAGE and probed with anti-FLAG antibodies 
(bottom right immunoblot). Arrows indicate SUMO modified species of Kv1.5 in the 
anti-HA and anti-V5 immunoblots and SENP2 in the anti-FLAG blot. B) Cos-7 cells 
were co-transfected with 0.1 µg of the indicated Kv1.5 plasmid, 0.1 µg pEGFP-C1 and 
0.5 µg pCMV FLAG SENP2 (71-590). Voltage dependence of steady-state inactivation 
in the presence of SENP2 was obtained from 7 and 6 cells for WT and K221/536R 
respectively. Data in the absence of SENP2 are from Figure II-7C. 
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the glucose transporters GLUT1 and GLUT4 (160,171), the two-pore potassium leak 
channel K2P1 (164) and the G-protein-coupled receptor mGluR8 (162) further supports 
the view that SUMOylation is an important regulatory mechanism for integral membrane 
proteins. 
In this report, we have demonstrated that disruption of Kv1.5 SUMO modification 
has a significant effect on the biophysical properties of the channel. Notably, loss of 
SUMOylation elicits a substantial phenotype even though only a small fraction of the 
total cellular Kv1.5 appears to be SUMOylated. Interestingly, neither Ubc9 nor SUMO 
appear to be limiting, since overexpression of SUMO3 and Ubc9, did not shift the V50 of 
WT Kv1.5 in the depolarizing direction.  Furthermore, although SUMOylation of channel 
expressed at the plasma membrane was detected, this population did not appear 
selectively targeted for SUMOylation on the basis of our surface biotinylation assays.  
Given the oligomeric structure of the channel modification of only one of the eight sites 
per tetramer may be sufficient to exert a functional effect.  Alternatively, transient 
SUMOylation may be sufficient to establish a long-lived assembly or functional state of 
the channel. The ability of SUMO to exert substantial regulatory effects even at low 
stoichiometries is also observed for other target proteins such as transcription factors and 
appears to be more the norm than the exception. There are however, proteins that are 
modified at high levels such as the K2P1 channel (164), RanGap (116) and the A40R 
vaccinia virus protein (172). For this second class, SUMO may be functioning as an 
essential structural assembly element as opposed to serving a transient modulatory one. 
Thus, in the case of the K2P1 channel, SUMOylation is an absolute gatekeeper 
preventing any access to conducting states of the channel (164), whereas in Kv1.5 this 
modification plays a more modulatory role.  
Although the basis for the effects of SUMOylation on inactivation of Kv1.5 is not 
fully understood, the juxtamembrane location of the modification sites may be 
instructive. The electrostatic environment in this region is thought to influence the 
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voltage-sensitivity of Kv channels (45). The surface of SUMO is highly charged. 
Notably, one hemisphere is rich in basic residues whereas the opposite face is 
predominantly acidic. Conjugation of SUMO may modulate the local electrostatic 
environment and thereby influence voltage-sensitive steps. The selective effects of 
SUMOylation on the voltage dependence of inactivation, but not activation however, 
argue that SUMOylation affects steps other than the voltage sensitive transitions along 
the usual path towards activation. Certain Kv channel  -subunits confer rapid N-type 
inactivation to Kv1.5 by providing an N-terminal inactivation peptide. Intriguingly, the 
first SUMOylation site (K221) is three residues downstream from an acidic region in the 
T1-S1 linker that is thought to facilitate N-type inactivation by positioning the 
inactivating peptide in close vicinity to the pore (32). SUMOylation could regulate  -
subunit-dependent N-type inactivation through direct steric hindrance or by altering the 
local electrostatic environment. The current experiments were conducted in cells that do 
not express  -subunits so exploring the role of SUMO modification of Kv1.5 in the 
context of various  / -subunit combinations will likely be informative. The effects of 
SUMO modification in contexts such as transcriptional regulation are likely due to the 
promotion of protein-protein interactions (146,153,173). Notably, a critical surface in 
SUMO essential for transcriptional inhibition (152) is the site of interaction for I/L/V rich 
SUMO-interacting motifs present in multiple proteins (149,174), including some 
associated with membrane proteins (171). Since Kv1.5 functions as part of a multi-
protein/lipid complex comprised of proteins with scaffolding, cytoskeletal and enzymatic 
activities, SUMO modification of Kv1.5 may function by modulating these interactions.  
Given the functional effects of SUMOylation, SUMO proteases or E3 enzymes 
that target Kv1.5 are likely to exert important regulatory functions. In this regard, the K+ 
channel associated protein KChAP (99) has been shown to be a member of the PIAS 
family of proteins originally identified as negative regulators of several transcriptional 
responses (175). PIAS proteins possess intrinsic SUMO-specific E3 activity (133) and 
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most of their transcriptional effects depend on this function. While the regulatory 
consequences of KChAP association with Kv1.5 remain to be determined, the effects on 
surface expression observed for other Kv channels occur in a transcription-independent 
manner (175). In addition, since the SUMOylation pathway is sensitive to redox signals 
(176), SUMOylation may contribute to the oxygen-sensing properties of Kv1.5 in the 
pulmonary vasculature (87). Clearly, alterations in the SUMOylation of Kv1.5 have the 
potential to alter the excitability of both atrial myocytes and vascular smooth muscle cells 
by modulating either the action potential duration or resting membrane potential. Thus, 
mechanisms that regulate Kv1.5 SUMOylation afford a novel link between signaling 
pathways and cellular excitability. 
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CHAPTER III: ACUTE AND BIDIRECTIONAL EFFECTS OF SUMO 
MODIFICATION ON THE Kv1.5-MEDIATED IKUR CURRENT IN 
CARDIOMYOCYTES2 
INTRODUCTION 
In the human heart, Kv1.5 is selectively expressed in the atria (69) and mediates 
the ultrarapid K+ current (Ikur) critical to action potential phase II repolarization (12).  
These properties have identified Kv1.5 as a promising target for the development of 
novel antiarrhythmic medications intended to increase atrial refractoriness in patients 
with atrial fibrillation, while sparing the risk of potentially life-threatening, ventricular 
side-effects. 
In the previous chapter, we identified that Kv1.5 is post-translationally modified 
by all three isoforms of SUMO at two conserved consensus SUMOylation motifs 
centered on lysines 221 and 536, and that loss of SUMOylation, either by disruption of 
these motifs or expression of the SUMO-specific protease SENP2, leads to a selective 
~15 mV hyperpolarizing shift in the voltage-dependence of steady-state inactivation of 
the channel.  These findings identify SUMO modification as a new point of regulation of 
Kv1.5 function and strongly suggest a potential role for SUMOylation in the regulation of 
Kv1.5-mediated Ikur current in cardiomyocytes. 
It is important to note that the studies in heterologous systems described in 
Chapter II involved complete and persistent loss of SUMOylation through mutations or 
co-expression of SENP2, which could reflect stable alterations in the biosynthesis and 
                                                 
2 The data from this chapter are planned for publication as “Benson, M, Kaur K, McEwen D, Martens JR, 
Iñiguez-Lluhí JA.  The Acute and Bidirectional Effects of SUMO Modification on Kv1.5-Mediated Ikur 
Current in Cardiomyocytes.” 
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assembly of Kv1.5 complexes.  Thus, these experiments did not address whether 
SUMOylation could serve as an acute and rapid regulatory mechanism acting on pre-
existing channels at the plasma membrane.  Furthermore, the experiments did not address 
whether this regulatory mechanism is operational in the native cellular context of 
cardiomyocytes where Kv1.5 serves its physiological functions, or whether 
SUMOylation has additional roles in the regulation of Kv1.5-mediated currents.  
In the work described in this chapter, we aimed to probe the role of SUMO 
modification on the regulation of Kv1.5-mediated Ikur current in cardiomyocytes and to 
examine whether the effects of Kv1.5 SUMOylation can be regulated acutely.  As 
described below, we show that loss of SUMOylation of Kv1.5, by either disruption of the 
SUMOylation motifs or inclusion of purified, recombinant SENP2 in the patch pipette 
during our electrophysiological recordings, leads to a significant, hyperpolarizing shift in 
the voltage-dependence of steady-state inactivation of expresssed Kv1.5 in HL-1 atrial 
myocytes.  This acute effect of SENP2 on Kv1.5 is dependent on the presence of intact 
SUMOylation motifs since SENP2 has no effect on the inactivation of the SUMOylation-
deficient Kv1.5 K221/536R mutant.  Furthermore, we find that inclusion of SENP2 in the 
patch pipette during whole-cell electrophysiological recordings of acutely-dissociated 
mouse ventricular myocytes leads to a hyperpolarizing shift in the voltage-dependence of 
steady-state inactivation of endogenous Ikur current.  Conversely, inclusion of SUMO1 in 
the patch pipette during these recordings leads to an opposite, depolarizing shift in the 
voltage-dependence of inactivation of Ikur current in these cells.  We find that this 
regulatory mechanism extends to human cardiomyocytes, as inclusion of SUMO1 in the 
patch pipette during recordings from acutely-dissociated human atrial myocytes results in 
a similar depolarizing shift in the voltage-dependence of steady-state inactivation of Ikur.  
To probe the mechanism by which infused SUMO leads to this shift, we took advantage 
of a SUMO1-∆GG mutant.  This form lacks the C-terminal di-glycine motif required for 
formation of the isopeptide bond between SUMO and its substrate, but retains an intact 
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binding surface known to facilitate the formation of non-covalent inter- or intra-
molecular interactions.  Inclusion of this SUMO1-∆GG mutant in the pipette solution 
recapitulated the effects of SENP2 and led to a significant hyperpolarizing shift in the 
voltage-dependence of steady-state inactivation of Ikur current, suggesting that the 
mechanism of action by which SUMO regulates Ikur current may be through the 
facilitation of inter- or intra-molecular interactions with the channel.  Importantly, while 
we found that infusion of SUMO1, SENP2, or SUMO1-∆GG had no effect on the current 
densities of other outward K+ currents such as Ito or Iss,  infusion of either SENP2 or 
SUMO1-∆GG led to a ~ 40% reduction in Ikur current density.  Consistent with the role of 
Ikur in cardiac repolarization, this treatment with SENP2 or SUMO1-∆GG led to a 
significant prolongation of the plateau phase of the action potential without affecting the 
resting membrane potential or the amplitude of the action potential. 
Together, these findings provide strong evidence that SUMO modification acutely 
regulates the voltage-dependence of inactivation of endogenous Ikur current in mouse and 
human cardiomyocytes.  Moreover, we find that modulation of the SUMOylation 
pathway can lead to significant functional consequences on the shape and duration of the 
cardiac action potential. 
EXPERIMENTAL PROCEDURES 
Expression plasmids and cell culture 
The expression vectors pCDNA3.1 hKv1.5 V5-His and pCDNA3.1 hKv1.5 
K221/536R V5-His have been previously described (165).  pET28b expression vectors 
bearing the N-terminal His-tagged human Senp2 catalytic domain (364-489) and C548S 
mutant were generous gifts of Christopher D. Lima (177) (Structural Biology Program, 
Sloan-Kettering Institute, New York, NY 10021, USA).  pET15b His6-SUMO1 was 
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prepared by inserting a full-length, human SUMO1 fragment generated by PCR into the 
NdeI/BamHI restriction sites of pET15b (Novagen, Gibbstown, NJ).  The  ∆GG mutant 
was generated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La 
Jolla, CA).  HL-1 cells were transfected using Lipofectamine 2000 reagent (Invitrogen, 
Carlsbad, CA) and maintained on gelatin/fibronectin-coated wells in Claycomb medium 
(Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum, 0.1 mM 
norepinephrine, 2 mM L-glutamine, and 100 U/ml penicillin/streptomycin as described 
(178). 
Expression and purification of recombinant proteins 
BLR(DE3) pLysS cells (Novagen) containing pET15b His6-SUMO1, pET15b 
His6-SUMO1 ∆GG, pET28b His6-SENP2, or pET28b His6-SENP2 C548S were grown 
at 37 °C in LB medium containing 25 µg/ml chloramphenicol, 12 µg/ml tetracycline, and 
50 µg/ml of either carbenicillin (for SUMO1 constructs) or kanamycin (for SENP2 
constructs). Cultures in the logarithmic growth phase were induced with 1 mM isopropyl-
1-thio-β-D-galactopyranoside for 2 h at 37 °C.  Cells were harvested by centrifugation at 
8,000 × g for 15 min at 4 °C and lysed in either Buffer A (50 mM NaH2PO4, 300 mM 
NaCl, 10 % glycerol, 10 mM imidazole, 5 mM β-mercaptoethanol, EDTA-free Complete 
Miniprotease Inhibitor mixture tablets (1 tablet/10 ml), pH 8.0) for SUMO1 constructs, or 
Buffer A containing no protease inhibitors for SENP2 constructs.  After lysozyme 
treatment (40 µg/ml for 30 min) and sonication at 4 °C, the suspension was centrifuged at 
35,000 rpm at 4 °C for 30 minutes, and the supernatant was incubated with Ni2+-NTA 
agarose beads (Qiagen) with rocking for 60 minutes at 4 °C.  The resin was washed with 
10 bed volumes of Buffer A, followed by 2 bed volumes of Buffer A containing 20 mM 
imidazole. Protein was eluted in Buffer A containing 250 mM imidazole. All proteins 
were exchanged into Buffer C (50 mM NaH2PO4 (pH 8.0), 50 mM NaCl, 5 mM β-
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mercaptoethanol, 10% glycerol) via gel filtration, quantitated using a Bradford assay, and 
stored at -80 °C. 
Isolation of murine ventricular myocytes 
Single ventricular myocytes were isolated from adult (2-3 months old), male 
C57/black mice as previously described (179) by Dr. Kuljeet Kaur in the laboratory of 
Dr. Rick Neubig in our department.  Briefly, and in accordance with the University of 
Michigan University Committee on the Use and Care of Animals, mice were anesthetized 
by pentobarbital, heparinized, and killed by cervical dislocation.  Hearts were rapidly 
removed and retrogradely perfused using a modified Langendorff apparatus with 
calcium-free perfusion buffer (120.4 mM NaCl, 14.7 KCl, 0.6 mM KH2PO4, 0.6 mM 
Na2HPO4, 1.2 mM MgSO4-7H2O, 10 mM Na-HEPES, 4.6 mM NaHCO3, 30 mM 
taurine, 10 mM 2,3-butanedione monoxime (BDM), 5.5 mM glucose, pH adjusted to 7.0 
with HCl, continually maintained at 37°C and bubbled with 100% O2) for 4 minutes at 
approximately 4 ml/min.  The heart was then enzymatically digested by perfusion with 
Mycoyte Digestion Buffer (Perfusion Buffer + 2.4 mg/ml collagenase II (Worthington 
Biochemical Co, Lakewood, NJ)) for 3 minutes at 4 ml/min.  Subsequently, CaCl2 was 
added to a final concentration of 40 µM, and perfusion was continued until the heart 
appeared pale, swollen, and fibrillar (~8 minutes).  The heart was removed from the 
cannula, and the right and left ventricles were cut into small pieces in Myocyte Stopping 
Buffer (Perfusion Buffer + 10% calf serum + 12.5 µM CaCl2).  The pieces were gently 
triturated until they were dissociated into rod-shaped, single cells.  ATP was added to a 
final concentration of 2 mM, and Ca2+ was gradually reintroduced in a four-step process 
over ~8 minutes until the calcium concentration was 1.2 mM.  Isolated myocytes were 
stored in Myocyte Culture Medium (DMEM, 0.1% BSA, 100 U/ml penicillin, 2 mM 
glutamine) at 25°C until use. 
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Isolation of human atrial myocytes 
A specimen of atrial pectinate muscle was obtained in accordance with the 
University of Michigan Institutional Review Board from a donor heart that failed criteria 
for successful cardiac transplantation.  Single atrial myocytes were isolated using a 
modified protocol as previously described for the isolation of human ventricular 
myocytes (180) by Dr. Dyke McEwen in the laboratory of Dr. Jeffrey Martens.  Briefly, 
tissue that had been maintained on ice was transferred to ice-cold Storage Buffer (100 
mM NaCl, 5.4 mM KCl, 1.5 mM MgSO4, 10 mM NaOAc, 1.5 mM NaH2PO4, 15 mM 
NaHCO3, 10 mM glucose, 10 mM taurine, 10 mM HEPES, pH 7.4), and pectinate muscle 
from the right and left atria were collected and minced into small pieces using a scalpel 
and fine scissors.  These pieces were incubated in Wash Buffer (Storage Buffer + 5 mM 
nitrilotriacetic acid (NTA) + 15 mM BDM, pH 7.0) for 10 minutes, rinsed briefly in 
Storage Buffer, digested for 30 minutes in Protease Buffer (Storage Buffer + 4 U/ml 
Protease Type XXIV (Sigma-Aldrich), 400 U/ml Collagenase Type II (Worthington 
Biochemical Co), 15 mM BDM, 1.25 µM CaCl2, pH 7.4), and further digested for 
approximately 60 minutes in Hylauronidase Buffer with occasional, gentle trituration 
(Storage Buffer + 198 U/ml hylauronidase (Sigma-Aldrich), 400 U/ml Collagenase Type 
II, 15 mM BDM, 1.25 µM CaCl2, pH 7.4) until fully-dissociated, rod-shaped cells were 
apparent.  All incubations were conducted at 37°C with moderate shaking (500 rpm) and 
bubbled 100% O2.  Cells were resuspended in Incubation Buffer (Storage Buffer + 15 
mM BDM + 2 % BSA), and calcium was gradually reintroduced in a six-step process 
over ~ 60 minutes until the calcium concentration was 1.7 mM.  Cells were maintained at 
25°C until use. 
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Electrophysiology 
Whole-cell patch clamp recordings were conducted using a patch-clamp amplifier 
(Axopatch 200B, Axon Instruments, Foster City, USA) as previously described (74,86).  
For experiments in the HL-1 cell line, cells transfected with 0.5 µg pEGFP (Clontech) 
and 0.5 µg of either pCDNA3.1 Kv1.5 V5-His or pCDNA3.1 Kv1.5 KRKR V5-His were 
trypsinized 24 h after transfection and resuspended in HL-1 supplemented medium using 
established protocols (178).  A 200 µl aliquot of these cells was placed in a recording 
chamber mounted on the stage of an inverted microscope and allowed ~ 30 minutes to 
settle before being superfused with Bath Solution (in mmol/l): NaCl 110, KCl 4, MgCl2 
1, CaCl2 1.8, HEPES 10, and glucose 1.8; adjusted to pH 7.35 with NaOH.  Fluorescent 
cells with 2-6 nA of total current were selected for analysis.  For primary 
cardiomyocytes, a 200 µl aliquot of cells was placed in the recording chamber, allowed 
five minutes to settle, and continuously superfused with Bath Solution.  Only non-
beating, single, rod-shaped cells were selected.  All experiments were conducted at room 
temperature.  Patch pipettes were pulled from borosilicate glass capillaries (World 
Precision Instruments, Sarasota, FL, USA) and had resistances in the range of 2-5 MΩ 
when filled with pipette solution containing (in mmol/l): potassium aspartate 110, KCl 
20, NaCl 8, HEPES 10, K4BAPTA 10, K2ATP 4, MgCl2 1, CaCl2 1; adjusted to pH 7.2 
with KOH.  Pipette series resistance in the whole-cell mode was in the range of 2–10 MΩ.  
Capacitave surface area, access resistance, and input impedance were determined based 
on the capacitave transients elicited by symmetrical 10 mV voltage clamp steps from -80 
mV.  A holding potential of -80 mV was maintained in all experiments.   
For HL-1 cells, the protocol to obtain steady-state inactivation curves consisted of 
a 5 second conditioning pulse applied in 10 mV steps as indicated followed by a 500 ms 
test pulse at +30 mV.  Peak current amplitude at each test pulse was plotted as a function 
of conditioning pulse potential and fit to a Boltzmann equation using Prism 5 software 
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(GraphPad).  Data from each cell was normalized to both maximal and minimal current 
values derived from the fit. 
For isolated primary cardiomyocytes, Ikur was calculated as the difference 
between peak current and the current at the end of a 3-second test pulse to +30 mV.  A 
100 ms prepulse to -40 mV was included to inactivate Ito (74).  Iss was determined as the 
current remaining at the end of the test pulse, and Ito was calculated as the difference in 
current between the peak of the test pulse and the peak of a corresponding test pulse 
lacking the -40 mM prepulse (74).  The protocol to measure the steady-state inactivation 
of Ikur consisted of a 5-second conditioning pulse applied in 10 mV steps as indicated, 
followed by a 100-ms prepulse to -40 mV, and a 3-second test pulse to +30 mV (74).  
The Ikur amplitude after each conditioning pulse was normalized to the maximal 
amplitude of this current.  Ikur values as a function of conditioning potential were fit to the 
Boltzmann equation.  The resting membrane potential was determined in current clamp 
mode and nulling all currents.  Action potentials were elicited using a 2 ms trigger pulse 
of 2 nA and monitored at 0.1 Hz.  The magnitude of the action potential was calculated as 
the difference between the peak of the action potential and the resting membrane 
potential. 
For infusions of purified, recombinant proteins, protein samples prepared as 
described above were thawed on the day of the experiment, exchanged into fresh pipette 
solution using a Bio-Spin 6 gel filtration column (Biorad, Hercules, CA), and quantitated 
using a Bradford assay.  Samples were diluted into pipette solution to achieve the 
indicated concentrations, and loaded directly into the pipette with no back-filling. 
Statistical analysis 
Statistical analyses were performed using Sigma Plot 9.0 (Systat Software) and 
Prism 5 (GraphPad).  Data are expressed as mean +/- s.e.m.  Unpaired Student’s t-tests 
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were performed as indicated, and statistical significance was assigned to p < 0.05.  
Comparison of V50 values was carried out with an F test applied to global fits of pooled 
vs separate sets using Prism5 software. 
RESULTS 
SUMO modification acutely regulates Kv1.5 inactivation in HL-1 atrial myocytes 
To probe the functional role of the SUMOylation motifs in Kv1.5 in atrial 
cardiomyocytes, we characterized the voltage-dependence of steady-state inactivation 
elicited by expression of Kv1.5 forms harboring intact or disrupted SUMOylation motifs 
in HL-1 immortalized mouse atrial myocytes.  As seen in Figure III-1, disruption of the 
Kv1.5 consensus SUMOylation motifs with double K221/536R substitutions, led to a 
significant, ~ 6.5 mV hyperpolarizing shift in the half-maximal voltage of steady-state 
inactivation (V50) from the WT value of -10.02 +/- 1.82 (n=10) to -16.59 +/- 1.26 mV 
(n=9) (p < 0.0001).  This shift occurred without significant alterations in the extent of 
inactivation (35.3 +/- 3.9 and 35.5 +/- 2.4 % for WT and K221/536R, respectively). 
Our previous findings, (described in Chapter II) that loss of SUMOylation induces 
a hyperpolarizing shift in the voltage-dependence of steady-state inactivation of Kv1.5 in 
heterologous systems, argue strongly in favor of SUMOylation (rather than other lysine-
directed modifications) as the mechanism responsible for the functional effects of the 
motifs in HL-1 cells.  However, to test this hypothesis, we made use of a variant of the 
SUMO-specific protease SENP2 (His6-SENP2 364-489) that displays enhanced activity 
against multiple SUMOylated substrates and localizes to the cytoplasm.  For simplicity, 
we refer to this form as SENP2 in the remainder of the thesis.  Similar to our approach in 
Cos7 cells, we reasoned that reducing the levels of SUMOylation of WT channel by 





















Figure III-1. SUMO Modification Acutely Regulates Kv1.5 Inactivation in HL-1 
Atrial Myocytes. 
HL-1 cells were co-trasnsfected with 0.5  g each of pEGFP-C1 (to identify 
transfected cells) and a pCDNA3.1-based vector for the expression of the indicated Kv1.5 
variant and whole whole-cell patch-clamp recordings were conducted as described in 
Experimental Procedures.  333 nM purified, recombinant SENP2 was included in the 
patch pipette, as indicated.  Data represent average +/- SEM.  (A) The voltage-
dependence of steady-state inactivation was fit to a Boltzmann equation.  (B) The V50s of 
steady-state inactivation are plotted from the fit in Panel A. 
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state inactivation.  In contrast to our studies in Cos7 cells in which we co-expressed 
SENP2 with WT channel, we chose to probe the acute effects of SENP2 on Kv1.5 
regulation by generating purified, recombinant forms of the protein and including the 
preparations into the pipette solution during our electrophysiological recordings.  As can 
be seen in Figure III-1, inclusion of SENP2 in the pipette solution produced a significant 
~ 6.5 mV hyperpolarizing shift in the voltage-dependence of steady-state inactivation in 
HL-1 cells. The treatment shifted the V50 from -10.03 +/- 1.82 (n=10) to -16.55 +/- 1.63 
mV (n=5) (p < 0.0001) with no significant alteration in the extent of inactivation (43.4 +/- 
4.7% (n=5) (p = 0.23).  This shift was indistinguishable from that of the K221/536R 
mutant (p = 0.91), and importantly, was dependent on the integrity of the SUMOylation 
motifs in Kv1.5 since inclusion of SENP2 in the pipette solution did not alter the V50 of 
the SUMOylation-deficient K221/536R mutant (V50 = -15.68 +/- 1.67 mV (n=8); p = 
0.24).  The shift induced by SENP2 was detectable immediately at the initiation of 
recordings (which were started ~ 1 minute after establishment of the whole-cell 
configuration) and were stable for the duration of the recording (> 10 minutes).  Infusion 
of a purified, recombinant form of SUMO1 (His6-SUMO1) had no effect on the voltage-
dependence of steady-state inactivation (V50 = -10.22 +/- 1.49 mV (n=3)), consistent with 
our observation that co-expression of WT SUMO3 had no effect on the voltage-
dependence of inactivation of Kv1.5 in Cos7 cells. 
Taken together, these findings provide strong evidence that loss of SUMOylation, 
by either point mutations at the SUMOylation motifs or acute exposure to the SUMO-
specific protease SENP2, leads to a hyperpolarizing shift in the voltage-dependence of 
steady-state inactivation in immortalized HL-1 atrial myocytes in a manner similar to that 
observed in Cos7 cells. 
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Isolation of Ikur current in acutely-dissociated mouse ventricular myocytes 
Our characterization of the specific effects of SUMO modification on the isolated 
properties of Kv1.5 coupled with the ability to acutely modulate SUMOylation allowed 
the opportunity to examine the consequences of altering SUMOylation on the 
electrophysiological properties of acutely dissociated myocytes.  In these cells, Kv1.5 is 
embedded in its natural context and mediates Ikur, a well-characterized outward current 
important for repolarization and establishment of the action potential duration.  By taking 
advantage of the characterized effects of SUMOylation on Kv1.5 this approach can not 
only reveal effects of SUMOylation on Kv1.5 in its native context, but also can reveal the 
full impact of this regulatory mechanism on the endogenous complement of proteins that 
give rise to the specific electrophysiological properties of cardiac myocytes.  
To this end, we conducted whole-cell patch-clamp studies of acutely dissociated 
mouse ventricular myocytes.  These cells are useful model system because in rodents, 
Kv1.5 is expressed in both atrial and ventricular myocytes.  Moreover, the ultrarapid-
delayed rectifier potassium current (Ikur) in these cells has been extensively characterized. 
This current is mediated by Kv1.5 (74) and can be isolated from other outward currents 
based on its specific kinetic and pharmacologic properties (12,74).   
As shown in Figure III-2A), and consistent with previous studies (74), whole-cell 
voltage-clamp recordings of mouse ventricular myocytes revealed that sustained 
depolarization to +30 mV from a holding potential of -80 mV yielded a rapidly-
activating, slowly inactivating, outward current.  The inactivation of this current displays 
three major kinetic components.  The rapidly (τ ~ 17 ms) inactivating component (Ito) is 
known to be mediated by members of the Kv4 family (181).  A second component that 
inactivates more slowly (Ikur) is mainly mediated by Kv1.5 (Figure III-2A).  A third, non-
inactivating component (Iss), is revealed at the end of the trace and is mediated by Kv2.1 




















Figure III-2. Isolation of Ikur Current in Acutely-Dissociated Mouse Ventricular 
Myocytes.   
(A) Ito, Ikur, and Iss were isolated from total, outward K+ current in acutely-
dissociated ventricular myocytes as described in the text.  Ito was calculated as the 
difference between the total outward current and IKslow.  Ikur was calculated as the 
difference between IKslow and Iss.  And Iss was the current remaining after treatment with 
100  M 4-AP.  (B)  A raw trace of the total outward K+ current in these cells obtained by 
depolarization from a resting potential of -80 mV to +30 mV.  Inset shows an isolated 
mouse ventricular myocyte. 
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Ito, Ikur and Iss can be separated using established protocols as shown in Figure III-2B 
(74).  A brief (100 ms) depolarizing prepulse to -40 mV is sufficient to inactivate the Ito 
component without affecting Ikur or Iss.  A depolarization to +30 mV that incorporates a 
100 ms pre-pulse to -40 mV thus reveals a current carried exclusively by Ikur and Iss. This 
component is referred to as Ikslow.  As had been previously described (74), we confirmed 
that by the end of a 3-second test pulse to +30 mV, Ikur current inactivates completely and 
only noninactivating Iss persists.  In this manner, Ito can be revealed as the difference 
between the total outward current and Ikslow.  Using the two pulse protocol, the peak 
amplitude of Ikur can thus be defined as the peak Ikslow amplitude – Iss. 
Consistent with the pharmacological properties of the underlying channels, (12) 
treatment of the cells with 100  M of the potassium channel blocker 4-aminopyridine (4-
AP) inhibits the Ikur component without affecting Ito or Iss (Figure III-2B).  Using the 
above two-pulse protocol, it is thus possible to isolate Ikur and study its inactivation 
properties.  
SUMO modification acutely regulates inactivation of Ikur in mouse ventricular 
myocytes. 
Given that SUMOylation alters the inactivation properties of Kv1.5, we focused 
initially on this property of isolated Ikur (Figure III-3).  Using the two-pulse protocol, we 
measured the voltage-dependence of steady–state inactivation of Ikur as has been 
previously described (74), we confirmed that by the end of the 3-second test pulse, Ikur 
current had inactivated completely and only 4-AP-insensitive Iss persisted (Figure III-3A).  
This enabled us to calculate the voltage-dependence of steady-state inactivation by 
measuring the difference in current between the peak (IKslow) and the end (Iss) of the test 
pulse (IKslow – Ikss = Ikur) and plotting this value as a function of the potential of the 
conditioning pulse.  Two representative traces from the voltage-dependence of steady-


















Figure III-3. The Voltage-Dependence of Steady-State Inactivation of Endogenous 
Ikur Current in Mouse Ventricular Myocytes. 
The voltage-dependence of steady-state inactivation of endogenous Ikur current in 
acutely-dissociated ventricular myocytes could be determined using a 5-second 
conditioning pulse in 10 mV intervals from -80 mV to +20 mV, followed by a 100 ms 
“inactivating pre-pulse” to -40 mV to inactivate Ito, followed by a 3 sec test pulse to +30 
mV.  (A) The 3 second test pulse from the protocol for the voltage-dependence of steady-
state inactivation is shown.  Treatment with 100  M 4-AP demonstrates that Ikur has 
completely inactivated by the end of the pulse and only 4-AP-insensitive Iss remains.  Ikur 
was calculated as the difference in current between the peak (IKslow) and end (Iss) of this 
test pulse.  (B) A raw trace from the protocol for the voltage-dependence of steady-state 
inactivation with 2.5  M SENP2 included in the pipette solution.  Conditioning pulses to 
-40 and -30 are indicated in red and orange, respectively. (C) A raw trace with 20  M 
SUMO1 included in the pipette solution. 
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B was collected with 2.5  M SENP2 included in the pipette solution, and the trace in 
Panel C was collected with 20  M SUMO1 included in the pipette solution.  Comparison 
of these traces shows that while Ikur has undergone substantial inactivation after a 
conditioning pulse of -40 mV (highlighted in red) in the presence of SENP2, significantly 
less inactivation is observed at this potential in the presence of SUMO1.  Quantitation of 
these results (Figure III-4), shows that inclusion of SENP2 in the pipette solution leads to 
a small, but statistically significant ~ 2.4 mV shift in the voltage-dependence of steady-
state inactivation relative to control recordings in the absence of the protein.  SENP2 
shifted the V50 from -35.97 +/- 0.78 mV (n=17) in its absence to -38.31 +/- 0.81 mV 
(n=6) in its presence (p = 0.016).  Conversely, inclusion of SUMO1 in the patch pipette 
during these recordings led to a small but significant ~ 2.1 mV depolarizing shift in the 
voltage-dependence of steady-state inactivation of Ikur, shifting the V50 from -35.97 +/- 
0.78 mV (n=17) in its absence to -33.81 +/- 0.74 mV (n=19) in its presence (p < 10-4).  
The ~ 4.5 mV shift in V50s induced by infusion of SENP2 compared to infusion with 
SUMO1 was highly significant (p < 10-4).  The effects of these proteins appear to be 
restricted to Ikur, since we did not observe significant effects on Iss current density.  
Moreover, SUMO1 had no significant effect on Ito current density (data on the effect of 
SENP2 on Ito was not collected) (Figure III-4, inset). 
Consistent with our studies of Kv1.5 in Cos7 and HL-1 cells, these data provide 
evidence that loss of SUMOylation in acutely-dissociated mouse ventricular myocytes 
leads to a hyperpolarizing shift in the voltage-dependence of steady-state inactivation of 
endogenous Ikur current.  In contrast, infusion of purified SUMO1 into these cells leads to 
a significant depolarizing shift in the voltage-dependence of steady-state inactivation of 
Ikur current.  Notably, this effect of SUMO1 was not detected in HL-1 cells suggesting 
that the basal SUMOylation state of Kv1.5 may be lower in ventricular myocytes 






















Figure III-4. SUMO Modification Acutely and Reversibly Regulates Inactivation of 
Ikur in Mouse Ventricular Myocytes. 
(A) The voltage-dependence of steady-state inactivation of endogenous Ikur in 
acutely-dissociated mouse ventricular myocytes was recorded with either 3  M SENP2 
or 20  M SUMO1 included in the patch pipette, as indicated. (B) The V50s of inactivation 
as calculated from the fits in A are plotted. 
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effects on outward currents since the current densities of Ito and Iss are unaffected by this 
treatment. 
SUMO modification acutely regulates endogenous Ikur current in human atrial 
myocytes 
As mentioned in Chapter I, Kv1.5 is an attractive target for atrial fibrillation 
therapy because of its functional role and atrial specific expression.  In an effort to 
determine if the regulatory effects of SUMOylation on the inactivation of Ikur current are 
present in human cardiac tissue, we conducted whole-cell patch clamp studies of acutely-
dissociated human atrial myocytes.  The cells were derived from a single human donor 
heart that failed criteria necessary for successful cardiac transplantation.  As shown in 
Figure III-5, inclusion of SUMO1 preparations in the pipette solution during these 
recordings led to a ~5.7 mV depolarizing shift in the voltage-dependence of steady-state 
inactivation of Ikur current, altering the V50 from -44.56 +/- 2.67 mV (n=5) in its absence 
to -38.83 +/- 1.85 mV (n=3) in its presence (p<0.02).   Inclusion of SENP2 in the patch 
pipette during these recordings had no appreciable effect on the voltage-dependence of 
inactivation -43.98 +/- 3.21 mV (n=2) (p=0.87).  These initial findings are consistent with 
the effects of SUMOylation on the properties of Kv1.5 and indicate that the regulatory 
effects of SUMO modification on Ikur current are indeed operational in the human heart.  
The fact that infusion of SUMO1 rather than SENP2 alters the inactivation of Ikur argues 
that the basal SUMOylation state of Kv1.5 may be lower in the human atrial preparation 





















Figure III-5. SUMOylation Acutely Regulates Endogenous Ikur Current in Human 
Atrial Myocytes. 
The voltage-dependence of steady-state inactivation of endogenous Ikur current 
from acutely-dissociated human atrial myocytes.  Recordings were in the presence of 14 





A conjugation-deficient SUMO functions in a dominant-negative manner to regulate 
Ikur current in mouse ventricular myocytes 
To probe the mechanism by which infused SUMO1 regulates the inactivation 
properties of the Kv1.5-mediated Ikur current in cardiomyocytes, we took advantage of a 
conjugation-deficient variant of SUMO1 (SUMO1-∆GG).  This form lacks the C-
terminal di-glycine motif required for activation and conjugation to target proteins.  
Nevertheless, this form bears an intact effector binding surface required for non-covalent 
interactions with SUMO-binding partners (Figure III-6).  If SUMO1 regulates Ikur current 
in cardiomyocytes by providing a binding surface for the formation of inter- or intra-
molecular interactions, an excess of non-conjugatable form of SUMO may compete with 
the SUMO moiety attached to the channel and prevent the establishment of the relevant 
interactions.  We would therefore predict that SUMO1-∆GG may act in a dominant-
negative manner to interfere with the normal function of Kv1.5 SUMOylation.  In this 
view, this protein may exert effects similar to SENP2 on the Ikur current.   
As seen in Figure III-7, inclusion of SUMO1-∆GG in the pipette solution during 
whole-cell patch clamp studies of acutely-dissociated mouse ventricular myocytes led to 
a significant, ~ 3.5 mV hyperpolarizing shift in the voltage-dependence of steady-state 
inactivation of Ikur, altering the V50 from -35.97 +/- 0.78 mV (n=17) in its absence to -
39.41 +/- 0.57 (n=11) in its presence (p <10-4).  This shift was indistinguishable from that 
caused by infusion of SENP2 (-38.32 +/- 0.81 mV (n=6); p = 0.06) and occurred without 
significant effects on the current densities of Ito or Iss (Figure III-9).  The ~ 5.6 mV 
difference between the V50s of inactivation in the presence of WT- and ∆GG-SUMO1 
was highly significant (p < 10-4). 
Consistent with a dominant-negative mechanism, these findings indicate that 
inclusion of SUMO1-∆GG in the patch pipette recapitulates the effects of SENP2 on the 







Figure III-6. SUMO Contains a Binding Surface that Facilitates the Formation of 
Inter- and Intra-Molecular Interactions with SIM-Containing 
Proteins. 
(A) Homology modeling of SUMO2 was carried out using Swiss PDB viewer 
software (SPDBV V3.7) using the crystal structure coordinates of SMT3 (residues 20 to 
98) as a template.  The critical residues K33, K35, K42, R50, V30, I34, and T38 that 
make up this binding surface are highlighted in red.  The C-terminal, di-glycine motif that 
is necessary for the covalent interactions of SUMO are highlighted in blue.  (B) A model 
of the SUMO binding motif ([D] [VI] [LQE] [VIE] [V]) of RanBPII in complex with the 
binding surface of SUMO2 based on the crystal structure of the RanBPII/SUMO2 






















Figure III-7. Conjugation-Deficient SUMO1-∆GG Functions as a Dominant-
Negative Mutant and Regulates Ikur Current in Mouse Ventricular 
Myocytes. 
(A) The voltage-dependence of steady-state inactivation of endogenous Ikur 
current in acutely-dissociated mouse ventricular myocytes was recorded in the presence 
of 20  M SUMO1-∆GG, as indicated.  Data from SENP2 and SUMO1 are from Figure 
3.4.  (B) The V50s of steady-state inactivation as calculated from the Boltzmann plot in A. 
 95
they suggest that the mechanism of action by which SUMOylation regulates Ikur current 
may involve the facilitation of inter- or intra-molecular interactions with the channel. 
Analysis of the effects of SUMO on the kinetics of IKur inactivation 
The experiments described above demonstrate that SUMOylation affects the 
voltage-dependence of steady-state inactivation.  This process depends on multiple 
kinetic parameters governing both the onset and recovery from inactivation.  As an initial 
step to examine the mechanism of SUMOylation on the inactivation of Ikur, we examined 
in more detail the kinetics of inactivation after a strong depolarizing pulse to +30 mV 
where reliable estimates of kinetic parameters can be obtained.  
The time course of inactivation of Ikur after a strong depolarizing pulse is 
complex.  Previous characterization of Kv1.5 inactivation has revealed that the time 
course of inactivation can be well-described by fitting to a bi-exponential function with a 
fast time constant on the order of 102 ms and a slower time constant of approximately 1-2 
seconds (182). 
Using a similar protocol to that described above for the voltage-dependence of 
inactivation, Ikur current was accessed using a three-second depolarizing pulse to +30 mV 
from a holding potential of -80 mV immediately following a 100-ms pre-pulse to -40 mV 
to inactivate Ito (74).  This current (Ikslow) is composed of Ikur and the non-inactivating 
component Iss.  During the +30 mV pulse, Ikur decays until only Iss remains.  
In control recordings, two populations of cells could be distinguished based on the 
kinetics of Ikur inactivation.  In more than half of the cells, (12 of 19 or 63%) both a fast 
and a slow component could be discerned.  The fast component had an average time 
constant of 179 ± 43 ms whereas the value for the slow component was 1242 ± 119 ms 



















Figure III-8. Analysis of the effects of SUMO on the kinetics of IKur inactivation 
The inactivating trace of Ikur at a sustained depolarizing pulse to +30 mV was fit 
to either a single- or bi-exponential equation. A) Time constants of inactivation for 
recordings best fit by a bi-exponential equation.  B) Time constants of inactivation for 
recordings best fit to a single-component.  C) Current densities of the fast and slow 
components.  The current density of the slow component includes all cells described by 





The time constant in these cells was indistinguishable form the value of the slow 
component observed in cells that displayed a fast component (Figure III-8B).   
Notably, inclusion of either SUMO1, SENP2 or SUMO1-∆GG preparations in the 
recording pipette solution did not alter the time constants of inactivation of either the fast 
or slow component (Figure III-8A,B).  It is important to note however, that the above 
measurements were obtained in response to a strong depolarizing pulse.  It remains 
possible that SUMOylation affects these parameters at potentials closer to the V50 of 
steady-state inactivation.  Closer inspection of the data however, revealed that although 
the proportion of cells displaying both fast and slow components was comparable for 
control and SUMO1 treated cells (63 vs 50%), this ratio was reduced to 31 and 33% in 
the case of SENP2 and SUMO1-∆GG preparations, respectively.  This suggested that the 
amplitude of the fast component may be affected by loss or interference with 
SUMOylation. Especially since a reduction in the amplitude may preclude its detection in 
this type of analysis.  We therefore examined the effect of the proteins on the amplitude 
of both the fast and slow components.  As can be seen in Figure III-8C, analysis of 
untreated cells revealed values of 6.6 ±0.99 and 12.9±1.6 pA/pF for the fast and slow 
components respectively.  Notably, although inclusion of SUMO1 preparations in the 
recording pipette did not significantly alter the amplitude values, inclusion of SUMO1-
∆GG led to a significant reduction in the amplitude of both the fast and slow components 
(p=0.03 and 0.03 respectively).  A reduction in the amplitude of the slow component was 
also observed for SENP2 but did not reach statistical significance.  Notably, the relative 
contribution of each component to the total current was unaffected with 29 ± 3 % 
corresponding to the fast component. 
Taken together, these results indicate that at +30 mV, altering SUMOylation does 
not influence the time constants of inactivation of Ikur.  It is important to note, that A 
more extensive characterization of the effects of SUMOylation on the inactivation of Ikur 
will require a detailed analysis of the kinetics of onset of inactivation as well as its 
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recovery but also an examination of the voltage-dependence of the relevant rate 
constants.  Importantly, the analysis did reveal that alterations in SUMOylation may 
influence the amplitude of Ikur.  Given that we did not observe changes in current density 
upon persistent disruption of Kv1.5 SUMOylation in Cos7 cells (Chapter II), this 
suggests that in the native context, acute alterations in SUMOylation may have additional 
regulatory effects on Ikur beyond alterations in the voltage dependence of inactivation. 
Manipulation of the SUMOylation pathway acutely regulates the current density of 
Ikur current in mouse ventricular myocytes. 
The kinetic analysis described above indicated that alterations in SUMOylation 
likely influence the current density of Ikur.  We therefore examined this possibility 
directly.  As can be seen in Figure III-9, we find that inclusion of WT SUMO1 
preparations in the recording pipette did not alter the Ikur amplitude.  In contrast, inclusion 
of SUMO1-∆GG led to a 48% reduction in Ikur current (9.17 +/- 0.88 pA/pF (n=13) 
relative to the control cells 17.53 +/- 1.84 pA/pF (n=17) (p= 0.001).  Likewise, inclusion 
of SENP2 caused a 42% reduction to 10.21 +/- 3.08 pA/pF (n=5).  This difference 
however fell short of statistical significance (p = 0.067) likely due to the relatively 
limited number of cells analyzed.  Importantly, these effects were specific, as WT 
SUMO1, SENP2, and SUMO1-∆GG had no significant effects on Iss current densities, 
and neither WT SUMO1 nor SUMO1-∆GG had a significant effect on Ito current density.  
This data indicates that in addition to regulating the inactivation properties of Ikur current, 
alterations in SUMOylation also influence overall Ikur current density.  Since SUMO1-
∆GG and SENP2 but not SUMO1 inhibit Ikur current density, the data are consistent with 
the view that reducing or antagonizing SUMOylation has a negative impact on Ikur 
density and argues that in the native context, acute alterations in SUMOylation could 
affect electrophysiological properties that depend on the amplitude of Ikur, such as the 





















Figure III-9. SUMO Modification Acutely Regulates the Current Density of Ikur 
Current in Mouse Ventricular Myocytes. 
Current densities of Ito, Ikur, and Iss were calculated as described in Experimental 
Procedures.  Data needed to calculate the current density for Ito in the presence of SENP2 





SUMOylation regulates the plateau phase of the action potential in mouse 
ventricular myocytes. 
Ikur current is the main outward potassium current that mediates phase-two 
repolarization in the action potential in mouse cardiomyoytes (74).  The findings that 
SENP2 and SUMO1-∆GG acutely modulate the voltage-dependence of steady-state 
inactivation and the total current density of Ikur in mouse ventricular myocytes, prompted 
us to probe the effects of SUMO modification on the action potential of these cells.  
Whole-cell current-clamp electrophysiological recordings of acutely–dissociated mouse 
ventricular myocytes indicated that inclusion of SUMO1 in the pipette solution did not 
have a major effect on the shape or duration of the action potential (Figure III-10A).  In 
contrast, inclusion of SENP2 or SUMO1-∆GG preparations in the patch pipette during 
these recordings, led to a specific prolongation of the plateau phase of the action 
potential.  This shift in the action potential duration (APD) was detectable soon after 
establishment of the whole-cell configuration and continued to develop over a period of 
approximately 10 minutes, at which point the APD remained constant Figure III-10B. 
The effects of SENP2 or SUMO1-∆GG are most evident in the plateau phase of 
the action potential. As shown in Figure III-10C, this is reflected as a 3.0- and 4.0-fold 
increase in APD50, respectively.  The effect on the APD10, reflective of the notch phase, 
was considerably less dramatic.  The final stages of repolarization are also affected to a 
lesser extent since the fold increase in APD80 is comparable to the effects on APD50.  
Notably, the effects of the SUMO1-∆GG preparation on action potential duration are 
dependent on a native protein structure since heat treatment of the preparation for 10 
minutes at 95 °C inactivated the ability of the preparation to affect APD (last bars in 
Figure III-10C).  Consistent with the previous data, the effects of these proteins appear 





















Figure III-10. SUMOylation Leads to a Specific Prolongation of the Plateau Phase of 
the Action Potential in Mouse Ventricular Myocytes. 
(A) Raw traces from whole-cell current-clamp recordings of acutely-dissociated 
mouse ventricular myocytes in the presence of 20  M SUMO1, 2.5  M SENP2, or 20 
 M SUMO1-∆GG, as indicated.  (A) A 2- ms trigger current of 2 nA was used to induce 
the action potential at a frequency of 0.1 Hz.  (B) The duration of the APD50 (in 
milliseconds) was monitored over successive recordings (0.1 Hz) from establishing 
whole-cell configuration (C) The quantitation of data from A and B as described in the 
text.  The last, dark gray bars represent boiled SUMO1-∆GG. The # sign indicates 
statistical significance. (D) The amplitude of the action potential was calculated as the 
difference between the peak of the action potential and the resting membrane potential. 
(E) The resting membrane potential was recorded while holding the cells at 0 pA in 
current-clamp mode. 
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appreciably the amplitude of the action potential (Figure III-10D) or the resting 
membrane potential (Figure III-10E).   
Taken together, these initial findings provide exciting evidence consistent with 
the view that manipulation of the SUMOylation pathway can acutely regulate the 
duration of the plateau phase of the action potential. This reveals SUMOylation as a 
novel potential target for the development of antiarrhythmic medications aimed to 
prolong atrial refractoriness. 
DISCUSSION 
The studies presented in this chapter revealed that the Kv1.5-mediated Ikur current 
in cardiomyocytes can be acutely modulated by SUMO modification both at the level of 
its inactivation properties and its magnitude.  We find that infusion of purified, 
recombinant SENP2 into HL-1 cells and mouse ventricular myocytes leads to a 
hyperpolarizing shift in the voltage-dependence of steady-state inactivation of Kv1.5-
mediated current, while infusion of purified SUMO1 leads to an opposite, depolarizing 
shift in the V50 of inactivation of Ikur current in both mouse and human cardiomyocytes. 
Interestingly, SENP2 infusion has a significant effect on modulating the V50 of 
inactivation of over-expressed Kv1.5 current in HL-1 cells, while infusion of SUMO1 has 
very little effect.  Conversely, we find that in mouse and human cardiomyocytes, SUMO1 
has a more prominent effect than SENP2 on modulating the V50 of inactivation of 
endogenous IKur current.  This may suggest a difference in the basal SUMOylation “tone” 
between these cell types.  In this view, Kv1.5 may be more highly SUMOylated in Cos7 
and HL-1 cells under basal conditions, and thereby more susceptible to the effects of 
SENP2.  The tone of Kv1.5 SUMOylation may be lower in endogenous cardiomyocytes, 
enabling Ikur to be more responsive to the effects of exogenous SUMO1.  Differences in 
the SUMOylation tone of these cells could be due to differential expression of the SUMO 
conjugation machinery, accessory proteins that modulate Kv1.5 SUMO modification 
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(such as Kv  accessory subunits), or additional targets of SUMOylation that compete for 
the conjugation machinery.   
It is interesting to note that the value of the V50 of steady-state inactivation of 
Kv1.5 is different in cardiomyocytes than in Cos7 cells.  While the V50 of inactivation of 
WT human Kv1.5 was 0.33 +/- 1.2 mV in Cos7 cells, it was found to be -14.88 +/- 1.4 
mV in HL-1 atrial myocytes.  Likewise, while we detected an ~15 mV shift in the 
voltage-dependence of steady-state inactivation upon disruption of the SUMOylation 
motifs or treatment with SENP2 in Cos7 cells, we consistently detected this shift to be ~5 
mV in HL-1 cells, mouse ventricular myocytes, and human atrial myocytes.  As 
described in Chapter I, the biophysical properties of Kv channels are often dictated not 
only by the   subunits, themselves, but also by interactions of these subunits with other 
cellular components.  In this regard, accessory cytoplasmic subunits, lipid interactions, 
additional posttranslational modifications, and interactions with scaffolding proteins are 
all known to modulate the properties of Kv   subunits.  Thus, the finding that the V50s of 
steady-state inactivation of Kv1.5 are different in Cos7 cells and cardiomyocytes may 
imply the presence of regulatory effectors in cardiomyocytes that are absent in Cos7 
cells.   
Kv  accessory subunits are one such potential regulator.  These accessory 
subunits are known to be expressed in cardiomyocytes (183), but not in Cos7 cells, and 
have important effects on the inactivation properties of Kv1.5 (184).  It seems possible 
that SUMO modification could serve to modulate interactions of these accessory subunits 
with the channel.  It will be interesting in future experiments to probe whether 
interactions with Kv  accessory subunits, as well as other potential, as-of-yet un-
identified protein partners present in cardiomyocytes, are responsible for the effects of 
SUMOylation on Kv1.5 function. 
SUMO modification not only has important regulatory functions on the 
inactivation properties of Kv1.5-mediated Ikur current in mouse ventricular myocytes, but 
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also modulates the amplitude of this current.  Whereas infusion of SUMO1 has no 
appreciable effect on the density of Ikur current in these cells,  agents that reverse 
(SENP2) or antagonize the effects of SUMOylation (SUMO1-∆GG) leads to a substantial 
reduction in Ikur amplitude.  Notably, these effects are restricted to Ikur, since no effects on 
Ito or Iss total current density could be detected.  As Ikur amplitude is a critical factor in 
establishing the duration of the plateau phase of the action potential, this finding could 
have important clinical implications, especially since extending the refractory period is 
one of the goals of long-term atrial fibrillation therapy.  The initial studies presented in 
this chapter indicate that in mouse cardiomyocytes, both SENP2 and SUMO1-∆GG 
preparations led to significant and specific prolongation of the plateau phase of the action 
potential. In contrast, SUMO1 had no effect.  The observed prolongation is remarkably 
similar to the effects of clinically-used, Class III antiarrythmic drugs.  Given the selective 
expression of Kv1.5 in human atrial tissue, strategies that specifically inhibit the 
SUMOylation of this channel may thus provide an independent and chamber-selective 
mechanism to delay repolarization.  Such strategies could act synergistically with 
currently available pore-blocking drugs.  
The observation that the effects of SUMOylation on the total current density of 
Kv1.5-mediated Ikur current were limited to cardiomyocytes and not visible in Cos7 cells, 
suggests that the mechanism responsible for this regulation may be distinct from that 
underlying the effects of SUMOylation on the inactivation properties of Kv1.5.  Our 
finding that the effect of infused SENP2 on the voltage-dependence of steady-state 
inactivation of Kv1.5 in HL-1 cells was dependent on the presence of intact 
SUMOylation motifs in Kv1.5 provides strong evidence that SUMOylation is likely 
acting on the channel directly to regulate the inactivation properties.  However, our 
studies have not addressed whether the effects of SUMOylation on Ikur amplitude are 
dependent on SUMOylation of Kv1.5 directly.  As discussed in more detail in Chapter 
IV, it is possible that SUMOylation may regulate Ikur current by altering other 
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components of the cell that indirectly regulate Kv1.5.  For example, SUMO modification 
may regulate the delivery of Kv1.5 to the plasma membrane or its internalization.  The 
Martens laboratory has recently shown that Kv1.5 current density is tightly regulated by 
the dynamic processes of dynein-mediated endocytosis and recycling in HL-1 
cardiomycytes (108).  It will therefore be very interesting in future studies to probe the 
role of SUMOylation on the regulation of Kv1.5 internalization and transport. 
The finding that SUMO1-∆GG recapitulates the effects of SENP2 on both the 
amplitude and inactivation properties of the Ikur current in cardiomyocytes is consistent 
with the view that inter- or intra-molecular interactions are critical to the functional 
consequences of Kv1.5 SUMOylation.  As with most other forms of post-translational 
regulation, the effects of SUMO modification vary greatly depending on the target 
protein.  It has begun to emerge that a common mechanism by which SUMOylation is 
able to regulate such a diverse array of functional effects may be by its ability to 
modulate inter- and intramolecular interactions (122).  In addition to the covalent 
interaction between its C-terminal glycine and the target lysine of its substrate, structural 
and scanning mutagenesis analyses (152) have revealed that an evolutionarily conserved 
surface contributed by the β2 strand and α helix of SUMO provides a surface for 
interactions with many target proteins.  The structures of a PIASx peptide (149), thymine 
DNA glycosylase (150), and RanBP2 (151) in complex with SUMO via this surface have 
all recently been solved.  As SUMO1-∆GG is selectively missing the C-terminal di-
glycine motif required for formation of covalent interactions with target proteins, but 
retains an intact effector surface required for non-covalent interactions, this protein 
provides a unique tool to probe the functional importance of this functional surface.  The 
finding that SUMO1-∆GG has similar effects on Ikur as SENP2, suggests that this variant 
may be serving as a dominant-negative to endogenous SUMO by competing for inter- 
and intra-molecular interactions.  As discussed below in Chapter IV, a subset of proteins 
associated with the plasma membrane contain I/L/V-rich sequences resembling the 
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SUMO-interacting motifs (SIMs) known to interact with the effector surface of SUMO 
(171).  It will be very interesting in future studies to investigate whether such SIM-
containing candidate proteins contribute to the functional effects of Kv1.5 SUMOylation 
and to determine whether the same or distinct components mediate the effects on 
inactivation and current density. 
In contrast to our previous studies in Cos7 cells, in the present study we identify 
that the effects of SUMOylation on Kv1.5 and Ikur current can be modulated acutely.  The 
effects of SENP2 and SUMO1-∆GG on the action potential duration could be detected 
within ~ 1 minute of establishment of the whole-cell configuration and developed 
relatively quickly.  Although in most cases the effects of SUMO1, SENP2, and SUMO1-
∆GG on the voltage-dependence of steady-state inactivation were recorded after at least 5 
minutes, occasionally, we were able to obtain data early enough to monitor a shift in the 
V50 of inactivation in the same cell.  In this regard, future experiments in which protein 
diffusion is slowed by back-filling the recording pipette may prove useful to further 
characterize the onset of the effects.  The acute effects we have observed are consistent 
with the studies of K2P1 (164) and GluR6 (166) SUMOylation.  In inside-out, single-
channel studies of the K2P1 channel, exposure of K2P1 to the SUMO conjugation 
machinery suppressed channel activity within seconds, while subsequent exposure to 
SENP1 restored channel activity in a similar time frame (164).  Similarly, in whole-cell 
patch-clamp studies of the GluR6 kainate receptor, infusion of SUMO1 into CA3 neurons 
caused a rundown of kainate-receptor-mediated excitatory postsynaptic currents (KAR-
EPSCs).  This effect was half-maximal at ~ 1-2 minutes after gaining access to the cell.  
These results strongly suggest that SUMO modification of Kv1.5 and other ion channels 
occurs while the channel is at the plasma membrane.  This is consistent with the findings 
that Ubc9 can be detected in subcellular fractions from the plasma membrane in 
numerous, mammalian cell types.  This is also consistent with our findings described in 
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Chapter II, that surface-biotinylated Kv1.5 is SUMO modified with approximately the 
same stochiometry as that for total cellular Kv1.5. 
It is important to note that given the use of purified preparations, we cannot 
formally rule out the possibility that minor components in these preparations may have 
unsuspected effects.  This seems to be unlikely, however, since we have taken reasonable 
steps to insure the purity of the preparations.  Moreover, the preparations were purified in 
parallel, yet display opposing effects.  Furthermore, the effects are fully consistent with 
the results obtained with the expression approaches described in Chapter II. 
In conclusion, the findings presented in this chapter extend our initial studies in 
heterologous systems by demonstrating that alterations in SUMOylation modulate Kv1.5 
inactivation in the native context of cardiomyocytes, and that they can occur acutely.  The 
studies in this natural context also revealed additional effects on Kv1.5-mediated currents 
that were absent in simpler model systems.  Thus, the data indicate that reversing or 
antagonizing SUMOylation leads to a significant reduction in Ikur current density and a 
concomitant prolongation in the action potential duration.  Moreover, the opposing 
effects of agents that promote or antagonize SUMOylation suggest that cells have an 
intrinsic Kv1.5 SUMOylation “tone” that can be manipulated bidirectionally.  Taken 
together, the data raise the intriguing possibility that manipulation of the SUMOylation of 
Kv1.5 may provide a novel target for the highly specific pharmacological manipulation 
of Ikur current in patients with atrial fibrillation. 
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CHAPTER IV: CONCLUSION 
Through the work of this thesis, we have established that Kv1.5, which encodes 
the major outward K+ current responsible for phase-two repolarization in human atrial 
cardiomyocytes, serves as a target for reversible, posttranslational modification by small 
ubiquitin-like modifier (SUMO) proteins.  We demonstrated that this modification occurs 
at two conserved consensus SUMOylation sequences centered on lysines 221 and 536, 
and that this modification has important functional consequences on the inactivation 
properties of the channel.  Furthermore, we have found that this novel form of Kv 
channel regulation is intact in mouse and human cardiomyocytes.  Through the use of 
purified, recombinant components of the SUMOylation conjugation machinery, we show 
that alterations in SUMOylation result in the specific regulation of the voltage-
dependence of steady-state inactivation and total current density of native Kv1.5-
mediated Ikur current in cardiac myocytes.  Consistent with the role of Kv1.5 in 
controlling the shape and duration of the action potential, we find that reversing 
SUMOylation or antagonizing its effects leads to reductions in the amplitude of Ikur and 
as a consequence, specifically prolongs the plateau phase of the action potential in a 
manner that mimics the pharmacologic blockade of Ikur by antiarrythmic drugs. 
These findings are significant as they represent the first report of the SUMO 
modification of a voltage-gated ion channel and only one of a handful of reports 
demonstrating the SUMOylation of a protein located at the plasma membrane.  Kv1.5 
represents a promising target for the development of ventricular-sparing, antiarrhythmic 
medications for treatment of atrial fibrillation.  These findings have substantial 
implications for the development of novel therapeutic modalities since they reveal a 
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hitherto unrecognized regulatory mechanism that can serve as a potential new, highly-
specific target for the pharmacological manipulation of Ikur current. 
As described in the Introduction, at the onset of this thesis in 2004, numerous 
global proteomic analyses had repeatedly identified non-nuclear targets for 
SUMOylation, and the SUMOylation conjugation machinery had long been known not to 
be limited to the nuclear compartment. However, the overwhelming majority of well-
described targets of SUMOylation were located in, or near the nucleus.  The only 
proposed targets for SUMO modification at the plasma membrane were the GLUT1 and 
GLUT4 glucose transporters (160).  This initial study was important not only for 
providing the first example of SUMOylation of integral membrane proteins, but also for 
establishing that the SUMO E2 Ubc9 could be detected in subcellular fractions from the 
plasma membrane of 3T3-L1 adipocytes, L6 skeletal muscle myoblasts, and terminally-
differentiated myotubes.  Following this initial report, it was not until 2005 that the 
potassium leak channel K2P1 (164) and the metabotropic glutamate receptor mGluR8 
(162) were shown to serve as targets for SUMOylation.  The K2P1 study again 
demonstrated that Ubc9 could be detected at the plasma membrane (this time in Xenopus 
oocytes).  Our report of the SUMO modification of Kv1.5 was published in 2006.  Since 
then, it has recently been shown that the ionotropic kainate receptor GluR6 (166) and 
numerous metabotropic glutamate receptor (mGluR) subunits (159) are targets for SUMO 
modification. 
SUMO MODIFICATION OF PROTEINS AT THE PLASMA MEMBRANE 
Together, these reports clearly identify an emerging role for the SUMO modification of 
ion channels at the plasma membrane.  The extent to which this regulatory mechanism 
contributes to membrane protein function however, remains to be established.  In an 
initial analysis, we have examined the complement of SUMO modified proteins present 
at the plasma membrane.  As can be seen in Figure IV-1, SUMOylation of multiple 
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proteins is readily detected and the pattern is distinct to that observed for soluble proteins.  
This indicates that analysis of SUMOylation in this compartment is likely to be quite 
revealing.  Although the identity of the target proteins remains to be determined, 
scanning of the human ProSite database using a search profile based on functionally 
characterized synergy control motifs in transcription factors (144) and a description filter 
of “channel,” identifies that numerous ion channels contain high-scoring motifs ( Figure 
IV-2).  Included in these are multiple members of the voltage-gated K+, Ca2+, and Na+ 
families.  Interestingly, while members of the Kv4 family known to mediate Ito current in 
cardiomyocytes are absent from this list, the HERG channel (Kv11.1), which mediates 
the Iss current in cardiomyocytes (73), contains a high-scoring motif on its cytoplasmic 
N-terminus ( Figure IV-2).  While we find that infusion of SUMO1, SENP2, or SUMO1-
∆GG has no effect on the current density of HERG-encoded Iss, this clearly raises the 
possibility that SUMO modification may have other effects on the biophysical properties 
of this important channel. 
Intriguingly, as well, a recent genotyping screen has revealed the occurrence of a 
naturally-occurring missense mutation in a patient with Long-QT syndrome that disrupts 
a flanking proline residue in a putative SUMOylation motif in HERG (P114S) (185).  
This finding is very interesting in light of a recent report of a similar nonsynonymous 
polymorphism in Kv1.5 (P532L) that maps to the well-conserved upstream proline of the 
second Kv1.5 SUMOylation motif.  Remarkably, this polymorphism, which is carried by 
1.1% of African Americans, confers a substantial reduction in the ability of quinidine to 
block Kv1.5 (186,187).  As described in Chapter I, the conservation of Pro/Gly residues 
flanking the core SUMOylation motifs reflects their role as terminators of secondary 
structure elements and suggests that they facilitate exposure of the SUMOylation site to 
the conjugation machinery.  Consistent with this idea, analysis of transcription factor 
SUMOylation by our group indicates that substitution of the proline residues flanking the 




















Figure IV-1. Multiple Plasma Membrane Surface Expressed Proteins in Cos7 Cells 
Appear to be Targets for SUMOylation. 
Forty-eight hours after transfection with HA-SUMO3, Cos7 cells were surface 
biotinylated (as indicated) using a cell-impermeant, amine-reactive ester biotinylation 
reagent and lysed in the presence of 1% CHAPS and 20 mM NEM, as indicated.  
Following sonication, whole cell lysates were centrifuged at 16,000 x g for 15 min, and 
soluble protein was loaded onto either a streptavidin-agarose resin.  After sequential 
washes with Buffer 1, 2, and 3 (as described in Chapter II Experimental Procedures), 
protein was eluted in SDS loading buffer, separated by SDS-PAGE, and visualized by 
Western blotting using an HA antibody.  HA-immunoreactive bands represent NEM-
sensitive species (lane 2) that were surface biotinylated (note absence of species in lane 
3). 
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interaction with the SUMO E2 conjugating enzyme Ubc9 and a concomitant reduction in 
SUMOylation (unpublished data).  An examination of whether the putative SUMOylation 
site in HERG is indeed functional and the potential relation with the P114S mutation 
associated with Long-QT syndrome is likely to be revealing. 
It is also interesting to note that the Kv accessory proteins KChIP1, KChIP4, and 
Kv  4.1 all contain high-scoring SUMOylation motifs.  While little is known about the 
interactions or functional effects of Kv 4.1, the other two proteins, KChIP1 and KChIP4 
are well-known to interact with members of the Kv4 family and to alter the current 
densities and biophysical properties of these channels (188).  As Kv4 family members 
mediate the Ito current in cardiomyocytes, this raises the possibility that while Kv4 family 
members do not appear to contain SUMOylation motifs, critical regulators of these pore-
forming subunits may be subject to this form of regulation.   
A less stringent scan of the human ProSite database using a profile containing 
only the core SUMOylation motif ([ILV]-K-X-[ED]) and a description filter of “channel” 
yielded many additional hits not identified in the above search (205 hits in 123 
sequences).  Included in these hits were multiple isoforms of serotonin receptors, ATP-
binding cassette (ABC) transporters, cyclic nucleotide-gated (CNG) channels, inward 
rectifier potassium (Kir) channels, ryanodine receptors (RyR), and two-pore potassium 
channels (among many other families of membrane-associated proteins).  Many of these 
identified motifs appeared to be located in regions of the proteins accessible to the 
cytoplasmic SUMO conjugation machinery.   
These intriguing observations coupled with our analysis of Kv1.5 support the 
view that SUMO modification is likely to be an important and widespread regulatory 
mechanism at the plasma membrane and that it can have a significant impact on the 
control of the electrical properties of excitable cells and in particular in the heart. 
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Acc # | Symbol | (Size aa) Description SUMOylation Motif 
|Q09470|KCNA1|  (495) Voltage-gated potassium channel subunit Kv1.1 135 - 145: Gf...IKeEerplP 
    190 - 200: Pe...LKdDkdftG 
|P16389|KCNA2|  (499) Voltage-gated potassium channel subunit Kv1.2 131 - 141: Gy...IKeEerplP 
|P22460|KCNA5|  (613) Voltage-gated potassium channel subunit Kv1.5 218 - 228: Gf...IKeEekplP 
    532 - 540: Pav..LKeEq...G 
|Q03721|KCNC4|  (635) Voltage-gated potassium channel subunit Kv3.4 20 - 32: PsktcLKeEmak.G 
|Q12809|KCNH2|  (1159) Voltage-gated potassium channel subunit Kv11.1 114 - 120: P....VKnEd...G 
|Q9ULD8|KCNH3|  (1083) Voltage-gated potassium channel subunit Kv12.2 115 - 121: P....IKnEk...G 
    786 - 797: GragaLKaEag..P 
|Q9UQ05|KCNH4|  (1017) Voltage-gated potassium channel subunit Kv12.3 115 - 121: P....IKnEm...G 
|Q9H252|KCNH6|  (994) Voltage-gated potassium channel subunit Kv11.2 114 - 120: P....VKnEd...G 
|Q9NS40|KCNH7|  (1196) Voltage-gated potassium channel subunit Kv11.3 1093-1105: Peas.IKtDrsfsP 
|Q96L42|KCNH8|  (1107) Voltage-gated potassium channel subunit Kv12.1 115 - 121: P....IKnEk...G 
|Q9UNX9|IRK14|  (436) ATP-sensitive Inward rectifier K(+) channel Kir2.4 50 - 57: Grf..VKkD....G 
|Q9NZI2|KCIP1|  (227) Kv channel-interacting protein 1 (KChIP1) 175 - 182: Pv...LKeDt...P 
|Q6PIL6|KCIP4|  (250) Kv channel-interacting protein 4 (KChIP4) 198 - 205: Pv...LKeDa...P 
|Q9Y244|POMP|  (141) Voltage-gated K channel beta subunit 4.1 34 - 44: Gfsc.VKnEll..P 
|Q8IZS8|CA2D3|  (1091) Voltage-gated calcium channel subunit alpha-2/delta-3 225 - 235: Pg...IKwEpdenG 
|Q15878|CAC1E|  (2312) Voltage-gated calcium channel subunit alpha Cav2.3 852 - 860: Ggs..LKgDg...G 
|O43497|CAC1G|  (2377) Voltage-gated calcium channel subunit alpha Cav3.1 653 - 663: Pc...LKaDsgacG 
|O95180|CAC1H|  (2353) Voltage-gated calcium channel subunit alpha Cav3.2 938 - 948: GckfsLKtDt...G 
|Q9P0X4|CAC1I|  (2223) Voltage-gated calcium channel subunit alpha Cav3.3 1932-1945: PvrswLKhDssqaP 
|Q13698|CAC1S|  (1873) Voltage-gated calcium channel subunit alpha Cav1.1 1472 - 1481: GtalkIKtE....G 
|Q92736|RYR2|  (4967) Cardiac muscle ryanodine receptor-calcium channel (RyR2) 4381 - 4389: Gld..LKrEg...G 
|A8K7I4|CLCA1|  (914) Calcium-activated chloride channel family member 1) (hCLCA1) 754 - 766: GqitdLKaEihg.G 
|Q9UQC9|CLCA2|  (943) Calcium-activated chloride channel family member 2) (hCLCA2) 662 - 670: Gadv.IKnD....G 
|Q9Y696|CLIC4|  (253) Intracellular chloride ion channel protein p64H1 6 - 17: Plng.LKeEdke.P 
|P35498|SCN1A|  (2009) Voltage-gated sodium channel subunit alpha Nav1.1 1748-1759: Pgss.VKgDcgn.P 
|Q99250|SCN2A|  (2005) Voltage-gated sodium channel subunit alpha Nav1.2 1738-1749: Pgss.VKgDcgn.P 
|Q9NY46|SCN3A|  (2000) Voltage-gated sodium channel subunit alpha Nav1.3 1733-1744: Pgss.VKgDcgn.P 
|P35499|SCN4A|  (1836) Voltage-gated sodium channel subunit alpha Nav1.4 1560-1571: Pgts.VKgDcgn.P 
|Q9UQD0|SCN8A|  (1980) Voltage-gated sodium channel subunit alpha Nav1.6 1134-1147: GstidIKpEveevP 
|P51172|SCNND|  (638) Nonvoltage-gated sodium channel 1 subunit delta) (SCNED) 580-592: Gass.IKpEasqmP 
|Q8IWT1|SCN4B|  (228) Sodium channel subunit beta-4 precursor 82 - 91: Gt...VKnEksd.P 
|Q9BX84|TRPM6|  (2022) Melastatin-related TRP cation channel 6 1995-2006: Gle..IKiEsaeeP 
|Q9Y5S1|TRPV2|  (764) osm-9-like TRP channel 2) (TrpV2)(OTRPC2) 421 - 428: Ph...LKaEv...G 
|Q9BQR3|PRS27|  (290) Channel-activating protease 2 (CAPH2)(Marapsin) (Pancreasin) 205 - 216: Pkt..IKnDmlcaG 
|Q8TDI7|TMC2|  (906) Transmembrane channel-like protein 2 (cochlear-expressed) 7 - 15: G....LKeEarg.G 
 
 
 Figure IV-2. Identification of Membrane Ion Channels that Contain Synergy 
Control Motif SUMOylation Sequences. 
Using the ExPASy: ScanProsite Tool, the UniProtKB/Swiss-Prot protein database 
was scanned using the sequence [PG]-X(0,4)-[ILV]-K-X-[ED]-X(0,4)-[PG] with the 
species filter “human” and the description filter “channel” and the match mode 
“greedy/overlaps/no includes.”  All 38 hits on 35 sequences are shown. 
 114
 
MULTIPLE EFFECTS OF SUMO ON KV1.5 MEDIATED CURRENTS 
In mouse ventricular myocytes, we find that SUMOylation has important 
regulatory effects on at least two properties of native Ikur current.  In addition to the bi-
directional effects of SUMO1 and either SENP2 or SUMO1-∆GG on the voltage-
dependence of steady-state inactivation of Ikur, we find that infusion of SENP2 or 
SUMO1-∆GG leads to a substantial decrease in Ikur total current density.   Importantly, 
these multiple effects are restricted to Ikur current since SUMO1, SENP2, and SUMO1-
∆GG infusion had no effect on current densities of Ito or Iss. 
It is interesting to note that we detect differences in how SUMOylation modulates 
these two properties of Kv1.5 in different cell types.  For example, whereas SUMO 
modification regulates the voltage-dependence of steady–state inactivation of Kv1.5-
mediated current in Cos7 cells, HL-1 cells, mouse ventricular myocytes, and human atrial 
myocytes, we find that SENP2 regulates Kv1.5-mediated Ikur current density in mouse 
ventricular myocytes, but not in Cos7 cells.  As discussed further below, this difference 
suggests that the regulation of Kv1.5 inactivation and amplitude by SUMOylation may be 
mediated by distinct mechanisms.  While effects of SUMOylation on the voltage-
dependence of steady-state inactivation of Kv1.5 are visible in all cell types we have 
examined, the dominant direction and magnitude are characteristic of different cells.  
Likewise, the impact of SUMO modification in the regulation of Kv1.5 mediated current 
density appears restricted to cardiomyocytes.  
Furthermore, whereas we find that the voltage-dependence of steady-state 
inactivation of Ikur current in mouse ventricular myocytes is bi-directionally regulated by 
the opposing effects of SUMO1 and either SENP2 or SUMO1-∆GG, the total density of 
Ikur current is affected only by agents that reverse SUMOylation (SENP2) or antagonize 
its effects (SUMO1-∆GG), but not by SUMO1 itself.  This may suggest that the voltage-
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dependence of steady-state inactivation and the current density of Ikur have different 
sensitivities to regulation by SUMOylation.  While the voltage-dependence of steady-
state inactivation is responsive to increases or decreases in the SUMOylation state of the 
cell, the regulation of Ikur amplitude by SUMOylation may have reached saturation under 
the basal “tone” of SUMOylation in these cells, and thus may not be sensitive to 
exogenous SUMO.  In this view, Kv1.5 amplitude might be expected to become sensitive 
to the effects of added SUMO1 in cells with low basal SUMOylation “tone.”  Therefore, 
it might be very interesting to probe the effects of SUMOylation on Ikur current density in 
human atrial cells.  Although the scarcity of cells prevented us from accurately assessing 
the effects of SUMOylation on Ikur amplitude, our findings that SUMO led to a 
depolarizing shift in the V50 of steady state inactivation of Ikur in these cells while SENP2 
had no effect, suggest that the basal SUMOylation tone is likely to be lower than in 
mouse ventricular cells.  
Together, these observations suggest that the mechanisms by which SUMOylation 
regulates the voltage-dependence of steady-state inactivation and current density of Ikur 
current in cardiomyocytes are likely distinct.  In the following section, I therefore 
describe potential mechanisms that may mediate the effects of SUMOylation on Kv1.5 
inactivation and current density. 
POTENTIAL BASIS FOR THE EFFECTS OF SUMOYLATION ON THE DENSITY AND 
INACTIVATION PROPERTIES OF THE KV1.5 MEDIATED IKUR CURRENT 
The effects of SUMO modification vary greatly depending on the target protein 
and range from changes in subcellular localization, to protein stability, to trafficking, to 
protein-protein interactions.  Recently, it has begun to emerge that a common mechanism 
by which SUMOylation is able to regulate such a diverse array of functional effects may 
be through its ability to modulate inter- and intra-molecular interactions (122).  In 
addition to the covalent interaction between its C-terminal glycine and the target lysine of 
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its substrate, a distinct effector domain on SUMO provides a surface for interactions with 
proteins that contain so-called SUMO-interacting motifs (SIMs).  While SIMs are just 
beginning to be recognized in proteins that are able to interact with SUMO, a number of 
proteins, including p73α (153), PML (149,153,154), Daxx (155), SAE2 (149), PIAS E3 
(149), RanBP2 (149,151), thymine DNA glycosylase (150), and RNF4 (156), have been 
identified to interact with SUMO through a loosely-defined V/I-X-V/I-V/I (149) 
hydrophobic sequence.  In many proteins, this hydrophobic core has been found to be 
surrounded by acidic residues, which likely serve to further stabilize interactions with 
SUMO.   
Because Kv1.5 functions as part of a multi-protein/lipid complex comprising 
proteins with scaffolding, cytoskeletal, and enzymatic activities, SUMO modification of 
Kv1.5 may function by modulating these interactions.  This model would be consistent 
with our observations, since the cell-type dependence of some of the effects of 
SUMOylation may be due to the expression in each cell of a different complement of 
potential interacting partners.  Indeed, our studies with the non-conjugatable SUMO1-
∆GG indicate that this variant may be functioning in a dominant-negative manner by 
competing for these interactions with endogenously SUMOylated channel.  
To identify potential binding partners within the Kv1.5/SUMO complex that may 
be facilitated by the effector surface of SUMO, we conducted a scan of the human 
ProSite database using a search sequence based on the identified SIM/SBMs from PIASx, 
PML, SAE2, Daxx, RanBP2, and thymine DNA glycosylase (149,151,155).  Comparison 
of these sequences revealed that the core hydrophobic motif could be described using the 
sequence [VI]-X-[VIE]-[VIL].  Additionally, in each of these cases, this motif was 
immediately flanked by either an N-terminal aspartic acid residue or a C-terminal aspartic 
acid/serine residue.  The N-terminal Asp or the C-terminal Asp/Ser residues were 
included in the search since these features have been found to be critical to binding of 
SIM/SBMs to SUMO (158).  This search, conducted with the descriptive filter “channel,” 
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yielded 154 hits in 101 sequences, and included multiple voltage-gated K+, Na+, and Ca2+ 
channels.  However, careful inspection of these hits revealed that, given the hydrophobic 
nature of this motif, many of them were located in the transmembrane domains of the 
channels, making them less likely candidates.  For example, Kv1.5 contains an I-A-I-V-S 
motif in the first six residues of the S1 transmembrane domain (residues 252-256) just 30 
residues downstream from the first SUMOylation site.  While it is potentially possible 
that this SIM/SBM could facilitate an intra-molecular interaction within Kv1.5, the 
detection of this sequence may be simply due to the enrichment of hydrophobic residues 
in transmembrane domains. 
Potentially more interesting, however, is the finding that the Kv 1.3 and Kv 2.1 
subunits each contain potential SIM/SBMs.  These sequences are located on the C-
termini of the subunits (400-404 and 348-393, respectively).  This suggests that a 
potential consequence of SUMOylation of Kv1.5 may be to modulate interactions with 
accessory Kv  subunits.  This may be particularly significant since recruitment of Kvβ 
subunits can influence the voltage dependence of steady-state inactivation of the channel. 
As more SUMO-interacting proteins are identified, and the definition of 
SIM/SBMs becomes more refined, it will be interesting to expand this initial search to 
include a larger pool of proteins not restricted to channel proteins (without the “channel” 
filter, the search yields more than one thousand hits).  It seems likely that potential 
candidates for SIM/SBM-mediated interactions may include adapter, scaffolding, and 
trafficking proteins.  Notably, the membrane-associated adaptor protein Daxx, which 
contains a SIM/SBM known to be critical to its role in transcriptional regulation, was 
found to interact with GLUT4 in a yeast-two-hybrid screen (171).  It remains to be 
determined, however, whether this particular interaction is dependent on GLUT4 
SUMOylation.  We anticipate that relevant SIM/SBM-mediated interactions with 
SUMOylated membrane proteins will be identified in the near future. 
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In addition to promoting the formation of inter- or intra-molecular interactions 
with Kv1.5, SUMO modification could potentially alter channel properties through 
modulating the local electrostatic environment of the channel.  As described above, this 
mechanism of action would be particularly attractive for describing the effect of 
SUMOylation on the regulation of Ikur inactivation, since we find this regulation to be 
largely independent of cell-type.  Both of the identified SUMOylation motifs in Kv1.5 
are located very near the transmembrane/cytosolic interface of the channel.  The 
electrostatic environment of this region is thought to influence the voltage-sensitivity of 
Kv channels (45).  The surface of SUMO is highly charged and has a significant dipole 
moment, with one hemisphere of the protein being rich in basic residues while the 
opposite face is predominantly acidic.  Conjugation of SUMO to the channel could thus 
serve to affect the juxtamembrane, electrostatic environment of the channel and influence 
voltage-sensitive steps.  The selective effects of SUMOylation on the voltage-dependence 
of inactivation, but not on activation (at least in Cos7 cells), however, argues that 
SUMOylation affects steps other than the voltage-sensitive transitions along the usual 
path toward activation. 
Similarly, and also consistent with a possible cell-type-independent mechanism 
for regulation by SUMOylation on the voltage-dependence of steady-state Ikur 
inactivation, SUMOylation could serve to induce specific conformational changes in 
Kv1.5.  As mentioned in Chapter I, SUMOylation has been shown to lead to 
conformational changes in target proteins.  The most well-defined example of this is the 
SUMOylation of the DNA repair enzyme DNA glycosylase (TDG).  Upon 
SUMOylation, TDG undergoes a conformational change induced by the formation of an 
intra-molecular interaction between the effector surface of SUMO and a SIM-containing 
domain of TDG.  This conformational change alters the affinity of TDG for DNA and 
thereby allows it to be released from its bound DNA (150).  Such a conformational 
change could be induced in Kv1.5 upon SUMOylation either through the formation of 
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similar intra-molecular interactions (with the SIM contained in Kv1.5 described above, 
for example), or through allosteric changes within the channel.  In either case, this effect 
of SUMOylation would be largely independent of interactions with other components of 
the cell. 
Although the effects of SUMOylation machinery components on the current 
density in cardiomyocytes appears restricted to Ikur, the specific target(s) responsible for 
these effects may extend beyond Kv1.5.  Thus, SUMOylation may not only be acting on 
Kv1.5 directly, but may also affect other proteins in cardiomyocytes that indirectly 
regulate Ikur function.  Our finding that the effect of infused SENP2 on the voltage-
dependence of steady-state inactivation of Kv1.5 in HL-1 cells was dependent on the 
presence of intact SUMOylation motifs in Kv1.5, provides strong evidence that 
SUMOylation is likely acting on the channel directly to regulate the inactivation 
properties.  However, while the effects of SENP2 and SUMO1-∆GG on total current 
density were specific for Ikur in mouse ventricular myocytes and did not affect other 
channels, our experiments did not address whether these effects were due exclusively to 
Kv1.5 SUMOylation.   
Interestingly, it is beginning to emerge that SUMOylation may play an important 
role in regulating the retrograde transport of proteins in cells.  The RNA-binding protein 
La has recently been shown to be SUMO modified in rat sensory neurons.  Whereas 
SUMOylated La binds dynein and shows retrograde transport from the axonal process 
back to the cell body, SUMOylation-motif-deficient La (K41R) binds kinesin and only 
displays anterograde transport.  This provides a striking view that SUMOylation may 
directly facilitate the binding of cargo proteins to the dynein motor protein responsible 
for retrograde transport.  Consistent with this, and as described in the Introduction, 
SUMOylation of the ionotropic kainate receptor GluR6 has recently been shown to 
facilitate kainate-evoked endocytosis of the receptor, while reduction of SUMOylation 
using SENP1 prevents this internalization.  As the dynein motor system is critical to 
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facilitating endocytosis, this suggests a further role for SUMOylation in facilitating 
dynein-mediated, retrograde transport.  Recent data from the group of Dr Martens has 
demonstrated that the steady-state current density of Kv1.5 in HL-1 cells is dependent on 
a dynamic balance between dynein-mediated internalization and delivery to the plasma 
membrane of recycled or newly synthesized channel (108).  In future studies, it will be 
very interesting to probe the role of SUMOylation in the regulation of Kv1.5 retrograde 
and anterograde transport. 
REGULATION OF THE SUMO MODIFICATION OF KV1.5-MEDIATED IKUR CURRENT 
SUMO E3 ligases and proteases. 
At steady-state, the status of Kv1.5 SUMOylation is dependent on the balance 
between the forward conjugation of SUMO to the channel and the reverse de-conjugation 
of the SUMO moieties.  We have identified Kv1.5 as a target of SUMOylation but the 
endogenous components responsible for the SUMOylation and de-SUMOylation of the 
channel remain to be defined.  As described in Chapter I, the conjugation of SUMO can 
be enhanced through the action of proteins with SUMO specific E3 ligase activity.  In 
this regard, the K+ channel-associated protein (KChAP) may participate in this role.  
KChAP is a 574-amino acid, cytosolic accessory protein known to couple with the 
functional Kv1, Kv2.1, and Kv4.3 channels (99,175).  It has recently been identified that 
KChAP is a splice variant of PIAS3, making it a member of the protein inhibitor of 
STAT (PIAS) gene family.  This group of proteins was originally identified as negative 
regulators of the JAK/STAT signaling pathway.  However, members of this family, 
including PIAS3, have been shown to possess SUMO-specific E3 ligase activity towards 
transcription factors (99,100,133).  KChAP associates only transiently with Kv channels 
through the N-terminus of α-subunits and the C-terminus of β-subunits (99).  
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Overexpression of KChAP can lead to increases in total expression of Kv1 α-subunits 
and an enhancement of Kv1 total current density without apparent changes in the gating 
of these channels (99).  The exact role and mechanism of action of this protein in Kv 
channel function and regulation remains ill-defined.  However, as PIAS proteins possess 
intrinsic SUMO specific E3 activity and can enhance the conjugation of SUMO to 
multiple substrates (133), these findings raise the intriguing possibility that the effects 
that KChAP have on the expression and electrophysiology of Kv channels may be related 
to the regulation of SUMO modification.  It will clearly be very interesting in future 
studies to determine if KChAP can serve as a functional SUMO E3 ligase and enhance 
Kv1.5 SUMO modification. 
It will also be very interesting to investigate the role of SUMO-specific proteases 
in regulating the SUMOylation of Kv1.5.  We have demonstrated in Cos7 cells, HL-1 
cells, and mouse ventricular myocytes, that Kv1.5-mediated current is sensitive to the 
effects of a catalytic fragment of SENP2.  Whether endogenous SENP2 plays a role in 
Kv1.5 regulation remains to be established.  As described in Chapter I, multiple members 
of the SENP family have been identified (SENP-1-3, and -5-8 in mammals) (135-137).  It 
is beginning to emerge that each of these members may display distinct subcellular and 
tissue distribution.  This has raised the interesting possibility that differential expression 
of SENP family members may play an important role in the regulation of SUMOylation.  
It will thus be very interesting in future studies to characterize the expression of the 
SENP family members in human atrial and ventricular cardiomyocytes and to examine 
the association of such isoforms with the plasma membrane compartment.  Given that 
proteases can be targeted by small molecule inhibitors, the identification of the relevant 
SUMO proteases could be instrumental in designing therapeutic strategies targeted at 
modulating the SUMOylation of Kv1.5. 
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Oxidative Stress 
The factors regulating the modification of target proteins by SUMO are only 
beginning to be appreciated.  Recent data suggest that SUMOylation is a 
developmentally-regulated process (189).  Moreover, various cellular stresses such as 
heat shock and osmotic stress have all been shown to lead to an increase of SUMOylation 
in many target proteins (113).  Intracellular oxidative stress, however, has emerged as 
perhaps the most powerful regulatory force to enhance the SUMOylation of a number of 
target proteins (113,190,191).  Our laboratory and several others have found that proteins 
that are SUMO modified often show an increase in high molecular mass SUMO 
conjugates (especially when modified by SUMO-2 or SUMO-3) when exposed to 
reactive oxygen species.  Presumably, these high molecular mass conjugates correspond 
to the formation of SUMO chains.  Cellular oxidative stress also can lead to the global 
redistribution of SUMO to different target proteins (192).  In Saccharomyces cerevisiae, 
for example, the presence of reactive oxidative species has been shown to distinctively 
shift the profile of SUMO conjugated species in a reproducible manner. Although the 
exact mechanisms involved are not fully understood, recent data indicate that oxidative 
stress may directly modulate the machinery responsible for SUMO conjugation and 
deconjugation (191).   
Using a Cos7 cell system, we have identified that SUMOylation of Kv1.5 is 
induced by oxidative stress in a dose-dependent manner in vitro.  As described in Chapter 
II, we observe that exposure of Cos7 cells to H2O2 leads to a shift from the Kv1.5 
SUMOylated species that we normally detect to higher molecular mass SUMO 
conjugates.  This type of experiment can provide preliminary evidence that the SUMO 
modification of Kv1.5 may be sensitive to oxidative stress.  It is important to note in this 
regard that Kv1.5 also plays an important role in the vasculature, particularly in the 
pulmonary circulation where it contributes to the vasoconstriction elicited by hypoxic 
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conditions (89).  SUMOylation of Kv1.5 may also contribute to this regulatory 
mechanism. 
An important and well-studied source of pathophysiological oxidative stress in the 
heart occurs during ischemia/reperfusion injury following a heart attack (193).  Although 
reperfusion following ischemia-induced damage of myocardium is essential to overall 
survival of the cells, oftentimes this re-oxygenation of damaged tissue can actually result 
in further insult due to the introduction of reactive oxygen metabolites  (193).  In an 
initial exploratory experiment, we find that global protein modification by SUMO1, as 
well as SUMO2/3, is greatly induced in vivo in living rabbit hearts that undergo a period 
of transient ischemia (30 minutes of left anterior descending (LAD) coronary artery 
occlusion) followed by four hours of reperfusion.  For this experiment, tissue from the 
region of heart that underwent ischemic injury (marked “Ischemia”) or from the 
surrounding region of the heart that was not supplied by the LAD coronary artery 
(marked “Normal”) was homogenized and lysed in the presence of the SUMO protease 
inhibitor NEM.  Lysates were then resolved by SDS-PAGE and probed with antibodies 
against either SUMO1 or SUMO2/3.  As shown in Figure IV-3, we detect a significant 
increase in total SUMOylated species.  This is consistent with our findings that oxidative 
stress can up regulate SUMOylation in vitro as described above, as well as a very recent 
report in the literature that transient ischemia can induce SUMOylation in cerebral tissue 
in a model for stroke (194).  In future studies, it will be very interesting to determine at 
what stage is SUMOylation upregulated and to probe the role of SUMOylation in the 
pathophysiological response to ischemia/reperfusion. 
CODA 
In conclusion, the work in this thesis has identified the novel regulation of Kv1.5 
by members of the SUMO family, and has determined that this regulation has important 




















Figure IV-3. Global Protein SUMOylation is Induced in Living Rabbit Hearts 
Following Ischemia/Reperfusion Injury. 
A period of transient ischemia induced in living rabbits by 30 minutes of left 
anterior descending (LAD) coronary artery occlusion was followed by four hours of 
reperfusion.  Tissue from the region of heart that underwent ischemic injury (marked 
“Ischemia”) or from the surrounding region of the heart that was not supplied by the 
LAD coronary artery (marked “Normal”) was homogenized and lysed in the presence of 
the SUMO protease inhibitor NEM, and this lysate was separated by SDS-PAGE and 
blotted with antibodies against either SUMO1 or SUMO2/3.  The tissue specimens were 
collected by Erin Booth and Adam Lauver in the laboratory of Dr Ben Lucchesi at our 
institution. 
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model systems, as well as in acutely dissociated mouse and human cardiomyocytes.  This 
raises the exciting possibility that the SUMOylation of Kv1.5 may provide a novel, 
highly-specific target for the pharmacological manipulation of Ikur current in patients with 
atrial fibrillation.  Furthermore, as we have identified that numerous other voltage-gated 
ion channels contain consensus SUMOylation motifs, SUMOylation may constitute a 
widespread mechanism for the adaptive tuning of electrically-excitable cells.  Indeed, we 
have collected data that indicate that infusion of purified SENP2 or SUMO1-∆GG into 
mouse cardiomyocytes leads to a selective decrease in Ikur current density and a 
prolongation of the plateau phase of the action potential.  These findings suggest that 
disruption of SUMO modification of Kv1.5 in cardiomyocytes may lead to important 
physiological and pathophysiological consequences.   
Although much more work clearly remains to be done to fully understand the role 
of SUMO modification in the regulation of Kv1.5, I feel fortunate to have been able to 
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